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SUMMARY
This study aimed to investigate the consequences of a transient focal ischaemic insult using 
a novel model of transient focal cerebral ischaemia that utilises the vasoconstrictor peptide 
endothelin-1 to induce temporary occlusion of the left middle cerebral artery (MCA) in the 
rat. Quantitative histopathology and in vivo autoradiographical techniques were used to 
assess this model and compare it to the standard model of permanent MCA occlusion 
originally developed in these laboratories (Tamura et al. 1981a). In vivo double-label 
autoradiography using the blood flow tracers [14C]iodoantipyrine (IAP) and 
[ " mTc]hexamethylpropylamine oxime (HMPAO) revealed that application of endothelin-1 
(2.5 nmol in 25 fil) to the MCA in the halothane-anaesthetised rat resulted in profound 
reductions in local cerebral blood flow throughout the territory of the MCA 5 min 
post-endothelin-1 application (measured by [99mTc]HMPAO). In the same animals 
reperfusion (measured by [14C]IAP) was apparent 2 h post-endothelin-1 application in both 
the cerebral cortex and caudate nucleus. Thus in this model endothelin-1 induces a period 
of profound ischaemia followed by gradual, spontaneous reperfusion.
In a separate study the same dose of endothelin-1 was found to induce a reproducible lesion 
(assessed by quantitative histopathology) located in the cortex and caudate nucleus 4 h 
post-endothelin-1 application in the anaesthetised rat. Neurones within the lesion exhibited 
the classic morphology characteristic of ischaemic cell change. Withdrawal of anaesthetics 
following transient MCA occlusion was found to reduce the volume of ischaemic damage 
measured at the 4 h time point when compared with maintained anaesthesia. This was 
probably due to the increase in blood pressure in conscious compared with anaesthetised 
rats. In contrast withdrawal of anaesthetics did not affect outcome 4 h following permanent 
MCA occlusion.
The volume of ischaemic damage was found to increase from 4 to 24 h post-transient MCA 
occlusion (23 ± 14 and 87 ± 14 mm3 (mean ± S.D.) respectively), while there was no 
significant difference in the volumes of ischaemic damage for permanent MCA occlusion at 
the same time points (131 ±37  and 126 ± 29 mm3 for 4 and 24 h post-MCA occlusion 
respectively). Thus it was concluded that the volume of ischaemic damage continues to 
increase after the onset of reperfusion in the endothelin-1 model of transient ischaemia. 
This result suggests that reperfusion injury (as yet undefined) may contribute to outcome in 
this model. Factors associated with both the ischaemic {e.g. severity of constriction 
induced by endothelin-1) and reperfusion {e.g. blood pressure 1 h post-MCA occlusion) 
phases were found to impact directly on lesion size assessed 24 or 72 h post-transient MCA 
occlusion.
xiii
Pre-treatment with the NMDA receptor antagonist MK-801 (0.12 mg/kg i.v. bolus 
followed by continuous i.v. infusion of 108 pg/kg/h at 0.6 ml/h) was found to significantly 
and dramatically reduce the volume of ischaemic damage (by more than 70%) in both the 
whole hemisphere and caudate nucleus following transient MCA occlusion, but only when 
the treatment was initiated 2.5 h pre-MCA occlusion. This result is in contrast to previous 
studies of permanent MCA occlusion in which the caudate nucleus was reported to be 
resistant to MK-801 or other neuroprotective agents. Thus the restoration of blood flow 
following a transient ischaemic insult renders the caudate nucleus potentially amenable to 
pharmacological intervention. When MK-801 treatment was started 1 h pre-MCA 
occlusion the transient hypotension induced by the drug was still present at the time of 
occlusion and no significant neuroprotection was observed.
Nitric oxide (NO) is an important mediator of vascular tone both centrally and in the 
periphery and has also been implicated in excitotoxicity in vitro. In an in vivo model of 
glutamate toxicity in the anaesthetised rat, pre-treatment with the NO synthase inhibitor 
L-NAME (10 mg/kg) signficantly reduced the volume of tissue damage measured 4 h 
post-onset of glutamate infusion into the parietal cortex, and was found to be of equal 
effectiveness as MK-801 (0.5 mg/kg) demonstrating the importance of NO as a mediator of 
excitotoxic damage. In contrast, in models of both permanent and transient MCA occlusion 
(using the 4 h paradigm in the anaesthetised rat) the protection achieved with L-NAME 
(3-30 mg/kg) was more modest that that observed for MK-801. The higher dose of 
L-NAME (tested only in the permanent MCA occlusion model) did not significantly alter 
the volume of ischaemic damage, while the lower dose (3 mg/kg) reduced the total volume 
of ischaemic damage by 16% (statistically significant) and 29% (not statistically significant) 
for permanent and transient MCA occlusion respectively.
In a series of parallel studies L-NAME (0.3-30 mg/kg) was found to significantly increase 
blood pressure and reduce cerebral blood flow in a dose-dependent fashion in the 
conscious, non-ischaemic rat with a prolonged (>3 h) duration of action. The reductions in 
cerebral blood flow (for 30 mg/kg L-NAME) were rather homogenous throughout the brain 
- reducing flow by approximately 25% when compared with saline controls. In the 
halothane-anaesthetised rat the pressor response to L-NAME (30 mg/kg) was attenuated but 
significant cerebral hypoperfusion was still present. Thus it is likely that the observed 
reductions in cerebral blood flow induced by L-NAME detracted from its inherent 
anti-excitotoxic properties and accounted in part for its weak efficacy against focal 
ischaemic damage in vivo.
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PREFACE AND DECLARATION
Stroke is the third most common cause of death in the Western world after heart disease 
and cancer (McCulloch et al. 1991). There is therefore a great need for investigation into 
the pathophysiology of cerebrovascular disease to improve the management of stroke 
patients and lead to the discovery of effective pharmacological treatments. In the past 
decade one of the most pertinent and useful animal models of cerebral ischaemia has proven 
to be permanent focal ischaemia (induced by middle cerebral artery (MCA) occlusion) in the 
rat. This model has yielded important insights into the pathogenesis of cerebral ischaemic 
damage and has been extensively used to assess the efficacy of putative anti-ischaemic 
drugs. However the utility of this approach is limited by the very fact that the ischaemic 
insult is permanent and consequently the potential beneficial or detrimental effects of 
restoring blood flow to the compromised tissue can not be investigated.
Continued vascular occlusion leads inevitably to tissue death due to depletion of oxygen 
and energy supplies. Therefore in the clinical situation some treatment strategies have been 
directed towards restoring blood flow to the ischaemic tissue in the belief that reperfusion is 
vital for long term survival. However there is evidence to suggest that reperfusion, 
instigated several hours following onset of ischaemia, may itself be associated with further 
pathological events that can potentially worsen outcome following stroke. The restoration 
of flow to an ischaemic region can promote vascular damage that may result in oedema 
formation and haemorrhagic transformation, factors which in turn are associated with 
increased mortality rates. In man spontaneous recanalisation of the occluded vessel occurs 
in approximately 20% of all stroke cases (Wardlaw & Warlow 1992). For embolic stroke, 
spontaneous reperfusion plus the increased use of thrombolytic and anti-thrombotic therapy 
designed to dissolve emboli, mean recanalisation rates can approach 90% of all patients. 
Thus potential reperfusion injury is a problem of increasing importance in the field of 
clinical stroke. To address this problem current experimental research is expanding to 
include models of transient as well as permanent focal cerebral ischaemia, since the 
transient ischaemia models allow the contribution of reperfusion to cerebral injury to be 
assessed.
xv
The primary aim of the current thesis is to further characterise a novel model of transient 
focal cerebral ischaemia, developed at the Wellcome Surgical Institute, that utilises 
endothelin-1 to induce temporary vascular occlusion of the MCA. The volume of 
ischaemic damage induced by this model will be assessed at different time intervals (4, 24 
and 72 h) following the onset of ischaemia. Our main hypothesis is that the volume of 
damage will continue to increase after the onset of reperfusion due to the contribution of 
'reperfusion injury' to the maturation of the lesion.
Secondly, the relative efficacy of different treatment strategies in permanent and transient 
focal ischaemia will be determined with the aim of improving our understanding of the 
processes underlying ischaemic/reperfusion injury in the endothelin-1 model. Finally, the 
physiological/ pathophysiological roles of nitric oxide, a novel mediator of cerebrovascular 
regulation and neurotoxicity, will be investigated in non-ischaemic and ischaemic animals.
This thesis comprises my own original work and has not been presented previously as a 
thesis in any form. Some of the experiments reported in this thesis were carried out in 
collaboration with other researchers: the double label autoradiography study was conducted 
jointly with Ms G Gartshore; the glutamate toxicity study was conducted with Dr H 
Fujisawa, Mr K Mackay and Ms S Browne; while Dr K Kasumoto performed permanent 
MCA occlusions for the first L-NAME drug study.
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1.1. CEREBROVASCULAR DISEASE IN MAN
'Stroke' is a generic term referring to cerebrovascular accidents where blood flow through 
a cerebral artery is interrupted resulting in damage in a discrete, focal area of the brain. The 
focal nature of stroke distinguishes it from the global ischaemic damage that occurs with 
complete interruption of the cerebrovascular supply e.g. following cardiac arrest. Stroke 
can be either ischaemic or haemorrhagic in origin. Ischaemic stroke, caused by occlusion 
of a vessel by emboli (e.g. blood clots carried in the bloodstream until they lodge in a 
vessel) or thrombosis (where the vessel slowly becomes blocked by debris and the onset of 
symptoms may be more gradual) account for approximately 84% of stroke cases while the 
remaining 16% are haemorrhagic in nature (Graham 1988). The incidence of occlusive 
stroke can be further subdivided into embolic (31%) and thrombotic (53%), while 
haemorrhagic stroke can be subdivided into spontaneous intracerebral haemorrhage (10%) 
and subarachnoid haemorrhage (6%).
Thrombosis is the major cause of stroke affecting the carotid and basilar arteries while 
embolism is more common for intra-cerebral arteries (Mohr et al. 1986). Most embolic 
strokes occur in the territory of the MCA (since this vessel is the main continuation of the 
internal carotid artery) and account for approximately one third of all stroke cases (Mohr et 
al. 1986). In man MCA occlusion results in contralateral hemiparesis and aphasia if the 
speech centre is affected. The degree of hemiparesis and the size of infarct are dependent 
on whether the obstruction is localised in the main trunk or a branch of the MCA (Olsen 
1991). MCA occlusions resulting in large infarcts with severe neurological symptoms are 
associated with the poorest outcome (Olsen 1991).
The majority of embolic MCA occlusions undergo spontaneous recanalisation: 25% by 24 
h post-onset of clinical symptoms, 65-90% within 1 week (Mohr et al. 1986; Dalai et al. 
1965). However, because the occurence of embolic stroke in the Western world is much 
less frequent than thrombotic stroke and the spontaneous reperfusion rate for thrombotic 
occlusion is much lower, overall approximately 20% of stroke patients will show 
recanalisation after 24 h (Wardlaw and Warlow 1992). The use of thrombolytic (e.g. 
tissue plasminogen activator) and/or antithrombotic (e.g. aspirin, heparin) therapy will 
however increase this figure. Recanalisation, if it occurs early enough (e.g. within 8 h), is 
associated with reduced infarct size and improved clinical outcome (Olsen 1986; 
Ringelstein et al. 1992). In contrast later reperfusion may not be beneficial (Ringelstein et 
al. 1992) and can be associated with much higher mortality rates than permanent occlusion 
(Irino et al. 1977), suggesting that reperfusion itself causes further injury to 
ischaemically-damaged tissue. Animal models of focal ischaemia are beginning to uncover 
potential contributors to reperfusion injury and these will be introduced in later sections.
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1.2. CEREBROVASCULAR ANATOMY OF HUMAN AND RAT
The major anatomical features of the cerebrovascular system in humans and normotensive 
rats are strikingly similar (Yamori et al. 1976). The brain in both species is supplied by the 
paired internal carotid and vertebral arteries that anastomose on the inferior brain surface to 
form the circle of Willis (see Figure 1). The internal carotid artery divides into 2 branches - 
the smaller branch forms the anterior cerebral artery (ACA), the larger branch and main 
continuation of the internal carotid artery becomes the middle cerebral artery (MCA). In 
man the cortical supply from the ACA is to the inferior frontal lobe and medial surfaces of 
the frontal and parietal lobes. Small penetrating branches such as the medial striate artery 
supply subcortical structures including the head of the caudate nucleus. The MCA supplies 
cortical rami to most of the dorsolateral surface of the cerebral hemispheres (except for 
border regions supplied by the ACA and posterior cerebral artery (PCA)). This includes 
the motor and sensory areas (controlling trunk, hand and face), and speech and language 
areas. Penetrating branches including the lenticulostriates supply the putamen and body of 
the caudate nucleus. The vertebral arteries join at the junction of the pons and medulla to 
form the basilar artery which bifurcates into the posterior cerebral arteries. The PCA 
supplies the inferior temporal and medial occipital lobes of the cerebrum.
In the rat the cortical territories of the 3 major cerebral arteries are essentially similar to man 
(Yamori et al. 1976; see Figure 2). The medial anterior portion of the caudate nucleus is 
supplied by branches from the ACA, while the lateral anterior and posterior portions are 
supplied by lenticulostriate branches from the MCA (Rieke et al. 1981; Yamori et al. 1976).
In both species the cerebral arteries are interconnected at the circle of Willis by the small 
anterior and posterior communicating arteries that act as potential alternative flow routes if 
one of the major supply vessels becomes occluded. Additionally both the rat and human 
possess numerous anastomoses between distal branches of the MCA and ACA or PCA 
resulting in cortical boundary zones where the tissue can receive blood supply derived from 
2 major vessels. In the rat ACA-MCA anastomoses are located dorsally at the cortical 
interface of the 2 vessels along the frontal-occipital axis. Connections between the PCA 
and MCA are located in the occipital region and run parallel to the transverse fissure 
separating the cerebrum from the cerebellum (Coyle & Jokelainen 1982). The collateral 
circulation is more extensive in the rat than man with 4-5 times the number of anastomoses 
between the ACA and MCA, however individual collateral diameter is less in the rat (Coyle 
& Jokelainen 1982). In both species the presence of an efficient collateral circulation can 
reduce the volume of infarcted tissue following an ischaemic insult (Yamori et al. 1976; 
Saito etal. 1987).
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Figure 1 Diagram of arteries at the base of the brain showing the interconnections that 
form the circle of Willis
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The blood supply to the brain is derived from the vertebral and internal carotid arteries 
which anastomose in the circle of Willis. The 3 major intracerebral arteries - the paired 
anterior, middle and posterior cerebral arteries - branch off from the circle of Willis and are 
interconnected by the anterior and posterior communicating arteries. The groups of central 
branches are anteromedial (AM), anterolateral (AL), posteromedial (PM) and posterolateral 
(PL). Adapted from Wilkinson 1986.
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Figure 2 Diagram of cortical blood supply in rats and humans













Adapted from Yamori etal. 1976 and Wilkinson 1986.
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1.3. ANIMAL MODELS OF CEREBRAL ISCHAEMIA
Many species (e.g. primates, cats, dogs, rodents) have been used in experimental models 
of cerebral ischaemia. However rodent models, and particularly the rat, are by far the most 
popular. The rat is particularly suited for this role for several reasons: 1) the 
cerebrovascular anatomy of the rat more closely resembles that of man (Yamori et al. 1976, 
see Section 1.2) than other species such as the cat or gerbil 2) the normal functioning of the 
rat central nervous system, particularly with regards to cerebrovascular regulation, is well 
documented 3) there are practical advantages associated with using a small, low cost animal 
that is more ethically acceptable than ’higher' species.
In this section I shall describe the most commonly used models of cerebral ischaemia in the 
rat. These models can be divided into 2 main groups 1) global or forebrain ischaemia - 
where the blood supply to the entire brain or cerebral hemispheres is reduced or eliminated 
completely and 2) focal ischaemia - where only blood supply to a localised brain region is 
affected.
1.3.1. Rat models of global ischaemia
Although originally developed as models of stroke, these models more closely mimic 
clinical conditions such as cardiac arrest and severe hypotension where blood supply to the 
entire brain is disrupted.
Complete gUMisghasmia
a) Decapitation ischaemia. Decapitation induces irreversible global ischaemia that can be 
maintained for any desired time period by keeping the whole head at 37°C. Alternatively 
the head can be subjected to controlled cooling to mimic post-mortem changes. The main 
advantage of this model is its obvious simplicity. It is particularly well suited to 
investigating changes in biochemical parameters or receptor function.
fr) Neck Tourniquet. The vessels in the neck are compressed by inflation of a pressure cuff 
(Levine & Marvin, 1960). This method interrupts blood supply to the brain stem and 
therefore causes major disruption of cardiovascular and respiratory control that results in a 
high mortality rate. The relevance of this model to any clinical condition (apart from 
strangulation) is also debatable.
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Incomplete global ischaemia
Incomplete or forebrain ischaemia models maintain blood supply to the brain stem and 
hence preserve normal cardiovascular control. These models involve extracranial occlusion 
of blood vessels which prevents complicating factors such as mechanical damage to the 
blood-brain barrier and brain parenchyma, and interactions with intracranial pressure, from 
influencing outcome. One advantage of these models over models of focal cerebral 
ischaemia is their comparative surgical simplicity which means they are widely used to 
study cerebral ischaemia despite their questionable relevance to stroke.
a) Bilateral occlusion of the common carotid arteries. In this model originally described by 
Eklof & Siesjo (1972) the common carotid arteries are exposed and occluded by ligation 
either permanently, or more usually, transiently for periods from 10-60 minutes. This 
technique is usually combined with systemic hypotension induced by controlled 
haemorrhage (Kagstrom et al. 1983) that is necessary to reduce cerebral blood flow 
sufficiently to obtain reproducible ischaemic damage.
b) Four Vessel Occlusion. This model involves permanent bilateral occlusion of the 
vertebral arteries by electrocoagulation under anaesthesia followed by transient bilateral 
occlusion of the carotid arteries which may be carried out in conscious rats (Pulsinelli & 
Brierley, 1979).
Both these models of transient global ischaemia induce selective neuronal necrosis in 
selectively vulnerable areas of the brain such as the CA1 region of the hippocampus 
(Pulsinelli et al. 1982, Smith et al. 1984). Both 2 vessel occlusion and 4 vessel occlusion 
produce variable results between laboratories (reviewed in Ginsberg & Busto 1989). This 
variability may be attributable to several factors including: 1) variations in the collateral 
vascular supply both between and within strains (Ginsberg & Busto 1989) and 2) the 
failure to monitor and/or maintain brain temperature. Following global ischaemia brain 
temperature falls rapidly, independently of core body temperature, due to interruption of 
the entire blood supply to the cerebral hemispheres. Moderate hypothermia (34°C) has a 
marked neuroprotective effect in these models (Busto et al. 1987) so that failure to control 
brain temperature introduces unacceptable variability.
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1.3.2. Rat models of focal ischaemia
The majority of intracerebral strokes involve occlusion of the middle cerebral artery (Mohr 
etal. 1986). Consequently animal models of focal cerebral ischaemia are predominantly 
models of MCA occlusion. This technique was originally described in large species such 
as primates (Hudgins & Garcia 1970; Symon 1970) and cats (O'Brien & Waltz 1973) 
using a transorbital surgical approach to expose the MCA. A reproducible infarct in these 
models could only be achieved with strict control of physiological parameters. This 
problem of variability (Morawetz et al. 1978; Garcia 1984), and the advantages associated 
with using the rat as an experimental species (see above), led to the development of rat 
models of MCA occlusion.
1.3.2.1. Models of permanent focal cerebral ischaemia
al Permanent MCA occlusion. Unilateral MCA occlusion in the rat was first reported by 
Robinson et al. in 1975. They employed a large frontoparietal craniectomy to expose a 
portion of the MCA distal to its origin from the circle of Willis. Ligation of the distal MCA 
resulted in a lesion of variable size restricted to the cerebral cortex, with apparent 
differences in the consequences of left and right MCA occlusion (Robinson & Coyle 
1980). Later studies described a subtemporal approach that enabled the artery to be 
occluded closer to its origin (Albanese et al. 1980; Tamura et al. 1981a). The method 
reported by Tamura et al. has become the standard model of MCA occlusion in the rat 
although the artery is more frequently occluded by electrocoagulation rather than by a 
miniclip as described in the original articles (Tamura et al. 1981b). Proximal occlusion of 
the MCA results in a reproducible lesion incorporating a large proportion of the 
frontoparietal cortices and the dorsolateral caudate nucleus. The most consistent lesion is 
produced by electrocoagulation of the MCA from where it crosses the inferior cerebral vein 
distally to below the olfactory tract proximal to the lenticulostriate end-arteries that supply 
the caudate nucleus (Bederson et al. 1986).
The variability in lesion size produced by distal MCA occlusion can be reduced by 
combining the MCA occlusion with temporary contralateral and/or permanent ipsilateral 
common carotid artery occlusion (Chen et al. 1986; Brint et al. 1988) to reduce collateral 
perfusion of the MCA territory. However this still produces a lesion that is restricted 
predominantly to cerebral cortex with little sub-cortical necrosis. An alternative strategy to 
improve reproducibility of lesion size for either proximal (Duverger & Mackenzie 1988) or 
distal (Brint et al. 1988) MCA occlusion is to use spontaneously hypertensive rats (SHR) 
rather than a normotensive strain. MCA occlusion in SHR results in a large consistent 
lesion due to the absence of a well defined collateral circulation in this strain. However the
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greater severity of the ischaemic insult also makes the SHR more resistant to treatment 
strategies that are effective in normotensive strains (Roussel et al. 1992a). Thus the 
differences in cerebrovascular anatomy between SHR and normotensive rats should be 
borne in mind in the interpretation of studies conducted solely in SHR.
b) Photochemically induced focal cerebral ischaemia. This method, introduced by Watson 
et al. 1985, induces a thrombotic cortical infarct by directing a light beam through the skull 
onto an intravascular photosensitive dye such as rose Bengal. The light initiates a 
photochemical reaction that induces platelet aggregation and thrombus formation. By 
adjusting the position and intensity of the light beam a thrombus can be produced in any 
cortical location.
Permanent MCA occlusion in the rat has become the most commonly used model in both 
mechanistic and pharmacological studies of focal cerebral ischaemia. The variability in 
infarct volume lies within acceptable limits (Duverger & Mackenzie 1988) so that relatively 
small numbers of animals are required to show statistically significant neuroprotection in 
drug testing. In particular, the repeated demonstration of the efficacy of glutamate receptor 
antagonists in these models has led to the current emphasis on excitotoxic mechanisms as 
the main mediator of cerebral ischaemic damage. The main disadvantage of the Tamura 
model of MCA occlusion is that electrocoagulation of the vessel results in permanent 
ischaemia with no possibility of reperfusion through the MCA. The increasing frequency 
of recirculation following stroke in humans has therefore necessitated the development of 
animal models of transient ischaemia to investigate the potential beneficial and/or 
detrimental effects of reperfusion on infarct size. Investigation of the underlying 
pathophysiology in these models may reveal secondary mechanisms occuring within the 
reperfusion phase that play an equal, or even greater, role than glutamate in determining 
final outcome.
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1.3.2.2. Models of transient focal cerebral ischaemia
As for permanent MCA occlusion, models of transient focal ischaemia were first developed 
in large species such as the monkey (Crowell et al. 1970) and cat (Kamijyo et al. 1977) 
before being adapted for the rat. Several of the strategies used to induce permanent MCA 
occlusion can be modified to induce transient occlusion:
ai Extravascular MCA occlusion. Where an aneurysm clip or ligature has been used to 
occlude the MCA, simple removal of the occluder may initiate reperfusion (Shigeno et al. 
1985). Because of the practical difficulty involved in placement of the clip or ligature 
below the olfactory tract most of these models involve distal MCA occlusion and hence 
induce a purely cortical infarct. These methods may produce unsatisfactory results for 2 
reasons. Firstly, as discussed above, a single point occlusion of the MCA produces a more 
variable region of ischaemia than electrocoagulation of a longer portion of the artery due to 
the presence of collateral supply. Therefore the initial ischaemic insult in these models is 
more variable than that achieved by electrocoagulation of the MCA. Variability in blood 
flow during the ischaemic phase may in turn influence the degree of reflow during the 
reperfusion phase (Tamura et al. 1980). However as for permanent distal MCA occlusion, 
initial variability can be reduced by using carotid artery occlusion in tandem with MCA 
occlusion and/or by the use of SHR (Kaplan et al. 1991; Buchan et al. 1992b). Secondly, 
placement and removal of the occluder may result in mechanical damage to the vessel 
(Shigeno et al. 1985) which may prevent adequate reperfusion from occuring.
b) Thrombolysis of photochemicallv induced occlusion. By administration of thrombolytic 
drugs to resolve the clot the photo-thrombotic model can be converted to a model of 
transient occlusion (Watson et al. 1987) that is particularly suited to studying the efficacy of 
such treatment strategies.
ci Intravascular MCA occlusion. In these models, introduced by Koizumi et al. 1986 and 
Zea Longa et al. 1989, a surgical thread or filament is inserted into the common carotid 
artery and gradually advanced via the internal carotid artery to occlude the origin of the 
MCA in the circle of Willis. By leaving the thread in this position permanent MCA 
occlusion can be achieved. More frequently, reperfusion is initiated by withdrawal of the 
thread back into the internal carotid artery to allow blood to reach the MCA via the circle of 
Willis. While placement of the thread is performed under anaesthesia, restoration of blood 
flow can subsequently be induced in the conscious rat. The 2 models differ in the type of 
thread used to induce the intraluminal occlusion - either heat-blunted (Zea Longa et al. 
1989) or silicone-coated (Koizumi et al. 1986). When used by researchers outwith the 
original laboratories the Koizumi method has proven more reliable (Laing et al. 1993) due
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to the larger diameter of the silicone coated thread that results in a more consistent reduction 
in cerebral blood flow and therefore a more reproducible lesion.
The noninvasive nature of this approach means surgical damage to the brain parenchyma is 
avoided and intracranial pressure changes due to oedema formation are not ameliorated by 
craniectomy. However vascular (particularly endothelial) damage caused by insertion and 
removal of the intraluminal filament may contribute to the gross oedema and high mortality 
rates observed in these models (Hara et al. 1990; Koizumi et al. 1989; Zea Longa et al. 
1989).
d) Endothelin-1 Induced MCA Occlusion
Preliminary studies conducted at these laboratories have established the validity of this 
approach. Firstly application of endothelin-1 (10 5 M) to the MCA, surgically exposed as 
for permanent MCA occlusion, was demonstrated to cause severe reductions in local 
cerebral blood flow of approximately 75% in core MCA territory 10 min post-application of 
the peptide (Robinson et al. 1990). In a second series of experiments the dose-dependency 
and time course of this ischaemia were investigated (Macrae et al. 1993). Endothelin-1 
(lO 7 M-10*4 M in 25 pi) induced a rapid reduction in blood flow in the caudate nucleus 
that was maximal at 10 min, followed by progressive return of flow (Figure 3). The initial 
ischaemia and the duration of action (expressed as the time taken for flow to return to 50% 
of control) were dose-dependent (Figure 4). Finally histopathological studies revealed 
endothelin-1 induced dose-dependent ischaemic damage 4 h post-application of the peptide 
(Macrae et al. 1993). The location of the lesion (frontal and parietal cortices and 
dorsolateral caudate nucleus) and volume of damage at the highest dose (25 pi x 10A M) 
were comparable to that achieved with permanent proximal MCA occlusion. Further 
characterisation of this model, including extension of survival time beyond 4 h, will form 
the basis of my thesis.
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Figure 3 Time course for alterations in blood flow in the ipsilateral caudate nucleus 
following application of endothelin-1 to the middle cerebral artery in anaesthetised rats
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Blood flow was measured using the hydrogen clearance technique. Endothelin-1 
(filled symbols) induced a rapid, marked reduction in striatal blood flow 
compared to the saline control (open symbols). The ischaemia was maximal at 
approximately 10 min post-endothelin-1 application to the MCA and was 
followed by progressive restoration of blood flow. From Macrae et al. 1993.
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Figure 4 Dose-dependency of the severity and duration of 
striatal ischaemia induced by endothelin-1









The magnitude of a) the initial marked ischaemia induced by 
endothelin-1 and b) the duration of action (expressed as time taken 
for flow to return to 50% of original value) of the peptide are 
dose-dependent. Data derived from Figure 3. * p < 0.05 comparison 
with saline control. From Macrae et al. 1993.
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A superficially similar model has recently been described using intracortical, perivascular 
injection of endothelin-1 (120 pmol in 3 |il) to induce vasoconstriction of the MCA in 
conscious rats (Sharkey et al. 1993). This approach remains to be extensively 
characterised but, unlike our model, does not appear to induce reperfusion within 3 h of 
endothelin-1 application (Sharkey et al. 1993).
1.3.3. Histopathological Features of Ischaemic Damage
The type and extent of cell damage following experimental cerebral ischaemia depends both 
on the model used (focal or global) and the duration of the ischaemic insult. Transient 
global ischaemia results in delayed neurodegeneration that becomes apparent 1-3 days after 
induction of ischaemia (Kirino 1982; Pulsinelli et al. 1982). In these models neurones are 
selectively affected while other cellular elements within the brain remain morphologically 
normal. The neuronal necrosis is also selective in that it affects particular vulnerable 
populations of neurones such as pyramidal cells in the CA1 region of the hippocampus. As 
discussed previously models of global ischaemia do not mimic human stroke and the 
morphological changes observed are more similar to those found in the brains of patients 
who have suffered brief cardiac arrest which show evidence of selective neuronal necrosis 
in certain areas of the cortex, hippocampus and cerebellum at post-mortem (Graham 1977). 
Animal models of focal ischaemia result in cellular damage within the vascular territory of 
the occluded artery. The damage is initially restricted to neurones, but if the ischaemic 
insult is of sufficient duration then other cellular elements (oligodendrocytes, astrocytes, 
microglia and blood vessels) become recruited to the lesion to form a cerebral infarct 
which, by definition, must include all cell types within the affected tissue.
Following all types of hypoxia, neurones undergo a series of well defined morphological 
changes termed the ischaemic cell process. Ischaemic cell change was first described by 
Spielmeyer in 1922 (quoted in Brown 1977) and has subsequently been further 
characterised by others (Brown 1977). The ischaemic cell process proceeds via 4 stages 
from subtle changes in the cytoplasm to eventual complete cell loss as follows:
1) Microvacuolation: under the light microscope microvacuoles may be visible as small 
circular or oval spaces in the cytoplasm. Ultrastructural analysis has shown that 
microvacuoles are swollen mitochondria and endoplasmic reticulum. In this early stage the 
nucleus and cell body appear normal.
2) Ischaemic Cell Change: in the transition from microvacuolation to ischaemic cell change 
the cell body and nucleus become shrunken and triangular in shape, and the nucleolus
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disappears. The cytoplasm is eosinophilic and the nucleus is also densely stained.
3) Ischaemic Cell Change with Incrustations: in this stage further shrinkage of the 
cytoplasm and nucleus occurs. Small densely stained spherical bodies - incrustations - 
appear close to the cell surface. The incrustations are caused by indentation and 
compression of the cytoplasm by adjacent swollen astrocytic processes.
4) Homogenizing Cell Change: finally the cell undergoes progressive degeneration. The 
incrustations are lost and the cytoplasm becomes progressively paler and homogenous. 
Eventually this process leads to the formation of 'ghost cells' and ultimately cell loss.
The ischaemic cell process is a vital process requiring a minimal supply of energy to initiate 
it. Thus ischaemic cell change is most easily identifiable towards the edge of a lesion at the 
boundary between ischaemic and normal tissue where some degree of flow is maintained 
by the collateral circulation. Neurones within the core of an ischaemic region (e.g. 
dorsolateral caudate nucleus following permanent MCA occlusion) may appear 
morphologically normal due to the complete absence of cerebral blood flow. Such 
neurones are assumed to be within the infarcted region if they are totally surrounded by 
neurones demonstrating the characteristic morphology of ischaemic cell change.
The ischaemic cell process described above occurs only in neurones. Thus, strictly 
speaking, tissue exhibiting ischaemic cell change should not be referred to as an area of 
infarct but as 'an area exhibiting changes associated with early evidence of infarction'. The 
unstated assumption being that with continued ischaemia the selective neuronal necrosis 
will progress to infarction incorporating neurones, glia and blood vessels. At 4 h 
post-permanent MCA occlusion (the time point used for acute histopathological studies in 
this thesis) only the neuronal cell bodies and neuropil show evidence of necrosis. 
Neurones that have undergone ischaemic cell change appear triangulated and intensely 
stained with pyknotic nuclei (incrustations may also be present) while the surrounding 
neuropil is spongiform in appearance. By 24 h other cellular elements have been recruited 
to the lesion and a true infarct is formed.
In fixed tissue prepared for histology there are 3 types of artefact (dark cell change, 
hydropic cell change and perineuronal and perivascular spaces) that may be misinterpreted 
as evidence of hypoxic damage (Brown 1977). These artefacts arise from inadequate 
fixation or perfusion of the fixative at too low or too high a perfusion pressure, and thus 
can be minimised by careful monitoring of the fixation procedure. In general artefacts can 
be distinguished from true ischaemic cell change by their distribution outwith the territory 
supplied by the occluded vessel.
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1.4. MEDIATORS OF ISCHAEMIC/REPERFUSION INJURY
1.4.1. Energy failure and acidosis
The brain is unique in its reliance on the aerobic oxidation of glucose for its energy 
supply (Sokoloff 1981). Despite this dependence on glucose the carbohydrate stores in 
the brain are sufficient to maintain energy production for only 5 min (Pulsinelli 1985). 
Therefore depletion of oxygen and glucose following the onset of cerebral ischaemia has 
an immediate and potentially lethal effect upon cerebral energy metabolism. ATP and 
phosphocreatine levels fall to undetectable levels within 2 min of global ischaemia (Siesjo 
et al. 1990) at which point all energy-dependent processes will cease to function. In this 
respect failure of the Na+/K+/ATPase membrane pump resulting in rapid loss of ionic 
homeostasis may be of critical importance (Lees 1991). Failure of normal homeostatic 
mechanisms leads to an efflux of K+ from cells that is countered by entry of Na+, Cl' and 
water resulting in cytotoxic oedema formation (Yang et al. 1992). In addition loss of the 
Na+ gradient that normally drives glutamate re-uptake (Lees 1991) will lead to 
accumulation of this potentially cytotoxic neurotransmitter (see Section 1.4.3.).
In an attempt to maintain ATP levels during ischaemia any residual glucose will be 
metabolised anaerobically to lactic acid and C 02. Accumulation of lactate and C 0 2 
results in severe tissue acidosis during ischaemia (Kobatake et al. 1984; Mabe et al. 
1983). Acidosis can damage cells by inactivation or denaturation of enzymes and other 
proteins, alteration of neurotransmitter reuptake, disruption of mitochondrial function and 
promotion of free radical formation through the release of free Fe2+ (Siesjo et al. 1989; 
Welch & Barkley 1986). Lactic acid formation is dependent on the amount of glucose 
present (Gardiner et al. 1982), therefore tissue damage is more severe in hyperglycaemic 
animals (Duverger & MacKenzie 1988) particularly in regions of incomplete ischaemia, 
where a minimal glucose supply is maintained (Prado et al. 1988).
If complete energy failure is prolonged then cells will ultimately die, but mitochondrial 
function (assessed by restoration of normal ATP and phosphocreatine levels) can be 
recovered if reperfusion occurs within 1 h following global ischaemia (Pulsinelli & Duffy 
1983). However despite this recovery, cell damage may continue due to induction of a 
biochemical cascade of pathological events triggered by an increase in intracellular [Ca2+] 
during the ischaemic phase (see below). Similarly in the focal ischaemic penumbra (a 
border zone between the central ischaemic core and normal viable tissue where collateral 
perfusion is sufficient to maintain minimal ATP levels), alterations in Ca2+ homeostasis 
may be the critical factor in determining whether damage becomes irreversible.
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1.4.2. Calcium
Ca2+ plays an important role in many cell processes including the control of cell 
metabolism, enzyme function, intercellular signalling and growth and differentiation 
(Cheung et al. 1986). The precise regulation of intracellular Ca2+ levels is therefore 
critical for normal cell functioning. Under resting conditions, the free intracellular Ca2+ 
concentration ([Ca2+]i) of neurones is 10~7M while extracellular Ca2+ concentration is 
10 3M (Vibulsreth et al. 1987). This steep concentration gradient is normally maintained 
by 2 Ca2+-extruding pumps (a Ca2+-ATPase and an electrogenic Na+/ Ca2+exchanger 
energised by the Na+/K+-ATPase pump) and by active sequestration of Ca2+ into 
intracellular organelles such as endoplasmic reticulum and mitochondria (Siesjo & 
Bengttson 1989). Loss of normal Ca2+ homeostasis was first postulated as the 
mechanism of cerebral ischaemic injury in 1981. The Ca2+ hypothesis, as originally 
formulated, proposed that energy failure during ischaemia leads to elevated [Ca2+]j that 
activates a biochemical cascade of Ca2+-dependent processes resulting ultimately in cell 
death (Siesjo 1981).
Since the formulation of the Ca2+ hypothesis it has been repeatedly demonstrated that 
[Ca2+]j (measured directly or indirectly) increases during an ischaemic insult (Benveniste 
et al. 1988; Rappaport et al. 1987; Uematsu et al. 1989). This was originally thought to 
be due to Ca2+ entry through voltage-sensitive Ca2+ channels (VSCC) activated by 
membrane depolarisation as a result of ATP depletion (Harris et al. 1981). More recently 
the role of glutamate in causing Ca2+ influx (particularly via the NMDA receptor gated ion 
channel) has been recognised (Benveniste etal. 1988, see Section 1.4.3.). In addition to 
Ca2+ accumulation during focal ischaemia, further accumulation may occur after the onset 
of reperfusion following a period of transient focal ischaemia (Greenberg etal. 1991; 
Hara et al. 1990). This is probably due in part to free radical-induced inactivation of the 
Ca2+-extrusion pumps (Araki et al. 1992; Hirosumi et al. 1988) since [Ca2+]j does 
decline during the reperfusion phase following pre-treatment with the free radical 
scavenger superoxide dismutase (Araki et al. 1992). Thus Ca2+ accumulation may 
contribute to neuronal injury during both focal ischaemia and reperfusion.
Ca2+ has many potentially cytotoxic effects. Firstly Ca2+ can disrupt mitochondrial 
function by uncoupling oxidative phosphorylation that will lead ultimately to cellular 
dysfunction and death (Siesjo & Bengttson 1989). Secondly Ca2+ can activate several 
deleterious enzymatic pathways in the neurone that are detailed below. Ca2+ activates 
phospholipase A2, an enzyme that cleaves membrane phospholipids to release fatty acids 
including arachidonic acid. Once liberated arachidonic acid is rapidly converted, in the
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presence of oxygen, into prostaglandins, thromboxanes and leukotrienes via the 
cyclooxygenase and lipoxygenase pathways. These compounds can induce 
vasoconstriction, platelet aggregation and oedema formation which may exacerbate the 
original ischaemic insult (Kiwak et al. 1986). Moreover free radicals, produced as 
byproducts of arachidonic acid metabolism, can promote oxidative damage to membrane 
lipids, DNA and proteins (see Section 1.4.4.1.). Another source of free radical 
production is xanthine oxidase. This enzyme is produced from its normal form (xanthine 
dehydrogenase) by a Ca2+-activated protease. Free radicals are released when xanthine 
oxidase catalyses the conversion of hypoxanthine to uric acid (see Section 1.4.4.2.).
Ca2+ can also direcdy activate phospholipase C independent of a receptor coupled G 
protein (Verity 1992). Phospholipase C hydrolyses membrane phosphatidylinositides 
releasing 2 intracellular messengers inositol trisphosphate (IP3) and diacyl glycerol 
(DAG). IP3 promotes the release of further Ca2+ from intracellular stores, while DAG 
and Ca2+ activate protein kinase C. Protein kinase C regulates neuronal excitability by 
phosphorylation of membrane ion channels and can promote further Ca2+ influx via 
VSCC (Kaczmarek 1987).
The calpains are another family of Ca2+-activated proteases. The calpains can degrade 
cytoskeletal and membrane proteins (including receptors) and several enzymes (Melloni 
& Pontremoli 1989). Their capacity for causing severe cell damage is therefore 
considerable and calpain inhibitors can give significant protection against ischaemic 
damage (Rami & Krieglstein 1993).
By binding to the regulatory protein calmodulin (CaM) Ca2+ can activate a further series 
of enzymes including phospholipases, proteases and kinases that can cause further 
structural degradation (Grotta et al. 1990). Ca2+-CaM also stimulates nitric oxide 
production by activation of nitric oxide synthase. Nitric oxide is a free radical and may 
be an important mediator of excitotoxic and ischaemic damage (see Section 1.6.).
Due to the Ca2+ hypothesis of ischaemic cell injury VSCC antagonists have been 
investigated for potential neuroprotective efficacy in experimental ischaemia. The most 
commonly used Ca2+ antagonists are dihydropyridines e.g. nimodipine and nicardipine, 
and diphenylalkylamines e.g. flunarizine which bind to separate sites on the L-type Ca2+ 
channel (Wong et al. 1990). The results of studies utilising Ca2+ antagonists have been 
varied and contradictory. For example nicardipine and nimodipine have been reported to 
reduce Ca2+ accumulation during permanent focal ischaemia (Hadani et al. 1988) and in 
the reperfusion phase following transient focal ischaemia (Greenberg et al. 1991; Hara et
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al. 1990) while flunarizine did not prevent Ca2+ accumulation following global ischaemia 
(Hossmann et al. 1983). Similarly for histopathological studies, Ca2+ channel 
antagonists reduce ischaemic damage in some reports (Hara et al. 1990; Sauter & Rudin 
1986) but not others (Hossmann et al. 1983; Vibulsreth et al. 1987, and see Hossmann 
1989 for comprehensive review). Overall it appears that Ca2+ channel antagonists are 
more effective when administered prior to the onset of ischaemia (Mohammed et al. 
1985) rather than following it (Gotoh et al. 1986). This beneficial effect may be mediated 
by increased cerebral blood flow rather than prevention of neuronal Ca2+ influx (Gotoh et 
al. 1986).
The failure of VSCC antagonists to reliably reduce ischaemic damage probably reflects 
the multiple routes of Ca2+ influx and release that converge to increase [Ca2*], following 
ischaemia. The more recent development of N-type Ca2+ channel antagonists e.g. 
CNS1145 that inhibit glutamate release from presynaptic terminals may prove more 
effective as anti-ischaemic agents, by interrupting the ischaemic cascade upstream from 
the rise in [Ca2+]j (McBumey et al. 1992).
1.4.3. Glutamate
The dicarboxylic amino acids glutamate and aspartate are the main excitatory 
neurotransmitters in the brain (Monaghan etal. 1989). While activation of excitatory 
amino acid (EAA) receptors is essential for normal neuronal functioning, prolonged 
exposure to EAA can be neurotoxic. This was first demonstrated by Lucas and 
Newhouse (1957) who found that high concentrations of glutamate induced degeneration 
of mouse retinal neurones. The neurotoxicity of glutamate was confirmed by Olney and 
coworkers who showed that exogenous glutamate caused neuronal lesions within the 
brain (Olney et al. 1971; Olney 1978). The close correspondence between the excitatory 
and neurotoxic properties of a range of glutamate analogs led Olney to formulate the 
excitotoxic hypothesis in which he postulated that overactivation of EAA receptors was 
responsible for glutamate-induced neuronal death (Olney etal. 1971).
Before further reviewing the evidence that implicates glutamate in both excitotoxic and 
ischaemia-induced cell death it is necessary to introduce the basic physiology and 
pharmacology of glutamatergic neurotransmission. Glutamate and its related EAA 
agonists act at 5 different receptor subtypes, each with distinct pharmacological and 
physiological properties, which may be colocalised within a single synaptic unit. The 
EAA receptor subtypes, named according to their most selective agonists, are: N-methyl-
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D-aspartate (NMDA); kainate; amino-3-hydroxy-5-methyl-isoxazole-4-propionate 
(AMPA, previously known as the quisqualate receptor); fra/is-1-amino-cyclopentyl-1,3- 
dicarboxylate (rra/i.y-ACPD, also called the metabotropic receptor) and 2-amino-4- 
phosphonobutyrate (AP4), (Monaghan et al. 1989). The NMDA, kainate and AMPA 
receptors are ionotropic i.e. coupled to an ion channel whereas signal transduction at the 
trans-ACPD receptor is mediated via phosphoinositide hydrolysis (Monaghan et al.
1989). The AP4 receptor may also be linked to a second messenger system involving 
cGMP hydrolysis and suppression of pre-synaptic glutamate release (Gasic & Hollmann 
1992). Glutamatergic transmission via these receptor subtypes is discussed below and 
summarised in Figure 5.
Fast excitatory synaptic transmission is mediated by AMPA and kainate receptors whose 
ion channels are selectively permeable to Na+ and K+ (although certain isoforms also 
permeable to Ca2+ have been identified (lino et al. 1990)). AMPA receptors are 
selectively antagonised by 2,3-dihydroxy-6-nitro-7-sulfamoxylbenzo(F)quinoxaline 
(NBQX), whereas other related compounds e.g. 6-cyano-7-nitro-quinoxaline-2,3-dione 
(CNQX) show limited selectivity between AMPA and kainate receptors (Monaghan et al.
1989). The NMDA receptor-gated ion channel, permeable to Ca2+ as well as Na+ and 
K+, does not contribute to normal synaptic transmission due to the presence of a 
voltage-dependent blockade of the ion channel by Mg2+ (MacDermott & Dale 1987). 
Removal of this Mg2+ block occurs during prolonged depolarisation which subsequently 
allows Ca2+ influx into the post-synaptic neurone (MacDermott & Dale 1987).
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Figure 5 Schematic representation of a glutamatergic synapse
Glutamate released from the pre-synaptic terminal mediates fast synaptic transmission via 
the AMPA and kainate receptors which are permeable to Na+ and K+. Subsequent 
membrane depolarisation removes the Mg2+-blockade of the NMDA receptor-gated ion 
channel allowing Ca2+ influx into the post-synaptic neurone. Intracellular Ca2+ can also be 
increased via the trans-ACPD  receptor that stimulates mobilisation of Ca2+ from 
intracellular stores. At certain synapses glutamate interacts with the presynaptic AP4 
receptor to inhibit further glutamate release. Overactivation of post-synaptic glutamate 
receptors is also prevented by a high affinity, Na+-dependent glutamate uptake mechanism, 
present in both neurones and glia, that removes glutamate from the extracellular space.
Abbreviations: NMDA: N-methyl-D-aspartate; AMPA: amino-3-hydroxy-5-


























































The activity of the NMDA receptor-ion channel complex can be modulated at several 
distinct pharmacological sites located both on the receptor and within the ion channel 
(Monaghan et al. 1989). Glutamate and NMDA binding to the transmitter recognition site 
can be inhibited by competitive antagonists including 2-amino-5-phosphonovalerate 
(AP5) and 3-(2-carboxypiperazin-4-yl)propyl-l-phosphate (CPP). Glycine acts as a 
positive allosteric modulator at the strychnine-insensitive glycine binding site, and is 
necessary for agonist-activation of the receptor. Analogues of the non-selective 
excitatory amino acid antagonist kynurenate e.g. 7-chlorokynurenate act as selective 
antagonists at this site. Ifenprodil and related compounds act as antagonists at another 
allosteric modulatory site - the polyamine site (Carter et al. 1989). Within the ion 
channel, the divalent cations Mg2+ and Zn2+ can bind at separate sites to inhibit 
transmembrane ion flux. Finally, another class of antagonists including the dissociative 
anaesthetics ketamine and phencyclidine (PCP) bind at the phencyclidine site within the 
open channel. These noncompetitive antagonists are use-dependent in that an agonist 
must bind to the receptor and open the ion channel before the antagonist in turn can bind 
to its site. Dibenzocyclohepteneimine (MK-801), which is structurally related to PCP, is 
a more selective and potent antagonist at this site.
The trans-ACPD receptor, of which several subtypes have been proposed (Schoepp et al.
1990), is linked via a G protein to phospholipase C which hydrolyses phosphoinositide 
to release inositol-tris phosphate (IP3) and diacyl glycerol. IP3 stimulates the release of 
Ca2+ from intracellular stores. This receptor is also activated by quisqualate but is 
insensitive to AMPA. 2-amino-3-phosphonoproprionate (AP3) is a relatively selective 
antagonist at the trans-ACPD receptor (more accurately a weak partial agonist, Schoepp et 
al. 1990).
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In vitro experiments have established that excess glutamate is toxic to neurones and that 
the excitotoxic process involves 2 distinct components: 1) acute neuronal swelling due to 
depolarisation-mediated influx of Na+, Cl* and water and 2) delayed neuronal 
degeneration due to excessive Ca2+ influx mainly through the NMDA receptor gated ion 
channel (Choi 1987). Elevation of intracellular [Ca2+] promotes injury by activation of 
the cascade of potentially toxic pathways described in Section 1.4.2., and the Ca2+ 
accumulation induced by glutamate has been found to closely correlate with the extent of 
neuronal damage (Hartley et al. 1993). Although the NMDA receptor complex represents 
the major receptor gated ion channel for Ca2+ entry, the role of other EAA receptors is 
also of importance (Courtney et al. 1990). Membrane depolarisation following activation 
of AMPA and kainate receptors removes the Mg2+ blockade of the NMDA receptor ion 
channel and also allows Ca2+ influx through voltage-dependent Ca2+ channels. 
Intracellular Ca2+ can also be increased by activation of the trans-ACPD receptor which 
promotes release of Ca2+ from intracelluar stores. The importance of interactions 
between EAA receptor subtypes in mediating the increase in intracellular Ca2+is 
illustrated by the fact that both NMDA antagonists (Choi et al. 1988) and non-NMDA 
antagonists (Frandsen etal. 1989) are neuroprotective against glutamate toxicity in vitro.
EAA receptor antagonists were subsequently shown to inhibit hypoxic damage in vitro 
(Goldberg et al. 1987; Rothman 1984). This observation led to the extension of the 
excitotoxic hypothesis to propose that glutamate-induced neurotoxicity also underlies 
ischaemic neuronal damage. Under normal physiological conditions, the potential 
toxicity of glutamate is limited by a highly efficient, Na+-dependent glutamate uptake 
carrier system present in the plasma membranes of both glia and presynaptic neurones 
(Nicholls & Atwell 1990). Due to this efficient uptake mechanism glutamate must be 
administered at high concentrations (100 pM-1 mM with up to 30 min exposure time) to 
induce neurotoxicity in vitro (see Meldrum & Garthwaite 1991 for review). If the normal 
Na+ or K+ gradients are lost, e.g. by failure of the Na+/K +/ATPase pump during 
ischaemia, then the resultant decrease in the thermodynamic driving force for glutamate 
uptake means the glutamate carrier will reverse its direction and release glutamate into the 
extracellular space (Szatkowski et al. 1990). Thus simulated ischaemic conditions in 
vitro both potentiates the toxicity of exogenous glutamate (Novelli et al. 1988) and leads 
to accumulation of endogenous glutamate in the extracellular space (Cazevieille et al. 
1993; Pellegrini-Giampietro et al. 1990).
In vivo extracellular concentrations of glutamate and aspartate are dramatically elevated 
during global (Benveniste et al. 1984) and permanent focal ischaemia (Butcher et al.
1990), and there is a high correlation between the extent of ischaemic damage and the
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extracellular EAA concentration (Butcher et al. 1990; Gemba et al. 1992). However the 
most convincing evidence for a pivotal role of glutamate in the mediation of ischaemic 
damage in vivo is the significant protection achieved with both NMDA and non-NMDA 
receptor antagonists in a range of animal models (see McCulloch et al. 1991 for review). 
The neuroprotective action of NMDA receptor antagonists was first demonstrated in 
models of transient global ischaemia (Simon et al. 1984; Swan & Meldrum 1990). 
However neuroprotection in these early studies has subsequently been attributed to the 
hypothermia induced by NMDA receptor antagonists and/or the anticonvulsant action of 
these drugs (Buchan & Pulsinelli 1990; Ginsberg & Busto 1989). When brain 
temperature is strictly controlled the neuroprotective action of NMDA antagonists against 
global ischaemic damage is less dramatic (Gill & Woodruff 1990) or completely 
abolished (Buchan et al. 1991). It may be that the severe acidosis that occurs during 
global ischaemia (which can reduce Ca2+ influx through NMDA receptor gated ion 
channels (Takadera et al. 1992)) acts to limit NMDA receptor-mediated toxicity and 
thereby increase the relative importance of non-NMDA receptor mechanisms of injury. 
Thus AMPA receptor antagonists such as NBQX are neuroprotective in models of global 
ischaemia (Nellgard & Wieloch 1992; Sheardown et al. 1990).
In permanent focal ischaemia both competitive (Bullock et al. 1990) and noncompetitive 
(Park et al. 1988) NMDA receptor antagonists provide significant neuroprotection. In 
addition the noncompetitive antagonist MK-801 is equally effective when administered 
either pre- or 30 min post-permanent MCA occlusion in the rat (Park et al. 1988). Pre- or 
post-treatment with AMPA receptor antagonists also significantly reduces the volume of 
ischaemic damage following permanent MCA occlusion, but in this model AMPA 
antagonists are less efficacious than NMDA receptor antagonists (Gill et al. 1992). In 
contrast to permanent focal ischaemia the efficacy of EAA receptor antagonists against 
transient focal ischaemic damage has received little attention in the published literature. 
Therefore in this thesis the neuroprotective efficacy of MK-801 will be assessed using the 
endothelin-1 model of transient focal ischaemia.
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1.4.4. Free Radicals
A free radical is defined as any atom or molecule that contains one or more unpaired 
electrons (Halliwell 1989). Free radicals can be based on any atom but oxygen radicals are 
particularly implicated in ischaemic-reperfusion injury. Molecular oxygen can form
radicals by sequential, univalent reductions that produce superoxide (0 2#"), hydrogen 
peroxide (H20 2) and hydroxyl radicals (*OH) by the following reactions:
0 2 + le_ — > 0 2*- (1)
2 0 2*” + 2H+ —> H20 2 + 0 2 (2)
H20 2 + Fe2+ —> OH* + OH- +  Fe3+ (Fenton Reaction) (3)
H20 2 is not a free radical and is a comparatively weak oxidising agent. However because 
it is non-polar it can cross cell membranes and mediate local toxicity by generating highly 
reactive hydroxyl radicals. The Fe3+ formed in this reaction is then converted back to Fe2+ 
by reaction with superoxide:
Fe3+ + 0 2.- — > Fe2+ + 0 2 (4)
Combination of equations 3 and 4 gives the Haber-Weiss reaction:
Fe catalyst
0 2*- + H20 2 —> OH" + *OH + 0 2
Because the hydroxyl radical is more reactive than either superoxide or hydrogen peroxide, 
much of the toxicity of these 2 radicals is thought to be mediated by their combination to 
form hydroxyl radicals via the Haber-Weiss reaction. This reaction is dependent on a free 
iron catalyst which in vivo is normally derived from the metalloproteins ferritin or 
haemoglobin (Halliwell 1989).
1.4.4.1. Mechanisms of free radical induced tissue damage
Most free radicals are highly reactive. The presence of an unpaired electron means that 
radicals can initiate and propagate chain reactions since when a radical reacts with a 
nonradical another free radical must be formed. In vivo oxygen radicals can react with and
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damage proteins, DNA and membrane lipids.
Lipid Peroxidation. The structure of polyunsaturated fatty acids makes them highly
susceptible to *OH damage. The reaction is initiated by #OH abstracting a hydrogen atom 
from a carbon in the fatty acid chain to produce a lipid radical. This molecule then 
rearranges to form a conjugated diene which subsequently reacts with molecular oxygen to 
form a peroxy radical. This radical can then propagate the chain reaction by abstracting 
another H atom from a neighbouring fatty acid.
Lipid peroxidation can be detected by measuring the specific ultraviolet absorbance of 
conjugated dienes or more indirectly by the TB ARS (thiobarbituric acid reactive substance) 
test that detects a pink chromogen formed by the reaction of the peroxidation by-product 
malondialdehyde with thiobarbituric acid. However this test has been criticised for its 
nonspecificity and lack of correlation with other assays (Valenzuala 1991).
The brain membrane lipids are rich in polyunsaturated fatty acid side chains that make the 
brain particularly vulnerable to lipid peroxidative damage (Halliwell 1989). Lipid 
peroxidation initiates cross-linking between different membrane lipids and between lipids 
and membrane proteins that compromise the structural integrity of the membrane, 
decreasing its fluidity while increasing its permeability (Watson & Ginsberg 1989). 
Neuronal injury due to lipid peroxidation may be secondary to vascular injury in that free 
radical induced increases in the permeability of the cerebrovasculature may lead to the 
accumulation of vasogenic oedema (Kontos 1989).
In global ischaemia models, lipid peroxidation (estimated by the TBARS method) is 
negligible during ischaemia but increases on reperfusion to peak 30 min to several hours 
post-ischaemia depending on the severity of the original ischaemic insult (Bromont et al. 
1989; Yoshida et al. 1980). Using the more specific conjugated diene method significant 
increases in whole rat cortex have been reported (Sakamoto et al. 1991; Vanella et al.
1992), while others have found only small localised changes (Watson et al. 1984). 
Following transient focal ischaemia increases in conjugated dienes are very limited 
(Ginsberg et al. 1988) leading these authors to suggest that lipid peroxidation is not an 
important mediator of free radical induced damage (Ginsberg et al. 1988).
Protein and DNA oxidation Oxidation of proteins by free radicals can cause enzyme 
inactivation, cytoskeletal disruption and affect the conformational integrity of proteins so 
that they are recognised as 'foreign' by the immune system (Siesjo et al. 1989). Oxidative 
damage to proteins (assessed by increased protein carbonyl content) increases during the 
reperfusion phase following transient global ischaemia (Oliver et al. 1990). Oxidative
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inactivation of glutamine synthetase, the enzyme that degrades L-glutamate, may be of 
particular importance in relation to ischaemic/reperfusion injury since excess glutamate is 
neurotoxic. Glutamine synthetase is inactivated by oxygen free radicals in vitro (Schor 
1988). Following transient global ischaemia whole cortex glutamine synthetase activity is 
decreased during the first 3 hours of reperfusion (Oliver et al. 1990), although with longer 
reperfusion periods enzyme activity recovers (Oliver et al. 1990) and may even increase 
(Petito et al. 1992) due to astrocytic proliferation.
Free radicals can also damage DNA by strand breakage and modification of the nucleic acid 
bases (Floyd & Carney 1992). Subsequent activation of poly(ADP-ribose) synthetase to 
repair the strand breaks may further deplete energy supplies already compromised by 
ischaemia.
It has been suggested that free radical induced damage to proteins and DNA is more 
important in the pathogenesis of ischaemic-reperfusion injury than lipid peroxidation 
(Watson & Ginsberg 1989). However in some models of global and transient focal 
ischaemia no protein or DNA damage is detectable (Folbergrova et al. 1993; Krause et al. 
1992; White etal. 1992).
1.4.4.2. Sources of free radicals during ischaemia and reperfusion
Mitochondria The limited oxygen supply during ischaemia means that components of the 
electron transport chain (e.g. FAD) become reduced. With reperfusion the reduced 
molecules undergo autooxidation with generation of superoxide.
Xanthine Oxidase Production of free radicals via the xanthine oxidase pathway was first 
proposed by McCord from studies of intestinal ischaemia (McCord 1985). During 
ischaemia ATP can not be regenerated so that AMP levels increase. The AMP is 
catabolised via adenosine and inosine to hypoxanthine which accumulates during ischaemia 
(Hagberg et al. 1986; Hillered et al. 1989) Hypoxanthine is normally metabolised by 
xanthine dehydrogenase, but under ischaemic conditions this enzyme is converted to an 
oxidase by Ca2+-dependent proteolysis. With the restoration of oxygen during reperfusion 
xanthine oxidase catalyses the conversion of hypoxanthine to uric acid with the formation 
of superoxide.
Infusion of xanthine oxidase into the caudate nucleus induces oedema formation and 
neuronal injury (Chan et al. 1984). However the importance of this pathway as a source of 
free radicals during cerebral ischaemia-reperfusion is still debatable. Significant conversion
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of xanthine dehydrogenase to xanthine oxidase occurs following global ischaemia (Kinuta 
et al. 1989; Vanella et al. 1992), but only moderate (Lindsay et al. 1991) or no (Betz et al. 
1991) increases have been reported following permanent focal ischaemia. Free radicals 
produced by this mechanism are more likely to be formed in the cerebrovasculature since 
xanthine oxidase activity is higher in brain endothelial cells than brain parenchyma (Betz 
1985).
Arachidonic Acid Metabolism During ischaemia Ca2+ activation of phospholipases results 
in release of free arachidonic acid from membrane phospholipids (see Section 1.4.2.). 
With the restoration of oxygen supplies, metabolism of arachidonic acid by the 
cyclooxygenase and lipoxygenase pathways is initiated generating radical forms of 
prostaglandin H (PGH) synthase and the lipoxygenases. These enzyme radicals can
abstract hydrogen atoms from NADH or NADPH to produce free radical forms (NAD* or
NADP*) which in turn react rapidly with molecular oxygen to release superoxide (Kubreja 
et al. 1986; Chan et al. 1988). NMDA agonists have also been shown to generate 
superoxide by a Ca2+- and arachidonic acid-dependent process in vitro (Lafon-Cazal et al.
1993).
Intracerebral injection of arachidonic acid induces brain oedema (Chan et al. 1983) by a 
mechanism involving superoxide (Chan & Fishman 1980). However arachidonic acid can 
also induce membrane permeability changes independent of free radical mediated 
mechanisms (Villacara etal. 1989).
Polymorphonuclear Leucocytes and Macrophages During reperfusion these blood-borne 
cells may accumulate within the brain (see Section 1.4.5.). Prostaglandins and 
leukotrienes can activate NADPH oxidase in these cells resulting in the generation of 
superoxide (Lunec 1990). Leukocytes in turn can synthesize further prostaglandins and 
leukotrienes and thereby release more radicals.
Acidosis The accumulation of lactic acid under ischaemic conditions promotes the 
dissociation of protein-bound iron (Bralet et al. 1992; Rehncrona et al. 1989). Superoxide 
formed by one or more of the pathways discussed above would then be able to react with 
the free iron and form hydroxyl radicals via the Haber-Weiss reaction. In support of this 
mechanism infusion of Fe2+ into the rat cortex has been demonstrated to induce lipid 
peroxidation and oedema formation (Willmore & Rubin 1982).
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These potential pathways for free radical production are summarised in Figure 6. It can be 
seen that complete ischaemia 'primes' the brain for the generation of free radicals by 
inducing the formation of the necessary substrates. However free radical production in 
appreciable quantities is only initiated with the restoration of adequate oxygen supplies 
during reperfusion. In support of this theory increased oxygen levels during early 
reperfusion have been reported to exacerbate ischaemic damage (Halsey et al. 1991; Mickel 
et al. 1987) presumably by enhancement of free radical formation. The development of spin 
trapping techniques has enabled direct measurement of free radicals by electron spin 
resonance spectroscopy. These techniques show that low levels of free radicals are 
generated during global ischaemia (presumably because blood flow is not completely 
abolished) while at the onset of reperfusion a burst of free radical production occurs which 
then slowly decays back to the ischaemic level after 30-60 min reperfusion (Sakamoto et al. 
1991; Zini et al. 1992). Thus most free radical induced damage is likely to occur when 
blood flow is restored to previously ischaemic tissue, and free radicals may therefore be a 
major contributor to reperfusion injury.
1.4.4.3. Pharmacological inhibition of free radical-associated cerebral injury
The most convincing, though indirect, evidence for the involvement of oxygen radicals in 
ischaemic brain injury is the reported neuroprotective action of several antioxidant and 
radical scavenging drugs. Pharmacological treatment strategies aimed at reducing free 
radical damage can be divided into 3 types:
1) Scavenging of free radicals bv nonenzvmatic antioxidants
The endogenous antioxidants alpha-tocopherol (Vitamin E), ascorbic acid (Vitamin C) and 
glutathione can scavenge oxygen radicals in the normal brain. However under ischaemic 
conditions the concentration of these antioxidants falls (Kinouchi et al. 1991; Lyrer et al. 
1991; Uemura et al. 1991), due to reaction with free radicals (Hogg et al. 1993). This may 
compromise the ability of the brain to scavenge free radicals during reperfusion since it has 
been demonstrated that chemical depletion of glutathione prior to onset of ischaemia can 
exacerbate tissue damage (Mizui et al. 1992). To compensate for this effect, systemic 
adminstration of the lipophilic alpha-tocopherol prior to induction of global ischaemia 
reduces lipid peroxidation (Vanella et al. 1992) and improves neurological outcome 
(Yamamoto etal. 1983).
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Figure 6 Schematic representation of the generation of free radicals following ischaemia 
and reperfusion
The acidosis, energy store depletion and increase in free intracellular Ca2+ that occur during 
an ischaemic insult (described in more detail in the text) prime the brain for generation of 
free radicals following the onset of reperfusion and concomitant restoration of oxygen 
supplies. In addition invasion of blood-borne leucocytes from the periphery during 
reperfusion introduces another potential source of free radicals. The radicals can then 






















































































































c c o U S <  W S  hh < D
31
Spin-trapping agents such as phenyl-t-butyl-nitrone are essentially oxygen radical 
scavengers and can reduce ischaemic damage (Yue et al. 1992). Dimethylthiourea, a 
hydroxyl scavenger, can reduce ischaemic damage and oedema formation following 
permanent focal ischaemia (Martz et al. 1989) by a mechanism independent of changes in 
cerebral blood flow (Martz et al. 1990).
Tirilizad (U74006F) is one of a group of compounds, the 21-aminosteroids, that inhibit 
lipid peroxidation in vitro by a variety of mechanisms including free radical scavenging. 
The anti-ischaemic efficacy of tirilizad is controversial as it reduces ischaemic cell damage 
and oedema formation in some animal models but not others (reviewed in Hall 1993).
2) Scavenging bv specific enzvmes
Three enzymes - superoxide dismutase (SOD), catalase and glutathione peroxidase - exist 
specifically to 'detoxify' oxygen radicals (Freeman & Crapo 1982). SOD, which exists in 
2 forms (Mn-SOD in mitochondria; CuZn-SOD in cytosol) catalyses the dismutation of 
superoxide to produce hydrogen peroxide;
SOD
202** + 2H+ -----> H2O2 + O2
To prevent formation of hydroxyl radicals, catalase and glutathione peroxidase then 
convert the hydrogen peroxide to water by the following reactions:
catalase
2 H 2 O 2  ------->  2 H 2 O  +  O 2
glutathione peroxidase 
H20 2 + 2 glutathione -----> 2H20  + glutathione disulphide.
Levels of these 3 enzymes are relatively low in the brain (Schmidley 1990). Glutathione 
peroxidase is relatively resistant to ischaemia, but SOD is depleted following permanent 
focal ischaemia (Michowiz et al. 1990; Imaizumi et al. 1989). Transgenic mice that 
overexpress CuZn-SOD (3.1-fold higher than control) show significantly less oedema and 
a reduced infarct size following permanent focal ischaemia than their nontransgenic controls 
(Kinouchi et al. 1991).
Pretreatment with SOD conjugated to polyethylene glycol (PEG) (in order to prolong the 
plasma half-life of SOD) either alone (He et al. 1993; Matsumiya et al. 1991) or in 
combination with PEG-catalase (Liu et al. 1989) reduces the volume of ischaemic damage
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following transient focal ischaemia in cats and rats. The site of action of PEG-SOD is 
probably intravascular as PEG-SOD has a very slow uptake rate into the brain (Yoshida et 
al. 1992). Liposomal entrapped SOD (designed to facilitate access to the brain) also 
reduces ischaemic damage and oedema formation following permanent focal ischaemia in 
rats (Imaizumi et al. 1990). However post-ischaemic treatment with either PEG-SOD 
(Matsumiya et al. 1991) or liposome-entrapped SOD (Chan 1992) is ineffective.
31 Inhibition o f Xanthine Oxidase
Pre-treatment with the xanthine oxidase inhibitors allopurinol and oxypurinol reduces 
neuronal damage and oedema following permanent focal ischaemia (Betz et al. 1991; Martz 
et al. 1989; Lindsay et al. 1991). Oxypurinol is also effective 1 h post-onset of ischaemia 
(Lin & Phillis 1991). However the neuroprotective doses of allopurinol are higher than 
those necessary to inhibit xanthine oxidase suggesting allopurinol may be acting by another 
mechanism - possibly as a hydroxyl radical scavenger (Moorhouse et al. 1987).
1.4.4.4. Interactions between glutamate neurotoxicity and free radical-induced cell damage
The exact relationship between these 2 mechanisms of cell injury remains undetermined, 
but increasing evidence suggests they form part of a common pathway. The 
glutamate-induced elevation in intracellular Ca2+ can stimulate free radical production via 
arachidonic acid metabolism, xanthine oxidase production and activation of nitric oxide 
synthase (see Section 1.4.2. and Lafon-Cazal et al. 1993). In addition glutamate may 
stimulate free radical production by a mechanism independent of the ionotropic and 
metabotropic receptors (Bondy & Lee 1993). Thus free radicals may be an important 
mediator of glutamate toxicity. In support of this a variety of free radical scavengers 
attenuate glutamate-induced neurotoxicity in vitro (Miyamoto et al. 1989; Monyer et al. 
1990; Yue et al. 1992) and cultured neurones derived from transgenic mice overexpressing 
CuZn-SOD show increased resistance to glutamate-induced neuronal swelling and cell 
death (Chan etal. 1990). A bidirectional cooperativity may exist between glutamate and 
free radicals because free radicals can also promote further glutamate release (Gilman et al. 
1992; Pellegrini-Giampetro etal. 1988) that can be attenuated by free radical scavengers 
(Cazevieille et al. 1993; Pellegrini-Giampetro et al. 1990). Combined treatment with the 
free radical scavenger dimethylthiourea and the NMDA receptor antagonist MK-801 has no 
additive effect on oedema formation following permanent focal ischaemia (Oh & Betz 
1991) suggesting free radicals and glutamate promote oedema formation in vivo by a 
common mechanism.
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1.4.5. Leucocytes and mediators of inflammation
Leucocytes, both polymorphs and monocytes/macrophages, have been implicated in the 
pathogenesis of cerebral ischaemic damage. Originally the delayed accumulation of 
leucocytes seen several days after the onset of stroke (Alcala et al. 1978) or permanent 
MCA occlusion (Garcia & Kamijyo 1974) led to the hypothesis that leucocytes were only 
involved in the phagocytic removal of dead tissue and scar formation (Kochanek & 
Hallenbeck 1992). However it has recendy become apparent that leucocyte accumulation is 
much more pronounced following transient focal ischaemia. Leucocytes accumulate in 
brain microvessels within 1 h of reperfusion following MCA occlusion (del Zoppo et al. 
1991) and begin to infiltrate brain parenchyma within the MCA territory by 3 h (Shiga et al.
1991), with marked infiltration at 24 h (Barone et al. 1992; Shiga et al. 1991). This early 
accumulation of leucocytes following transient focal ischaemia raises the possibility that 
leucocytes may be directly involved in ischaemic/reperfusion injury.
There are several possible mechanisms by which leucocytes could contribute to 
reperfusion-injury (Kochanek & Hallenbeck 1992). Firstly leucocytes may induce 
post-ischaemic hypoperfusion by physically occluding brain capillaries or by the release of 
vasoconstrictive prostaglandins and leukotrienes. Depletion of leucocytes prior to 
induction of ischaemia or reperfusion has been shown to reduce post-ischaemic 
hypoperfusion following transient global ischaemia in rats (Grogaard et al. 1989) and 
transient MCA occlusion in baboons (Mori et al. 1992). Secondly the release of a variety 
of potentially harmful mediators (Weismann et al. 1980) including glutamate (Piani et al.
1991), leukotrienes, free radicals, platelet activating factor, proteases and cytokines (see 
below) could induce direct cell damage, vasoconstriction and increased vascular 
permeability leading to oedema formation. Depletion of leucocytes reduces both the 
amount of oedema and volume of ischaemic damage assessed 24 h following transient 
MCA occlusion in rats (Chen et al. 1992; Shiga etal. 1991).
The cytokines are a family of peptides synthesized and released by macrophages, microglia 
and other cell types that mediate a diverse range of physiological functions related to the 
immune system, cell growth and repair. (Rothwell 1991). Within the CNS attention has 
focussed on interleukin-1 (IL-1) as a possible mediator of both beneficial and detrimental 
responses following brain injury. IL-1 is constitutively expressed at low levels in neurones 
and glia (Yao et al. 1992), but following brain injury or stimulation by lipopolysaccharide, 
activated microglia dramatically increase their production of IL-1 (Giulian et al. 1988; Yao 
etal. 1992). IL-1 has been proposed to mediate wound healing by inducing nerve growth 
factor (Rothwell 1991), and promoting astrogliosis and neovascularisation (Giulian et al. 
1988). More recently induction of IL-16 mRNA has been reported following permanent
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MCA occlusion in SHR (Liu et al. 1993) and within 15 min of the onset of reperfusion 
following transient global ischaemia (Minami et al. 1992). The timing of the peak levels of 
IL-1B mRNA in these studies (12 h and 4 h respectively) suggests the IL-1 could be 
derived from both intrinsic microglia and invading monocytes/macrophages from the 
periphery.
While IL-1 is postulated to play a beneficial role by promoting growth and repair following 
brain injury, some of its actions may be detrimental in the context of cerebral ischaemia. 
IL-1 is pyrogenic (Rothwell 1991), and hyperthermia is known to exacerbate ischaemic 
damage (Morikawa et al. 1992a; Xue et al. 1992a). In addition IL-1 can stimulate 
arachidonic acid metabolism and induce NO synthase (Rothwell 1991), both of which may 
promote free-radical damage and increase oedema formation. In support of this zinc 
protoporphyrin, a selective IL-1 antagonist, decreases oedema 24 h following 1 h transient 
MCA occlusion in the rat, while intracerebral administration of IL-1 exacerbates oedema 
formation in the same model (Yamasaki et al. 1989). Intraventricular administration of an 
IL-1 receptor antagonist (IL-lra) has also been reported to reduce the volume of ischaemic 
damage (assessed from TTC stained sections) 24 h post-permanent MCA occlusion (Relton 
& Rothwell 1992). IL-1 may also be directly implicated in excitotoxidty since pre-infusion 
of EL-Ira reduces the volume of striatal damage induced by the selective NMDA agonist 
cis-2,4-methanoglutamate (Relton & Rothwell 1992). In contrast interleukin-6 , the 
synthesis of which is induced by IL-1 (Rothwell 1991), co-infused with NMDA selectively 
protects striatal cholinergic neurones in vivo against excitotoxic damage (Toulmond et al.




Within this thesis endothelin-1 is utilised purely as a tool to induce transient focal ischaemia 
in the ra t However a brief review of the structure and physiology of endothelin-1 is 
presented herein to give insight into the mechanism of action of this novel vasoconstrictor 
peptide.
1.5.1. S tructure and synthesis of endothelin-1
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide synthesized and released by 
endothelial cells. The first 'endothelium derived contracting factor' to be identified, it was 
isolated from porcine aorta endothelial cells by Yanagisawa et al. in 1988. DNA 
sequencing revealed that ET-1, originally called porcine endothelin, was a 21 amino acid 
peptide. The compound was renamed endothelin-1 with the subsequent discovery of 2 
further isoforms endothelin-2 (ET-2) and endothelin-3 (ET-3) (Inoue et al. 1989). The 
endothelins show close homology - all are 21 amino acid peptides with 2 disulphide bonds 
between the cysteine residues, but ET-2 and ET-3 differ from ET-1 in 2 and 6 of their 
amino acid positions respectively (Figure 7a). Each of the peptides derives from a separate 
gene that synthesizes a preproprotein precursor that is cleaved in 2 stages to yield the active 
endothelin peptide (Yanagisawa et al. 1988). The processing path for the formation of 
ET-1 from preproET-1 is shown in Figure 7b. The synthesis of ET-1 is thought to be 
regulated predominantly at the level of mRNA transcription (Yanagisawa et al. 1988) and 
several stimuli e.g.thrombin, interleukin-1, phorbol esters and mechanical shear stress can 
increase the production rate of all 3 endothelins by induction of the appropriate 
preproendothelin mRNA (Rubanyi & Botehlo 1991).
Vascular endothelium only expresses the gene for ET-1 synthesis. However the 3 
endothelins are also expressed in a wide range of tissues (including heart, brain, intestine, 
kidney and adrenal glands) with differing distribution patterns e.g. ET-2 is predominantly 
located in the intestine and kidney (Shigeno & Mima 1990). Within the brain ET-1 and 
ET-3 have been located in neurones (Shinmi etal. 1989) and glia (MacCumber etal. 1990) 
as well as the cerebrovasculature (Yoshimoto et al. 1990).
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Figure 7 Structure and synthesis of the endothelin family of peptides.
a) The amino acid sequences (for rat and human) of the 21 amino-acid peptides 
endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3). Filled symbols 
represent differences in the amino-acid sequence of ET-2 and ET-3 compared to ET-1. 
Solid lines represent disulphide bonds between the cysteine residues.
b) Schematic representation of the biosynthesis of endothelin-1. The preproET-1 (203 
amino acids) undergoes proteolytic cleavage to form big ET-1 (39 amino acids), which in 
turn is cleaved by an endothelin converting enzyme to form ET-1 (21 amino acids). ET-2 
and ET-3 are formed by similar processing of separate precursor forms.
Adapted from Rubanyi & Parker Botelho 1991.
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Figure 7 Structure and synthesis of the endothelin family of peptides
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1.5.2. Receptors and signal transduction
Two structurally and functionally distinct endothelin receptors, classified as ETA and ETB 
have been cloned and sequenced (Sakurai et al. 1992). ETA is predominantly located in 
vascular smooth muscle and has higher affinity for ET-1 than ET-3, while ETB is found in 
the endothelium and has equal affinity for the 3 isoforms. Both receptors contain 7 
transmembrane domains that are the characteristic feature of the G protein-coupled family 
of receptors. Further subtypes of receptor have been proposed (Sokolovsky et al. 1992; 
Kloog et al. 1989; Samson et al. 1990) but the cDNA for these receptors has not yet been 
isolated. In the brain endothelin receptors have been located in all tissue elements including 
endothelium (Frelin et al. 1991), neurones (Jones et al. 1989; Niwa et al. 1991) and glia 
(Hosli & Hosli 1991). Binding sites for 125I-labelled ET-1, ET-2, ET-3 are located 
throughout the brain including cortex, striatum and hippocampus with the highest density 
of receptors in the cerebellum (Davenport & Morton 1991). The overall density of ET-1 
binding sites is higher than for ET-3 (Davenport & Morton 1991; Fuxe et al. 1989a). More 
recently in situ hybridisation has revealed ETA receptors on cerebral blood vessels and ETB 
receptors in glia (Hori et al. 1992).
ET-1 induces vasoconstriction by increasing the concentration of free Ca2+ within vascular 
smooth muscle cells via 2 pathways - intracellular Ca2+ mobilization and Ca2+ influx (See 
Figure 8). The relative contribution of these 2 pathways depends on the particular vascular 
bed being studied (see Luscher et al. 1992 for review). Initially ET-1 binds to the ETA 
receptor and activates phospholipase C via a G protein leading to formation of inositol 
trisphosphate and diacyl glycerol, and the subsequent release of Ca2+ from intracellular 
stores. ET-1 then indirectly activates voltage-dependent Ca2+ channels to allow Ca2+ 
influx into the cell. The ETB receptor is also coupled to phospholipase C by a G protein 
and can induce elevations in intracellular Ca2+ in endothelial cells by the same pathways. 
This increase in intracellular Ca2+ activates nitric oxide synthase and cyclooxygenase to 
stimulate production of nitric oxide (NO) and prostacyclin respectively (Emori et al. 1991; 
Hirata et al. 1993). ET-1 induces sustained increases in intracellular Ca2+ within neurones 
and glia by the same mechanisms (Chuang et al. 1991; Goldman et al. 1991; Greenberg et 
al. 1992) and can also increase NO production (Reiser 1990). However the action of ET-1 
on neuronal voltage-dependent Ca2+ channels has been disputed (Hamilton et al. 1989). In 
addition to phospholipase C endothelin receptors can couple to adenylate cyclase in 
vascular smooth muscle and endothelium via different G proteins (Ladoux & Frelin 1991; 
Eguchi et al. 1993).
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Endothelin receptors are coupled by G proteins to both phospholipase C and 
receptor-gated Ca2+channels. ET-1 can increase intracellular Ca2+by 2 
mechanisms. Following activation of the endothelin receptor, the early transient 
increase in C a2+ is mediated by activation of phospholipase C resulting in 
hydrolysis of membrane phospholipids and release of the second messengers 
diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3 ). IP3 subsequendy 
stimulates release of Ca2+ from intracellular stores. The delayed increase in 
intracellular Ca2+ is mediated by activation of Ca2+ channels and influx of 
Ca2+ into the cell.
Adapted from Shigeno & Mima 1990, and Greenberg et al. 1992.
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1.5.3. Vascular actions of endothelin-1
ET-1 is a potent vasoconstrictor both in vitro and in vivo. It induces contraction in a wide 
range of vessels, both arteries and veins, obtained from different species (Yanagisawa et al.
1988). The vasoconstriction induced by ET-1 is of prolonged duration and difficult to 
wash out due to the tight binding of the peptide to its receptor (Yanagisawa et al. 1988). In 
vivo systemic administration of ET-1 or ET-3 induces a biphasic blood pressure response: 
a transient decrease in blood pressure followed by a sustained increase in pressure (Inoue et 
al. 1989). The hypertensive response is mediated by direct vasoconstriction induced via 
the ETa  receptor, while the initial depression is initated indirectly via the ETB receptor 
which stimulates release of the vasodilators NO and prostacyclin from the endothelium 
(Sudjarwo et al. 1992).
As well as local control of vascular tone ET-1 has been postulated to have other important 
roles in the cardiovascular system including modulation of central cardiovascular control 
centres, direct effects on cardiac output and growth and proliferation of blood vessels (see 
Rubanyi & Botehlo 1991 for review).
ET-1 is also a potent constrictor of cerebral vessels of various sizes from different species 
(Jansen et al. 1989; Martin de Aguilera et al. 1990; Ogura et al. 1991; Yanagisawa et al. 
1988; Vila et al. 1989) with a long duration of action due to the slow dissociation rate from 
its receptor (Saito et al. 1989). In the rat topical application of ET-1 in situ to pial arterioles 
induces slight vasodilation (5% change in diameter) at low doses (10-10 M) and 
dose-dependent constriction at higher doses (e.g. 22% decrease in diameter with 107 M, 
Faraci 1989). There appear to be regional differences in the response to ET-1 since in the 
same study when ET-1 was applied to the basilar artery, the low dose did not induce 
vasodilation, while the constrictor response to the highest dose was significantly greater 
(Faraci 1989). In the cat ET-1 induces dose-dependent and prolonged constriction of both 
pial arterioles and veins (Robinson & McCulloch 1990). In peripheral vessels in vitro 
ET-1 was more potent, by an order of magnitude than other vasoconstrictors such as 
vasopressin (Yanagisawa et al. 1988). This is not the case for cerebral vessels in situ 
where ET-1 is approximately equipotent with other vasoconstrictors (Faraci 1989; 
Robinson & McCulloch 1990; McCulloch & Edvinsson 1984). In vivo it is likely that NO 
and prostacyclin released from the intact endothelium via stimulation of the ETB receptor 
may directly antagonise the vasoconstriction induced by ET-1 stimulation of the ETA 
receptor, thereby apparently reducing its potency. While ET-1 is therefore equipotent with 
other vasoconstrictors its unique characteristic is its very prolonged duration of action 
which markedly exceeds that of other vasoactive compounds (Edvinsson 1984; McCulloch 
etal. 1986).
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Due to the presence of the blood-brain barrier intraluminal ET-1 is less effective in inducing 
cerebrovasoconstriction than ET-1 applied to the adventitial side of the vessel (Ogura et al.
1991). Thus systemic administration of ET-1 does not decrease cerebral blood flow (Mima 
etal. 1989; Kadel & Heistad 1990) unless administered at high concentrations (Willette et 
al. 1990). These findings are consistent with the fact that cerebral microvessel endothelial 
cells secrete ET-1 mainly to the adventitial side (Yoshimoto et al. 1991b) and suggest a 
predominantly local role for ET-1 in the control of cerebrovascular tone. In contrast 
administration of ET-1 by routes that allow access to the abluminal side of cerebral vessels 
e.g. intrastriatal (Fuxe et al. 1992) or intracistemal (Macrae et al. 1991) injection cause 
profound reductions in local cerebral blood flow in structures in close proximity to the 
injection site.
1.5.4. Endothelin-l-induced ischaemic cell damage
The profound and prolonged vasoconstriction of cerebral vessels induced by ET-1 raised 
the possibility that local application of the peptide could cause a reduction in cerebral blood 
flow of sufficient severity and duration to induce ischaemic cell damage. Fuxe et al. 
(1989b) first reported that intrastriatal injection of ET-1 (1 |ig/|il) in Sprague-Dawley rats 
resulted in a purely striatal lesion located around the injection site. Subsequently they 
demonstrated that striatal blood flow, measured by laser Doppler flowmetry, was reduced 
by 60% immediately following administration of ET-1 (0.43 nmol/0.5 |xl) and was still 
significantly reduced (by 40%) 3 hours later (Fuxe et al. 1992). They concluded the small 
striatal lesion (6 mm3) induced by ET-1 was due to this local ischaemia as the vasodilator 
dihydralazine coinjected with ET-1 attenuated the ET-1 induced reduction in blood flow and 
reduced the area of striatal damage.
Similar topical application of ET-1 to the proximal MCA results in severe reductions in 
local cerebral blood flow throughout the territory of the MCA (Robinson et al. 1990). This 
is associated with dose-dependent ischaemic neuronal damage 4 h post-application of the 
peptide in the anaesthetised Sprague-Dawley rat (Macrae et al. 1993). These observations 
form the basis of our ET-1 model of transient focal cerebral ischaemia introduced in Section
1.3.2.2. and more fully characterised in this thesis.
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1.5.5. Endothelin-l-induced cytotoxicity
We have assumed that the neuronal lesions produced by ET-1 in our model of transient 
focal ischaemia, and also Fuxe's model of intrastriatal injection, are a direct result of the 
profound ischaemia induced by ET-1 and that mechanisms of excitotoxic cell death are 
initiated secondary to this ischaemic insult However it is also possible that the excitotoxic 
process contributes directly to the lesion induced by ET-1. ET-1 can induce sustained 
increases in neuronal intracellular Ca2+ (see Section 1.5.2.) and the role of elevated 
intracellular Ca2+in excitotoxicity is well documented (see Section 1.4.2.). In addition 
ET-1 can stimulate production of neuronal NO (Reiser 1990) which may be a mediator of 
glutamate-induced excitotoxicity (Dawson et al. 1991). However ET-1 is not likely to have 
a direct neurotoxic action since, unlike glutamate, it is not neurotoxic in cortical or cerebral 
culture (Lustig et al. 1992b; Nikolov et al. 1993). However under ischaemic conditions 
ET-1 can potentiate cell damage in vitro (Kataoka et al. 1989; Stawski et al. 1991). In 
vivo ET-1 can stimulate the release of excitatory amino acids (Lin et al. 1990) and increase 
the rate of cerebral glucose metabolism (Gross et al. 1992) factors that may potentiate the 
effect of an ischaemic insult. For example excitotoxic mechanisms may be contributing to 
ET-1 induced damage in Fuxe’s intrastriatal model since the vasodilator dihydralzine, 
which completely prevents the ischaemia induced by ET-1, can not completely antagonise 
the neuronal loss.
1.5.6. Possible pathological role of endothelin-1 in ischaemic in jury
It is possible that endogenous endothelin-1 contributes to the pathogenesis of ischaemic 
injury since severe hypoxia is known to stimulate de novo synthesis of endothelin-1 in the 
periphery (Hieda & GomezSanchez 1990; Horio et al. 1991) and plasma endothelin-1 
levels are elevated in patients with nonhaemorrhagic stroke (Ziv et al. 1992). 
Vasoconstriction induced by endothelin-1 could reduce collateral blood supply and 
exacerbate an ischaemic insult. Indeed pre-treatment with exogenous endothelin-1 (5 or 10 
pmol intracisternally) has been found to increase ischaemic damage assessed 48 h 
post-permanent MCA occlusion (electrocoagulation) in the mouse (Nikolov et al. 1993). 
However cerebral endothelial cells do not increase their production of endothelin-1 under 
hypoxic conditions (Yoshimoto et al. 1991a), and increased plasma levels of endothelin-1 
are not likely to induce cerebrovasoconstriction if the blood-brain barrier is intact. In 
addition the increases in endothelin-immunoreactivity observed following transient global 
ischaemia in rats and gerbils (Giuffrida et al. 1992; Willette et al. 1992; Yamashita et al. 
1993) are coincident with the appearance of delayed neuronal degeneration in these models 
and do not precede morphological evidence of ischaemic damage. Similarly for transient
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and permanent focal cerebral ischaemia significant elevations in endothelin-like 
immunoreactivity are not seen until 24 h post-ischaemia and are most marked at 72 h 
(D u v e rg e r  et a l  1992). Thus endothelin-1 is not likely to play a causative role in the 
pathogenesis of cerebral ischaemic injury. Instead it is possible that vasoconstriction 
induced by this late production of endothelin-1 acts to 'seal off an area of irreversibly 




1.6.1. Biosynthesis of n itric  oxide
Research into the biological role of nitric oxide (NO) has expanded rapidly over the last few 
years. It has become apparent that this simple gas is implicated in important physiological 
functions including vasodilation, platelet aggregation, neural transmission and 
macrophage-induced cytotoxicity (see Moncada et al. 1991 for review). Nitric oxide 
synthase (NOS), the enzyme that catalyses the production of NO in biological systems, 
exists as 2 major types. These are a constitutive form (cNOS) present predominantly in 
endothelial cells and neurones and an inducible form (iNOS) whose expression is induced 
in cells such as macrophages and glia in response to cytokines and other inductants. cNOS 
is Ca2+/calmodulin-dependent and releases NO rapidly and transiently in response to 
agonists that increase intracellular Ca2+ (Bredt & Snyder 1990; Mayer et al. 1990). In 
contrast iNOS is Ca2+-independent, and once expressed can continue to produce NO for 
days (Xie et al. 1992). iNOS was originally thought to be independent of calmodulin but is 
now known to contain calmodulin as a tightly bound subunit that makes it independent of 
Ca2+ transients (Cho et al. 1992). The DNA sequences for NOS derived from brain (rat 
cerebellum, Bredt et al. 1991), endothelium (bovine aorta, Lamas et al. 1992) and 
macrophage (mouse, Xie etal. 1992) have been elucidated and shown to be encoded by 3 
separate genes with 50-60% homology.
Both types of NOS (inducible and constitutive) release NO in the conversion of L-arginine 
to L-citrulline via an N-hydroxyl-L-arginine intermediate (see Figure 9). Molecular oxygen 
is required to donate one atom each to citrulline and NO, while NADPH donates 2 electrons 
for the formation of the intermediate and one electron for its further oxidation to citrulline. 
In addition both NOS forms require flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), tetrahydrobiopterin and heme as cofactors (Nathan 1992). cNOS 
also has distinct phosphorylation sites for several protein kinases (Bredt et al. 1992) 
including protein kinase C and Ca2+/calmodulin- dependent protein kinase II (CaM kinase 
II). CaM kinase II down-regulates rat cNOS activity (Nakane et al. 1991) while protein 
kinase C has been reported to both up-regulate (Marin et al. 1992; Nakane et al. 1991) and 
down-regulate (Bredt et al. 1992) NOS activity. NO can also act as a negative feedback 
system to limit its own synthesis possibly by interaction with the heme subgroup of NOS 
(Rogers & Ignarro 1992). In the absence of L-arginine, NADPH-reduced NOS can act as a 
diaphorase to reduce nitroblue tetrazolium to a formazan precipitate. This 'NADPH- 
diaphorase activity' can be used to detect NOS histochemically (Hope et al. 1991).
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Figure 9 The biosynthesis of nitric oxide from L-arginine
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Nitric oxide synthase
The enzyme nitric oxide synthase (NOS) catalyses the reaction of 
L-arginine with molecular oxygen to form L-citrulline and nitric oxide 
(NO). The reaction proceeds via at least one intermediate species 
(Nw-hydroxyl-L-arginine). NADPH, flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN), tetrahydrobiopterin (BH4 ) and heme are 
required as cofactors for the donation and cycling of electrons.
Adapted from Nathan 1992.
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1.6.2. Pharmacological inhibition of nitric oxide synthesis
NOS can be inhibited nonspecifically by compounds that prevent interaction with its 
various cofactors (Nathan 1992), while glucocorticoids e.g. hydrocortisone can inhibit the 
expression of iNOS but have no effect on cNOS (Radomski et al. 1990b). More specific 
inhibition is achieved with several structural analogues of L-arginine including 
NG-monomethyl- L-arginine (L-NMMA) and NG-nitro-L-arginine (L-NA). These NOS 
inhibitors act as competitive antagonists when co-administered with L-arginine, but can 
irreversibly inhibit NOS when administered alone (Dwyer et al. 1991; Feldman et al. 
1993). Some NOS inhibitors also act as weak muscarinic antagonists (Buxton et al. 1993), 
while both L-NMMA and L-NA are low potency, non-stereospecific inhibitors of electron 
transfer in iron containing enzymes such as cytochrome C (Peterson et al. 1992).
1.6.3. Nitric oxide and endothelium-derived relaxing factor
Furchgott & Zawadzki (1980) first demonstrated that endothelial cells released a labile 
substance that mediated acetylcholine induced relaxation of vascular smooth muscle. This 
agent - termed endothelium derived relaxing factor (EDRF) - was subsequently found to 
mediate the response to other vasodilators including bradykinin, substance P and histamine 
(see Ignarro 1990a; Moncada et al. 1991 for reviews). In 1987 EDRF was identified as 
NO by Palmer and co-workers who showed that bradykinin caused release of NO from 
endothelial cells in sufficient quantity to account for the biological activity of EDRF. 
EDRF/NO released from endothelial cells diffuses into the underlying smooth muscle 
where it induces vasorelaxation by increasing cGMP production. NO binds with high 
affinity to the heme group of soluble guanylate cyclase causing a conformational change 
that increases the enzyme’s activity and stimulates cGMP formation (Ignarro 1990b). 
cGMP alters the cascade involved in muscle contraction leading to relaxation. Inhibition of 
NO synthesis induces endothelium-dependent contraction of vascular rings in vitro and 
inhibition of acetylcholine dependent relaxation (Rees et al. 1990). Systemic adminstration 
of NOS inhibitors to conscious rats in vivo causes an immediate, sustained hypertensive 
response accompanied by bradycardia (Gardiner et al. 1990a; Rees et al. 1990). These 
results indicate there is a continual, basal release of NO that maintains the vasculature in a 
state of active vasodilation. The vascular effects of NO inhibition are found to varying 
degrees in all vascular beds and across species (see Ignarro 1990a; Moncada et al. 1991 for 
reviews). The vasodilation induced by NO is complemented by its ability to inhibit platelet 
aggregation and adhesion - effects that are also mediated by stimulating cGMP production 
(Radomski et al. 1987; Radomski et al. 1990a).
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1.6.4. Localisation of nitric oxide synthase in the brain
NO can not be visualised directly because of its lability. The gross localisation of NO was 
first estimated using a guanylate cyclase bioassay system. Highest NO enzymatic activity 
was reported in the cerebellum, intermediate activity in the striatum and cortex and lowest 
in the medulla (Forstermann et al. 1990). Immunohistochemical localisation of NOS using 
antisera raised against cerebellar NOS confirmed this distribution - with densest staining in 
the cerebellum and olfactory bulbs (Bredt et al. 1990). Immunoreactivity was found in 
discrete neuronal populations and in the vascular endothelium of cerebral vessels which in 
some cases were surrounded by NOS-immunoreactive nerve terminals. No NOS was 
found in glia suggesting the cNOS activity reported in cerebral astrocytes (Muiphy et al. 
1990; Agullo & Garcia 1992) may be overshadowed by iNOS (Simmons & Murphy 1993) 
that is not recognised by the neuronal NOS antisera. Interestingly the distribution of the 
NO precursor L-arginine is the reverse of that for cNOS with most 
immunoreactive-arginine located in astrocytes (Aoki et al. 1991).
Within the cortex, striatum and hippocampus, NOS-immunoreactivity is found in scattered, 
isolated medium to large aspiny neurones that respresent only 0.5-2% of the total neuronal 
number (Bredt & Snyder 1992; Valtschanoff et al. 1993). However these neurones 
possess a large number of processes that form a diffuse network of NOS-positive fibres 
throughout each region (Vincent & Kimura 1992). The regional distribution of NOS does 
not correspond to that of NMDA receptors (Garthwaite 1991) or any neurotransmitter. 
However in some areas NOS does colocalise with particular neurotransmitters or 
neuropeptides e.g. in the striatum NOS colocalises with somatostatin and neuropeptide Y 
(Bredt & Snyder 1992), whereas in the cortex NOS neurones all contain 
gamma-aminobutyric acid (Valtschanoff et al. 1993). NOS neurones can also be visualised 
histochemically using NADPH diaphorase staining (Vincent & Kimura 1992) which 
correlates well with immunocytochemistry in fixed tissue (Bredt et al. 1991). However 
other enzymes can also produce NADPH diaphorase staining in non-fixed tissue so that not 
all stained neurones can be attributed to NOS (Matsumoto et al. 1993). This probably 
explains why citrulline, the co-product of NO synthase was found in only a proportion of 
NADPH diaphorase positive neurones (Pasqualotto et al. 1991).
NOS-containing nerve fibres (assessed by NADPH-diaphorase staining or 
NOS-immunoreactivity) form a dense perivascular plexus in the anterior portion of the 
circle of Willis and the proximal anterior and middle cerebral arteries. In the basilar artery 
and more distal middle cerebral artery the density of NOS neurones is lower (Iadecola et al. 
1993; Nozaki et al. 1993). These fibres originate extracranially mainly from the 
sphenopalantine ganglia (Iadecola et al. 1993; Nozaki et al. 1993). Within the cortex a
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precise spatial relationship between NOS neurones (NADPH diaphorase-positive) and 
arterioles descending from the pial surface exists (Regidor et al. 1993). The close 
association between NOS neurones and both large cerebral arteries and the microcirculation 
suggests neuronal NO may regulate global changes in cerebral blood flow (but see also 
Section 6.5.) and more localised blood flow changes in response to metabolic demand.
1.6.5. Nitric oxide and glutamatergic signal transduction
Over a decade ago endogenous NO was known to stimulate soluble guanylate cyclase in the 
brain (Miki et al. 1977), while L-arginine had been identified as an endogenous activator of 
the enzyme (Deguchi & Yoshioka 1982). However it was not until the discovery of the 
vascular L-arginine-NO-cGMP pathway that a possible role of L-arginine derived NO in 
CNS function was further investigated. NO was discovered to mediate NMDA-induced 
elevations in cGMP in cerebellar culture (Garthwaite et al. 1988), and subsequently in 
neonatal and adult cerebellum (Bredt & Snyder 1989), hippocampus (East & Garthwaite 
1991) and striatum (Marin et al. 1992). The NMDA-induced NO production (measured by 
accumulation of cGMP or citrulline) could be antagonised by NOS inhibitors (L-NA being 
more potent than L-NMMA by an order of magnitude (East & Garthwaite 1991; 
Kiedrowski et al. 1992a) or mimicked by several NO donors (Southam & Garthwaite 
1991). In vivo NOS inhibition was demonstrated to inhibit both basal and excitatory amino 
acid-stimulated guanylate cyclase activity in mouse cerebellum (Wood et al. 1990).
The glutamate-induced increase in NO production was proposed to be mediated by Ca2+ 
influx since characterisation of neuronal NOS revealed the enzyme was Ca2+-dependent 
(Knowles et al. 1990) and activated by the same range of Ca2+ concentrations found on 
activation of NMDA receptors (Garthwaite 1990). Thus quisqualate, which only slightly 
increases intracellular Ca2+, minimally activates neuronal NOS in vitro (Garthwaite et al. 
1989). The route leading to increased Ca2+ may also be important for NOS activation since 
kainate, at concentrations that give equivalent Ca2+ influx to NMDA, is less effective than 
NMDA in stimulating NOS activity (Kiedrowski et al. 1992a). Thus neuronal NOS may 
be localised in the cytoplasm close to the NMDA receptor (Garthwaite 1990). In vivo both 
kainate and quisqualate can stimulate NO-induced cGMP production (Wood et al. 1990). It 
is likely that a substantial proportion of this in vivo response is mediated by non-NMDA 
receptors localised on astrocytes rather than neurones (Agullo & Garcia 1992).
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From this data the following model of NO mediated signal transduction at the glutamatergic 
synapse has been proposed (Garthwaite 1991; Knowles et al. 1990; see Figure 10). 
Glutamate released from the presynaptic terminal induces Ca2+ influx predominantly 
through NMDA receptor-gated ion channels. The increase in intracellular Ca2+ promotes 
calmodulin binding to NOS and activates the enzyme to produce NO from the conversion 
of L-arginine to L-citrulline. NO can then freely diffuse into neighbouring cells (neurones, 
glia or vascular smooth muscle) or back into the presynaptic terminal to activate guanylate 
cyclase and increase cGMP production. The elevation of intracellular Ca2+ required to 
activate NOS prevents NO-induced cGMP accumulation in the NOS neurone itself 
byactivation of a calmodulin- dependent cGMP phosphodiesterase (Mayer et al. 1992).
It is becoming increasingly apparent that increases in cGMP induced by other 
neurotransmitters e.g. noradrenaline and acetylcholine arc also mediated by NO (Castoldi et 
al. 1993; Agullo & Garcia 1991). The precise roles of cGMP in brain function remain to 
be established but involve cGMP-activated kinases, phosphodiesterases and ion channels 
(Goy 1991).
1.6.6. Proposed roles of nitric oxide within the nervous system
In the peripheral nervous system NO has been identified as the neurotransmitter of NANC 
(nonadrenergic-noncholinergic) nerves that mediate smooth muscle relaxation (Moncada et 
al. 1991). In the CNS NO may play a role in synaptic plasticity mediated by long term 
potentiation (LTP) and long term depression (LTD). The short-lived, highly diffusible 
nature of NO makes it an ideal candidate for the retrograde messenger necessary to transfer 
information back from the post-synaptic neurone to the pre-synaptic terminal to alter the 
strength of synaptic transmission (Gaily et al. 1990). NOS inhibitors block both LTP and 
LTD, while NO donors can promote both forms of synaptic plasticity (Bohme etal. 1991; 
Shibuki & Okada 1991). However because little or no NOS has been demonstrated in CA1 
pyramidal cells this proposed role for NO remains controversial (Morris & Collingridge 
1993).
Specific NO donors can modulate glutamatergic neurotransmission by reducing NMDA 
induced Ca2+ influx (Manzoni et al. 1992; Lei et al. 1992). Thus NO may act as a negative 
feedback mechanism to prevent overactivation of NMDA receptors. It is now known that
NO exists in distinct oxidation-reduction states: the reduced free radical form (NO*) and 
the oxidised nitrosonium ion (NO+) form (Lipton et al. 1993), and it is NO+ that can 
interact with the thiol group of the redox modulatory site on the NMDA receptor to
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Glutamate released from the pre-synaptic terminal activates the 
NMDA receptor resulting in increased free intracellular Ca2+, 
which in turn activates the calmodulin-dependent NO synthase to 
release NO from the conversion of L-arginine to L-citrulline. The 
freely diffusible NO can then pass into neighbouring target cells to 
activate guanylate cyclase (GC) and increase cGMP production. 
A calmodulin-dependent cGMP phosphodiesterase prevents 
cGMP accumulation in the NO-generator cell itself.
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down-regulate NMDA evoked ion currents (Lei et al. 1992). However paradoxically NO 
can also stimulate further release of glutamate and aspartate (Dickie et al. 1992; Lawrence & 
Jarrott 1993) which may act to potentiate glutamatergic transmission.
The NO donor sodium nitroprusside (SNP) has been demonstrated to inhibit glutamate 
binding to NMDA receptors (Fujimori & Pan-Hou 1991) and prevent NMDA-induced 
depolarisation (East et al. 1991), but these effects are due to the ferrrocyanide portion of 
SNP and are independent of its NO-releasing ability (East et al. 1991; Kiedrowski et al. 
1992b).
Within the CNS NO can mediate non-synaptic communication between neurones and 
nonneuronal elements such as astrocytes and blood vessels. For example NO produced by 
NMDA-stimulated cerebellar granule cells promotes cGMP accumulation in astrocytes 
which themselves lack NMDA receptors (Kiedrowski et al. 1992c). In addition the 
important role of neural NO in the control of cerebrovascular tone is becoming increasingly 
recognised. NOS inhibitors block neurally induced vasodilation in cerebral arteries (Toda 
& Okamura 1991) and pial arteriolar vasodilation induced by exogenous NMDA (Faraci & 
Breese 1993). An investigation of the role of NO in cerebrovascular regulation is included 
in this thesis and this subject will be addressed in more detail in the discussion.
1.6.7. Nitric oxide as a potential mediator of neurotoxicity
Dawson et al. 1991 originally proposed NO as a mediator of glutamate neurotoxicity in 
cortical cell culture. They demonstrated firstly that the NOS inhibitors L-NA and 
L-NMMA dose-dependently prevented NMDA-induced cell death with EC50 of 20 and 170 
pM respectively (Dawson et al. 1991), and secondly that the NO donor SNP induced 
neurotoxicity with a concentration-response curve and time-course of action very similar to 
NMDA. Since this report was published the role of NO in mediating glutamate toxicity in 
vitro remains controversial. Some studies have reported that NOS inhibitors attenuate 
NMDA-induced toxicity (Corasaniti etal. 1992; Izumi etal. 1992; Kollegeretal. 1993), 
while others found no beneficial effect (Demerle-Pallardy et al. 1991; Regan et al. 1993). 
Similarly while some authors find NO donors to be neurotoxic (Chen etal. 1991; Boje & 
Skolnick 1992) others do not (Kiedrowski et al. 1991). The neurotoxic effects of SNP 
have also been attributed to a mechanism independent of NO release (Izumi et al. 1993). 
These discrepant results may be explained by the recent finding that NO can exist in 2 
different redox states (see above) with distinct neuroprotective (NO+) and neurotoxic
(NO*) actions (Lipton et al. 1993). Enriching culture medium with the reducing agents
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cysteine or ascorbate, which will promote the formation of NO*, increases the 
neurotoxicity of NO donors in culture (Lipton et al. 1993). Thus differences in the amino 
acid content of the culture media used in different laboratories may affect the redox state of 
NO and convert it from a neurotoxin to a neuroprotective agent or vice versa.
The sustained release of NO from glia due to activation of iNOS by lipopolysaccharide 
(LPS) and/or cytokines does appear to be consistently cytotoxic to neurones (Boje & Arora 
1992; Chao et al. 1992). Commercially available culture medium is contaminated by 
endotoxin (containing LPS) in concentrations that can induce significant NO production 
from iNOS (Simmons & Murphy 1992). This unintended source of NO may also partly 
account for the contradictory results of NOS inhibition in vitro reported above.
1.6.8. Proposed mechanism of nitric oxide-induced toxicity
NO is a free radical and at high concentrations can directly induce cell damage e.g. DNA 
strand breakage (Nguyen et al. 1992). However in vivo the lower concentrations of NO 
and its short half-life (Gaily et al. 1990) suggest that it can not mediate toxicity directly. 
Beckman and colleagues first postulated that NO may mediate excitotoxic or ischaemic 
injury through participation in the generation of hydroxyl radicals by the following 
reactions:
NO* + 0 2*~ — > ONOO- 
ONOO- + H+ — > ONOOH
ONOOH —> HO* + N 02*
NO was proposed to react with superoxide to form peroxynitrite ( ONOO'). Peroxynitrite 
rapidly decomposes at physiological pH (<7.5) and temperature (37°C) to form hydroxyl 
radical and nitrogen dioxide (Beckman etal. 1990). This hypothetical reaction sequence 
was confirmed by Hogg et al. 1992 who demonstrated the generation of hydroxyl radicals 
from superoxide and nitric oxide. Recent evidence suggests that peroxynitrite may actually
undergo rearrangement to form a complex with N 02* and HO* characteristics rather than 
decompose into 2 separate species (Lipton et al. 1993).
This pathway represents an alternative mechanism to the Haber-Weiss reaction for the 
generation of hydroxyl radicals. The NO pathway may be of equal or greater importance 
than the Haber-Weiss reaction in vivo because it is not dependent on an iron catalyst 
(Beckman et al. 1990). Moreover peroxynitrite, as well as hydroxyl radicals, can directly
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induce tissue damage (Lipton et al. 1993; Radi et al. 1991). Although some authors view 
the scavenging of superoxide by nitric oxide as potentially cytoprotective (Kanner et al. 
1992; Rubanyi et al. 1991), the general consensus is that the increased formation of 
hydroxyl radicals will be cytotoxic.
It is now known that NOS can generate superoxide radicals (Pou et al. 1992). Production 
of both NO and superoxide by NOS is likely to promote NO-superoxide interaction and 
increase the formation of peroxynitrite and hydroxyl radicals. The biological importance of 
this interaction is illustrated by the fact that removal of superoxide with SOD prolongs the 
half-life of endothelial EDRF/NO (Gryglewski et al. 1986). In addition SOD attenuates 
neurotoxicity induced by NO donors confirming that combination of NO with superoxide is 
necessary to produce maximal toxicity (Dawson et al. 1993; Lipton et al. 1993). The 
anti-ischaemic efficacy of SOD (see Section 1.4.4.3.) may therefore be dependent not only 
on its ability to prevent hydroxyl radical formation but also on the stabilisation of NO 
thereby promoting vasodilation and possibly improving cerebral blood flow.
The increase in cGMP levels induced by NO is not likely to contribute to its neurotoxic 
action because cGMP analogues are not neurotoxic in cortex or cerebellum in vitro 
(Garthwaite & Garthwaite 1988; Lustig et al. 1992a).
Following the observations that NO mediates glutamate toxicity in vitro (Dawson et al. 
1991) and that NOS inhibitors protect neurones against hypoxia/reoxygenation injury in 
vitro (Cazevieille et al. 1993; Wallis et al. 1992) we wished to investigate the possibility 
that NO is also neurotoxic in vivo. Therefore we studied the effect of the NOS inhibitor 
L-NAME on cell damage invoked firstly in response to intracerebral administration of 
exogenous glutamate and secondly in response to ischaemia/rcperfusion in the permanent 
and transient (endothelin-1) models of middle cerebral artery occlusion. The roles of 
glutamate, Ca2+ and free radicals in ischaemic/reperfusion injury are well documented (see 
Section 1.4.). The possibility that NO mediates ischaemic/reperfusion injury is therefore 
attractive because it allows the merging of these 3 hypothesis into one final common 
pathway of neuronal death.
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2. MATERIALS AND METHODS
2.1. ANIMALS
Adult male Sprague-Dawley rats (approximately 300-350 g, Harlan Olac, U.K.) were used 
in all experiments. The rats received free access to food (labchow pellets) and water prior 
to experimentation. The experimental group sizes for each study are shown in the relevant 
results tables.
2.2. GENERAL SURGICAL PREPARATION
Anaesthesia Rats were weighed then placed in a clear perspex box for induction of 
anaesthesia. Anaesthesia was induced with 5% halothane in nitrous oxide: oxygen (70:30) 
and was subsequently maintained with 0.75-1% halothane (depending on individual 
animal's requirement for adequate anaesthesia). For rats maintained under anaesthesia 
throughout the experimental period the trachea was cannulated and the animal artificially 
ventilated via a small animal respirator pump. Rats intended to regain consciousness 
following surgery breathed spontaneously throughout and received anaesthetic gases via a 
small nose cone. Rectal temperature was monitored and maintained around 37°C by means 
of heating blankets and lamps.
Blood vessel cannulation The rat was placed on its back and small incisions made on either 
side of the groin to expose the femoral blood vessels. The femoral arteries and veins were 
cannulated using polyethylene catheters (outer diameter 0.96 mm, inner diameter 0.58 mm, 
length 15 cm) filled with heparinised saline (10 I.U. heparin/1 ml saline). The arterial 
catheters were used for continuous monitoring of blood pressure and for blood sampling to 
measure plasma glucose and blood gases. The venous catheters were used for 
administration of drug or vehicle and radioactive tracers where appropriate. The surgical 
sites were infiltrated with anaesthetic gel (survival animals only) and skin sutured. Blood 
samples were taken at regular intervals to monitor blood gases and, if necessary, the pump 
rate was altered to maintain gases within the following limits for anaesthetised rats: PaCC>2 
35-42 mmHg, P a02 >100 mmHg.
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2.3. MODELS OF CEREBRAL ISCHAEMIA/EXCITOTOXICITY AND 
HISTOLOGICAL QUANTIFICATION OF ISCHAEMIC DAMAGE
2.3.1. Induction of focal cerebral ischaemia 
Exposure o f middle cerebral angry
The left middle cerebral artery (MCA) was exposed using a subtemporal approach based on 
the method originally described by Tamura et al. 198 la. The rat was laid on its right side 
and a vertical incision (2 cm) made midway between the left eye and ear. The skin was 
retracted and the temporal muscle divided into 2. The muscle was detached from the bone 
and 2  retractors inserted to hold back the muscle and obtain a clear view of the 
infero-temporal fossa. The zygomatic arch was left intact and 2 further retractors inserted 
to improve the view of the foramen ovale. The remainder of the procedure was carried out 
using an operating microscope. A small circular craniectomy (2 mm diameter) was made 
using a saline-cooled dental drill. The skull opening was positioned approximately 1mm 
dorsal to the foramen ovale. The underlying dura membrane was opened with a fine needle 
to reveal the MCA. The main trunk of the MCA was exposed from where it crossed the 
inferior cerebral vein to proximal to the lateral olfactory tract. The lenticulostriate 
branch(es) that originate below the olfactory tract were usually visible (see Figure 11). In 
some experiments a fine temperature probe was then inserted into the ipsilateral temporalis 
muscle to monitor temperature during surgery.
Permanent MCA occlusion
The main artery was occluded by temparature-controlled (maximum 84°C) bipolar 
electrocoagulation (Bipolator T50, Fischer, Germany) from where it crossed the inferior 
cerebral vein to proximal to the origin of the lenticulostriate branch. All visible 
side-branches, including the lenticulostriate, were also coagulated. The artery was then 
transected midway between the inferior cerebral vein and olfactory tract to ensure the 
completeness of the occlusion and to prevent recanalisation. The time of transection was 
taken as the exact time of MCA occlusion. The retractors and temperature probe were then 
removed and the temporal muscle and skin sutured.
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The left middle cerebral artery (MCA) was exposed using a sub-temporal approach. For 
permanent MCA occlusion the artery was then occluded by electrocoagulation from where 
it crossed the inferior cerebral vein (A) to proximal to the origin of the lenticulostriate 
branch (B). For transient MCA occlusion endothelin-1 was topically applied to the same 




Following removal of the dura, the arachnoid membrane was pierced 3-4 times down either 
side of the MCA to facilitate access of endothelin-1 to the artery. Endothelin-1 (2.5 nmol, 
25 |ll x KHM; Peninsula Lab. Inc., USA) was applied using a microsyringe to the same 
portion of the artery that would be occluded for permanent MCA occlusion. Constriction 
of the main artery and lenticulostriate branch(es) was verified via the operating microscope. 
Only constrictions rated moderate (approximately 25% of the original diameter), severe 
(20% of the original diameter) or very severe (^20% of the original diameter) were 
included in the study. The degree of constriction was noted and the time of occlusion taken 
as when satisfactory constriction was achieved. The retractors were removed and the 
operation site closed as for permanent MCA occlusion.
Prior to application, the concentration of the endothelin-1 solution was verified by 
absorbance spectrophotometry at 280 nm using a molar extinction coefficient of 7250 for a 
10 mm path length (Douglas et al. 1991).
Sham procedure
The MCA was exposed as for transient MCA occlusion and the arachnoid membrane 
pierced. Saline (25 pi) was applied to the artery using a microsyringe. The retractors were 
removed and the wound sutured as above.
Survival animals for ischaemia studies
Under sterile conditions the right femoral artery only was cannulated. The cannula was 
shunted under the skin and exteriorised at the back of the neck. Thus blood samples could 
be taken for physiological monitoring both during surgery and the post-operative period. 
Following removal of a blood sample a concentrated heparin solution (0.1 ml) in a viscous 
medium (10,000 units heparin, 25 g polyvinyl pyrollidine, 50 ml saline) was injected into 
the cannula to keep the line patent (care was taken not to allow the heparin to enter the rat’s 
bloodstream). A permanent, transient or sham MCA occlusion was then performed as 
described above. All wounds were infiltrated with anaesthetic gel and sutured. A broad 
spectrum antibiotic (0.1 ml ampicillin s.c., to maintain patency of arterial cannula) and 2.5 
ml saline s.c. (to prevent dehydration) were administered (24 h and 72 h survival animals 
only). Anaesthetics were withdrawn and the animal allowed to regain consciousness. For 
long term survival (24 h and 72 h) rats were transferred to a special post-operative recovery 
room where their overall condition was closely monitored throughout the survival period. 
Rats were housed individually and received a special soft diet to encourage feeding.
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2.3.2. Tissue processing and histopathological quantification of ischaemic 
dam age
Perfusion fixation
Rats from recovery experiments were reanaesthetised. For all animals the halothane 
concentration was increased to 3% immediately prior to perfusion fixation. The animal was 
placed on its back and the thorax opened via a midline incision. A blunt needle was 
inserted into the left ventricle and passed into the ascending aorta. The right atrium was 
cut. Heparinised saline was infused until the perfusate ran clear (approximately 50 ml) 
followed by FAM (40% formaldehyde, acetic acid and absolute methanol in ratio of 1:1:8; 
approximately 150 ml). Both heparinised saline and FAM were perfused at a pressure of 
approximately 120-130 mmHg. The rat was decapitated and the head stored in FAM for 24 
h. The brain was then carefully removed and stored in 70% methanol prior to quantitative 
histopathology.
Tissue Processing
The cerebellum and olfactory bulbs were removed and the cerebrum cut into 4 equal 
coronal slices. These slices were embedded in paraffin wax blocks, then sections (10 pm) 
were cut and stained with haematoxylin and eosin or luxol fast blue and examined under a 
light microscope.
Quantification of ischaemic damage
Volumetric assessment was performed as described by Osborne et al. 1987. This method 
of quantification removes the confounding influence of oedema (brain swelling) from the 
measurement of volumes of ischaemic damage. Regions showing evidence of ischaemic 
cell change were transcribed onto scale drawings {e.g. see Figure 15) at 8 pre-selected 
stereotactic levels taken from the stereotactic atlas of Konig & Klippel 1963. The 
transcription of areas of ischaemic damage was performed blind by an experienced 
neuropathologist (Prof. D. Graham).
The areas of ischaemic damage in the whole hemisphere, cortex and caudate nucleus were 
measured at each level on the line drawings using an image analyser (Quantimet 970, 
Cambridge Instruments, U.K.). The areas of damage were then converted by integration 
to provide a total volume of ischaemic damage, normalised to the mean hemispheric volume 
of the adult male Sprague-Dawley rat (570 mm3).
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2.3.3. Induction of permanent global (decapitation) ischaemia
Conscious rats were killed by cervical dislocation and decapitated. The heads were placed 
in individual sealed plastic bags and maintained in a water bath at 37°C for 15 min to 4 h. 
The brains were then rapidly removed and processed for in vitro autoradiography. For the 
control group, brains were removed from the skull immediately following decapitation.
2.3.4. G lutam ate toxicity in vivo
Surgical preparation and induction of excitotoxic damage
Rats were anaesthetised, tracheostomised and the femoral vessels cannulated as described 
in Section 2.2. The rat was placed prone in a Kopf stereotactic frame and, using an 
operating microscope, a small craniectomy was made through the right parietal skull. The 
dura and arachnoid membranes were pierced and a microdialysis probe (Carnegie 
Medicine, Sweden; membrane length 3 mm, outside diameter 0.5 mm), angled at 15° to the 
sagittal plane, was inserted 3.5 mm into the parietal cortex (stereotactic surgery was 
performed by Dr. H. Fujisawa). The stereotactic co-ordinates for probe placement were 
anterior 0.0 mm, lateral 4.0 mm relative to Bregma. The microdialysis probe was perfused 
with mock cerebrospinal fluid (135 mM NaCl, ImM KC1,2mM KH2PO4, 1.2 mM CaCl2, 
ImM MgCl2, pH 7.4) followed by 0.5 M glutamate solution (0.5 M monosodium 
glutamate dissolved in mock CSF) at a flow rate of 1.5 pl/min for 90 min using a Carnegie 
Medicine CMA 100 infusion pump (Biotech Instruments, U.K.). Following the 90 min 
glutamate perfusion the probe was removed and the scalp wound sutured. The experiment 
was terminated by decapitation 4 h after the start of the infusion.
Quantification of damage
Immediately following decapitation the brains were removed and frozen in isopentane 
(-42°C). 20pm sections were cut on a cryostat using a cutting schedule in which 3 
consecutive sections were collected onto a microscope slide at 200 pm intervals throughout 
the brain. The sections were then stained with haematoxylin and eosin. The cortical 
damage was clearly visible to the naked eye as a region of pallor on the stained sections. 
The area of damage was measured directly from each section using an image analyser and 
averaged for each group of 3 consecutive sections. The total volume of damage was then 
determined by integration. This novel model of excitotoxicity in vivo has been 
characterised in previous studies (Fujisawa et al. 1993; Landolt et al. 1993).
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2.4. AUTORADIOGRAPfflCAL TECHNIQUES
2.4.1. In  vitro ligand binding 
Theory
Quantitative binding assays utilising ligands labelled with radioisotopes such as 3H or 125I 
have been widely used to characterise receptor populations within the brain. In the context 
of cerebral ischaemia assays can be used to detect changes in receptor number and/or 
affinity following an ischaemic insult. Assays measure the amount of ligand bound to the 
receptors at various ligand concentrations and are based on simple equilibrium reaction 
kinetics.
The binding of a ligand to its receptor can be expressed as the following reversible reaction:
K \
[R] + [L] < - >  [RL] (1)
k - i
where [L] = concentration of ligand; [R] = concentration of receptor,
[RL] = concentration of receptor-ligand complex= [B] = amount bound; 
k+1 = association rate constant; k4  = dissociation rate constant.
At equilibrium: k^jtRjfL] =k_![B] (2)
and the equilibrium dissociation constant for the ligand is defined as:
Kd = k,! _ [R][LJ
k+1 [B] (3)
Let represent the total number of receptors i.e.
Bmax = [R] + [RL]
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Substitution in equation 3 then gives:
K, = ( Bma> - [B]) [L]
[B] (4)
which can be rearranged to:
[B] = Bmax [L] .
[L ]+K d (5)
Equation 5 represent the concentration of ligand bound to the receptors as a function of 
concentration of ligand and is shown in Figure 12a. In practice the amount bound includes 
ligand bound to the specific receptor population and also nonspecific binding i.e. binding to 
other components of the assay system. Non-specific binding is non-saturable and 
proportional to the concentration of ligand present. In an assay non-specific binding is 
determined by the addition of a high concentration of an unlabelled 'displacer' ligand that is 
also a specific ligand for the receptor being studied. Subtraction of the amount of 
non-specific binding from total binding will give the amount of specific binding to the 
receptor.
Further rearrangement of equation 4 gives:
[B] _ Bmax [B]
[L] Kd Kd (6)
(y = m.x + c)
This equation (6), known as the Scatchard equation describes a straight line with slope 
equal to the negative reciprocal of the dissociation constant (-1/Kd) and intercept on the 
x-axis equal to total concentration of receptors (Bmax) (see Figure 12b). Thus if the 
concentrations of bound and free ligand at equilibrium are known, then Kd and B ,^  can be 
determined.
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Figure 12 Analysis of saturation data for the 










a) The total amount of bound radioligand is measured at increasing 
concentrations of radioligand until virtually all receptors are saturated. 
Non-specific binding is assessed in parallel by the addition of an excess 
amount of unlabelled ligand. Specific binding is then determined by 
subtracting the amount of non-specific binding from the total amount bound.
b) The data is then transformed using Scatchard analysis to describe the linear 
relationship between the ratio of bound to free ligand against the concentration 
of bound ligand. Extrapolation of this line to the X-axis gives an estimate of 
the total number of receptors (B max ), while the slope of the line is equivalent 
to the negative reciprocal of the equilibrium dissociation constant (Kd).
From McGonigle & Molinoff 1981.
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In the present study in vitro autoradiography was used to assess the effects of focal and 
global cerebral ischaemia on the adenylate cyclase-cyclic AMP second messenger system. 
Adenylate cyclase, an important mediator of intracellular signalling, catalyses the 
conversion of ATP to cyclic AMP. Many neurotransmitter receptors are coupled to 
adenylate cyclase via guanine nucleotide binding proteins (G proteins, Gs and G,) and
either stimulate (Dj dopamine, 6 adrenergic, A2 adenosine) or inhibit (D2 dopamine, a 2 
adrenergic, Aj adenosine) its activity (Cooper 1986; Kebabian & Caine 1979). We chose to 
study the Dj dopamine receptor because of the high density of Dj dopamine receptor 
binding sites in the caudate nucleus (Savasta et al. 1986) - one of the main neuroanatomical 
regions affected by proximal MCA occlusion. The tritiated ligands SCH23390 (a selective 
Dj antagonist (Kebabian & Caine 1979)) and forskolin were used to map D2 receptors and 
adenylate cyclase respectively. Forskolin at high concentrations (|iM) binds to a low 
affinity site on the catalytic subunit of adenylate cyclase and directly activates the enzyme 
(Seamon & Daly 1981). However at the concentrations used in the binding assay (nM), 
forskolin binds to a high affinity site located on the activated form of adenylate cyclase and 
provides a marker of the agonist-stimulated enzyme (Gehlert 1986).
Practice
At specified time intervals following induction of ischaemia (see individual experimental 
protocols, Section 5) the rat was decapitated and the brain rapidly dissected ou t The whole 
brain was frozen in isopentane (-42°C) for 10 min. Coronal sections (20 |im) were cut in a 
cryostat and thaw mounted onto gelatin-coated subbed slides. Three consecutive sections 
(2  for total binding on one slide, one for non-specific binding on another slide) were 
collected and allowed to dry at room temperature. Sections were stored in sealed plastic 
boxes at -20°C until required for binding assay.
Sections were removed from the storage freezer and dried rapidly in a stream of air at room 
temperature. For experiments combining in vitro autoradiography with [14C]IAP 
assessment of cerebral blood flow the [14C]IAP was first removed from the sections by 2 
x 15 min washes in the appropriate buffer (see Table 1). The sections were then redried 
prior to start of the binding protocol.
The binding protocols for both forskolin and SCH23390 binding follow the same general 
procedure (see Table 1 for specific details). Tissue sections were incubated at room 
temperature in the appropriate buffer containing a known concentration of the specific 
[3H]ligand. Non-specific binding was determined in parallel in adjacent sections by
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addition of an unlabelled displacer to the incubation buffer. The sections were incubated 
for a specific time calculated to allow equilibrium to be achieved. Unbound radioligand 
was then removed by washing the sections in cold fresh buffer (4°C) followed by a dip in 
distilled water (4°C). The sections were then dried in a stream of air and mounted onto 
cardboard together with a set of precalibrated standards (1105 - 24,148 nCi/g, Amersham 
Int., U.K.). The cards were then apposed to 3H-sensitive film (Hyperfilm-3H, Amersham 
Int., U.K.) for 7 (SCH23390) or 14 days (forskolin). The films were then developed and 
the resultant autoradiograms analysed using computer-assisted densitometry (see Section
2.4.3.). The binding protocols for [3H]forskolin and [3H]SCH23390 were based on the 









































































2.4.2. In vivo assessment of local cerebral blood flow
2.4 .2 .1. Local cerebral blood flow determ ination using [14C ]iodoan tipyrine
The iodoantipyrine (IAP) method of measuring local cerebral blood flow (CBF) is one of a 
group of techniques, utilising different tracer compounds, which are based on measuring 
the cerebral uptake of a metabolically inert, freely diffusible tracer from the arterial blood. 
This basic method was first introduced by Kety & Schmidt (1945) who used the inert gas 
nitrous oxide to measure CBF in man. The mathematical theory underlying their work was 
in turn derived from the Fick principle which states that the quantity of tracer taken up by 
an organ in time t equals the blood flow through the organ multiplied by the difference in 
concentration between the arterial blood delivered to the organ and the venous blood 
draining it. This can be expressed as follows:
where Q = quantity of tracer in the organ; F = blood flow through the organ; 
Ca and Cv = arterial and venous blood concentration of the tracer.
The Kety-Schmidt equation (Kety 1951) derived from the Fick principle is:
where Ci(T) equals the tissue concentration of the tracer at a given time, T, after 
injection of the tracer, X equals the tissue:blood partition coefficient which relates
solubility of the tracer in brain tissue:blood; Ca is the concentration of tracer in the 
arterial blood; t is the variable, time; and K is a constant defined as:
where F/W equals the rate of blood flow per unit mass of tissue; and m equals a 
constant (from 0-1) that represents the diffusion equilibrium between blood and 
tissue. The constant m is a measure of diffusion across the blood brain barrier, 
so with unrestricted diffusion m = 1.
Theory
Q = F (Ca-Cv)
the tracer concentration in the brain to that in the blood and is the ratio of the
K=mF/WX
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The general method based on this equation for quantitative determination of blood flow is 
as follows. The radiolabelled tracer is infused intravenously over a short period (30 s -1  
min) while timed samples of arterial blood are collected. At the end of the infusion period 
the animal is decapitated and the brain rapidly removed and sectioned. The radioactivity in 
discrete brain regions is then measured using quantitative autoradiography. Thus the rate 
of blood flow per unit mass of tissue (F/W) can be determined from the final concentration 
of tracer in the tissue (Ci(T)) - obtained from the autoradiogram, and the concentration of 
tracer in arterial blood from time 0 to T - obtained from the arterial blood samples.
Kety and colleagues originally measured CBF in non-primates using the inert gas 
[131I]trifluoroiodomethane as the tracer (reviewed in Sakurada et al. 1978). However there 
were several technical drawbacks associated with this tracer including difficulty in 
measuring a volatile gas and the relatively short half-life of 131I. [14C]antipyrine was then 
used but due to its relatively low lipid solubility it had poor diffusion across the blood-brain 
barrier (m<l) and consequently underestimated CBF. With the introduction of [14C]IAP a 
compound was found that fulfilled all the requirements for a suitable tracer (unrestricted 
diffusion across blood-brain barrier, metabolically inert, ability to be labelled with a 
convenient radioisotope). [14C]IAP has been demonstrated to have a relatively high lipid 
solventrwater partition coefficient It is uniformly soluble throughout all brain regions but 
is slightly more soluble in blood than brain with a brain tissue:blood partition coefficient of 
0.79 (0.78-0.80 dependent on method of determination, Sakurada et al. 1978).
The main advantage of the [14C]IAP method for determination of local CBF is the high 
degree of spatial resolution that enables 1CBF to be measured in numerous regions 
throughout the brain. The main disadvantage is that flow can only be measured at one time 
point since the brain has to be removed immediately following infusion of the tracer. 
However the temporal resolution can be improved by combining this method with another 
tracer e.g. hexamethylpropyleneamine oxime (see Section 2A.2.2.) to obtain blood flow 
measurements at 2 time points in the same rat.
Another limitation of the [14C]IAP method is that due to the high diffusability of the tracer 
it may underestimate flow in regions with very high blood flows such as the choroid plexus 
and also fail to detect heterogeneity within a region (e.g. cortical columns) due to diffusion 
of the tracer from regions of high flow to regions of low flow in the delay between 
decapitation and freezing (Williams et al. 1991). Diffusion of the tracer can be minimised 
by ensuring the brain is dissected out as rapidly as possible.
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Practice: [14C]iodoantipyrine determination of local CBF in the rat
The protocol used was based on the method of Sakurada et al. 1978.
General Preparation Rats were anaesthetised and polyethylene catheters inserted in the 
femoral arteries and veins as described in Section 2.2. For rats in which CBF was to be 
measured under anaesthesia a tracheostomy was performed and the rats were artificially 
ventilated. For rats intended for conscious CBF measurement no tracheostomy was 
performed. In these rats local anaesthetic gel was applied to the surgical sites, the skin 
was sutured and gauze pads covered with more gel taped over the wounds. The 
anaesthetics were then withdrawn. The rat's torso was enclosed in a surgical stocking and 
the lower half of the body wrapped in a loose fitting plaster cast. The plaster cast and the 
rat's hindlimbs were then taped to a lead brick for restraint The animals were allowed to 
recover for 2 h before the experimental procedure was initiated.
For both anaesthetised and conscious rats body temperature was monitored via a rectal 
probe and maintained around 37°C by heating lamps. Blood pressure was continuously 
monitored (from one arterial catheter) while blood gases were measured at regular intervals. 
The flow rate from the other arterial catheter was adjusted by means of a small metal cuff to 
give a drop rate of approximately 10-15 drops/10 s.
Measurement of local CBF A ramped infusion of 50 pCi [14C]IAP (1.5 ml) was 
administered intravenously over 30 s. During the infusion 18 timed samples of arterial 
blood were collected onto preweighed filter paper discs held in a perspex carousel. At the 
end of the 30 s the rat was decapitated using a guillotine and the brain rapidly dissected out 
The brain was immersed in isopentane (-42°C) for 10 min. The frozen brain was then 
mounted on a small metal chuck and coated with embedding medium. Immediately 
following decapitation the 18 filter paper discs containing the blood samples were placed in 
18 preweighed glass vials, sealed and reweighed to obtain the weight of each blood 
sample. After weighing hydrogen peroxide (0.4 ml) was added to each vial (to bleach the 
blood sample) followed by distilled water (1 ml), the vials were left at room temperature for 
30 min, then 10 ml scintillant was added. The radioactivity in each sample was determined 
by counting in a liquid scintillation counter (Model 1900CA, Canberra Packard, U.K.), 
and the number of counts per minute converted to absolute disintegrations per minute 
(dpm). The mean of 3 sets of counts (dpm) was then used, together with the sample 
weights, to calculate the 14C concentration (nCi/g) in each of the 18 timed samples and 
thereby obtain the arterial concentration curve for [14C]IAP.
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Tissue processing After freezing and embedding the brain was cut into coronal sections 
(20 Jim) using a cryostat. Tissue sections were thaw mounted onto glass coverslips and 
dried on a hotplate at 70°C. The coverslips were glued onto pieces of card together with a 
set of precalibrated 14C standards (44-1880 nCi/g) and apposed to 14C-sensitive film 
(SB-5, Kodak, U.K.) in sealed X-ray cassettes for 14 days. The concentrations of 
[14C]IAP in regions of interest on the resultant autoradiograms were then determined as 
described in Section 2.4.3.
Calculation of local CBF The experimental data (arterial concentration curve for [14C]IAP 
and final tissue concentrations of [14C]IAP) were entered into a computer program (BBC 
computer) to calculate absolute blood flow (ml/100  g/min) using a brain tissue:blood 
partition coefficient of 0.79.
2 . 4 . 2 . 2 .  L o c a l c e r e b ra l  b lo o d  flow  d e te r m in a t io n  u s in g  
[99n,Tc]-D,L-hexainetIiyl propyleneam ine oxime ( [ " “ T cJH M PA O )
Theory
[99mTc]HMPAO was originally developed as a SPECT (single photon emission 
computerised tomography) tracer molecule for measurement of CBF in man. HMPAO 
fulfils the criteria for such a tracer being a lipophilic, low molecular weight compound that 
easily crosses the blood-brain barrier and has high first-pass extraction from the blood to 
brain tissue (Andersen 1989). Once the lipophilic HMPAO has entered the brain it is 
rapidly converted by glutathione and other reducing agents to a hydrophilic form that can 
not traverse plasma membranes and becomes trapped within the brain tissue (Andersen
1989). The resultant regional distribution of the trapped tracer is therefore proportional to 
regional blood flow.
A 4 compartment model for the exchange of HMPAO between blood and brain has been 
proposed (Andersen 1989). The first and second compartments represent the freely 
diffusible lipophilic tracer in the blood and brain tissue respectively, while the third and 
fourth compartments represent the hydrophilic forms of the tracer retained in brain and 
blood (see Figure 13). The rate constants k3 and k5 represent the conversion of lipophilic 
form to hydrophilic form in brain and blood respectively. The conversion of the lipophilic 
form to the hydrophilic form is virtually irreversible so that the rate constants (k4 and k$) 
for re-conversion back to the lipophilic form are assumed to be zero. The rate of uptake of 
HMPAO from the blood to brain (Kj) is determined by the cerebral blood flow (F) and the 
first-pass extraction rate (E) which is itself variable and dependent on blood flow. The rate
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Figure 13 A four compartment model of hexamethylpropyleneamine oxime
(HMPAO) uptake in the brain
BRAIN
BLOOD
The freely diffusible lipophilic form of the tracer in the blood (Aj), 
crosses the blood-brain barrier and enters brain tissue (A2 ) where it 
undergoes conversion to a hydrophilic form (A3) which can not traverse 
plasma membranes and is retained in the tissue. The conversion of the 
lipophilic to hydrophilic form of the tracer also occurs in the blood (A4 ). 
The uptake of the tracer from blood to tissue (Ki) is directly related to 
blood flow. See main text for more details.
A = amount of tracer in each compartment.
Kj = transfer of HMPAO from blood to tissue.
k2 to k 6 = first order rate constants for transfer of HMPAO between A j , 
A2, A 3 and A 4.
From Andersen 1989.
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constant (k2) for diffusion of the lipophilic tracer back into the blood is equivalent to Kj 
divided by the blood:brain partition coefficient (X).
The conversion of lipophilic HMPAO to the hydrophilic form within the brain is not 
instantaneous (k3 = 0.8 ± 0.12 m in1, Lassen et al. 1988). This time lag allows some back 
diffusion of lipophilic HMPAO into the blood. As k2 is dependent on blood flow, wash 
out of the tracer will be higher at higher flow rates resulting in underestimation of CBF in 
regions of high flow. A correction factor has been derived (Lassen et al. 1988) to 
compensate for this initial preferential back-diffusion of [ " mTc]HMPAO from high flow 
regions.
Bractire
The lipophilic p ^ T c ] HMPAO complex is not stable in vitro and undergoes conversion to 
the hydrophilic form with a half-life of 2-4 h (Andersen 1989). As the hydrophilic form 
can not cross the blood-brain barrier, the [99mTc]HMPAO complex must be freshly 
prepared prior to use. Therefore the radio-isotope 99mTc, in the form of 
["mTcJpertechnetate, was mixed with D,L-HMPAO (Ceretec, Amersham International, 
U.K.) to form the P^TcJHMPAO complex immediately following surgical preparation of 
the animal in which blood flow was to be measured. The [ " mTc]HMPAO (0.7 ml i.v.) 
was then administered to the rat within 30 min of reconstitution (to prevent loss of the 
lipophilic form of the tracer) as recommended by Andersen 1989.
At the end of the experimental period the brain was removed and processed as described in 
Section 2.4.1. Tissue sections were apposed to [3H]-sensitive film together with a set of 
precalibrated standards (21330 - 174290 nCi/g " mTc tissue equivalent) for a nominal 
exposure time of 4 h (the exact exposure time being dependent on the delay between 
decapitation and apposition to the film). Tissue concentrations of [99mTc]HMPAO on the 
resultant autoradiograms were determined by densitometry with reference to the standards 
as described in Section 2.4.3. Unlike the [14C]IAP method of determining CBF, the 
[99mTc]HMPAO method does not give an absolute measurement of CBF. Instead relative 
CBF is estimated by expressing regional [99mTc]HMPAO uptake (obtained from the 
autoradiograms) as a percentage of the uptake in a pre-selected reference region - for this 
study the data was normalised to the cerebellum.
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2.4.3. Measurement of autoradiograms
Analysis of all autoradiograms was conducted using the Quantimet 970 imager analyser 
system (Cambridge Instruments, U.K.). This system firstly measures the optical density 
of the precalibrated standards (3H or 14C) to obtain a calibration curve of optical density 
versus ligand concentration (nCi/g tissue). The optical densities of the chosen regions of 
interest on the autoradiogram were then measured and subsequently converted to the actual 
tissue concentration of the particular ligand by reference to the standard curve.
For each neuroanatomical region studied 6 measurements of optical density were made 
from several tissue sections. The mean of these measurements was then converted to the 
tissue concentration of ligand for each region from each animal with reference to the 
standards. In studies combining in vitro receptor autoradiography with in vivo 
determination of local CBF, care was taken to ensure that optical densities were measured 
at exactly the same points on the different autoradiograms. For in vitro receptor 
autoradiography optical densities for specific binding were calculated by subtracting the 
values for nonspecific binding from those for total binding.
2.5. STATISTICAL ANALYSIS
Data in the main text and results tables are presented as means ± standard deviation. Data 
presented graphically is shown as means ± standard error of the mean to improve the clarity 
of the figures.
For CBF and ligand binding studies, data was evaluated by either paired or unpaired 
Student's f-tests where appropriate. For analysis of change in blood pressure over time, 
mean arterial blood pressures were compared by two-way repeated measure ANOVA 
followed by unpaired Student's r-tests with Bonferroni correction for simultaneous multiple 
comparisons (Wallenstein et al. 1980). For the evolution of ischaemic damage study 
volumes of ischaemic damage for permanent, transient and sham MCA occlusion groups 
were analysed separately by one-way ANOVA followed by unpaired Student’s f-tests with 
Bonferroni correction. In all other histology studies volumes of ischaemic damage were 
compared by unpaired Student's f-tests with Bonferroni correction where appropriate. In 
all cases differences were considered significant for p < 0.05.
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3. ALTERATIONS IN LOCAL CEREBRAL BLOOD FLOW FOLLOWING 
TRANSIENT FOCAL CEREBRAL ISCHAEMIA
3.1. In troduction
The endothelin-1 model of MCA occlusion was specifically designed as a model of 
transient focal ischaemia. It is therefore of critical importance to demonstrate that 
reperfusion does occur in this model, particularly as restoration of blood flow is not 
observed (within 3 h of endothelin-1 application) in the superficially similar model 
described by Sharkey et al. 1993. Therefore this study was designed to assess the acute 
changes in local CBF induced by topical application of endothelin-1 to the MCA in the 
anaesthetised rat.
In an earlier study it was demonstrated that, in our model, endothelin-1 applied to the MCA 
induces profound ischaemia followed by spontaneous restoration of blood flow in the 
caudate nucleus (Macrae et al. 1993). This study was conducted using the hydrogen 
clearance technique and hence was limited to measuring blood flow only at the site of probe 
placement. The present study was therefore designed to assess endothelin-1-induced 
changes in CBF throughout the entire cerebral hemispheres using the greater spatial 
resolution offered by in vivo autoradiographical techniques. The combined use of 2 
different radio-isotopes ([14C]IAP and [99mTc]HMPAO) enabled measurement of local 
CBF at 2 time points following application of endothelin-1 to the MCA. The time points 
were chosen with reference to the hydrogen clearance study in order to obtain a measure of 
local CBF at the time of most profound ischaemia (5 min post-endothelin-1 application) and 
at a time when CBF would be expected to be recovering (2 h post-application of 
endothelin-1).
3.2. Experim ental protocol
Rats underwent transient MCA occlusion (n = 12) induced by topical application of 
endothelin-1 to the MCA (see Section 2.3.1.). For illustrative comparison one animal was 
subjected to permanent MCA occlusion while 2 further rats underwent the sham procedure 
(saline applied to the MCA). Local CBF was measured 5 min and 2 h post-MCA occlusion 
using the tracers [99mTc]HMPAO and [14C]IAP respectively. The [99mTc]HMPAO 
complex was prepared immediately prior to MCA occlusion and in all cases administered to 
the rat within 30 min of preparation.
74
[ " mTc]HMPAO (0.7 ml, 224 MBq 99mTc) was injected intravenously over 30 s, 4 min 
post-MCA occlusion to allow for the lag time between administration and brain uptake 
(approximately 1 min). 2 h post-MCA occlusion local CBF was measured using the 
standard [14C]IAP protocol described in Section 2.4.2.1. The brain was removed and 
processed as quickly as possible to prevent excess loss of radioactive tracer due to the 
relatively short half-life (6 h) of " mTc. The frozen brain was cut into coronal sections (20 
pm) which were collected onto glass coverslips for autoradiographic determination of local 
CBF.
For the [99mTc]HMPAO image of blood flow, the sections were apposed to [3H]-sensitive 
film for approximately 4-5 h together with a set of precalibrated standards (21330 - 174290 
nCi/g " " T c  tissue equivalent). In addition a set of [14C]-standards was included to assess 
the degree of contamination by [14C] of the 99mTc-images. The actual duration of exposure 
for each individual experiment was determined by the lag time between decapitation and 
apposition to the film. The [99mTc]HMPAO film was then developed and the sections 
stored (behind lead bricks) for 4 days (equivalent to 16 half-lifes for " mT c ) to allow decay 
of 99mTc activity and prevent cross-contamination of " mTc onto the 14C image. The 
sections were then re-apposed to [14C]-sensitive film for 14 days, together with a set of 
[14C]-standards, to obtain the [14C]IAP image. The scintillation vials were also stored for 
4 days (to allow decay of 99mTc) prior to determination of [14C]-concentration in the 
arterial blood samples.
3.3. Results
Physiological variables measured immediately prior to MCA occlusion and 2 h post-MCA 
occlusion are shown in Table 2. Individual values were within the normal range and 
comparable between the 2 time points.
Temporal alterations in cerebral blood flow following transient MCA occlusion
Five min following application of endothelin-1 to the MCA there were reductions in local 
CBF throughout the hemisphere ipsilateral to the constricted MCA, while by 2 h 
post-endothelin-1 application local CBF had appreciably increased in those regions which 
had exhibited the most severe reductions in CBF at the 5 min time point. Autoradiograms 
(at the same level) 5 min and 2 h following onset of transient MCA occlusion from one 
animal are shown in Figure 14a-b. The increase in blood flow at the 2 h time point in 
regions which were densely ischaemic 5 min post-endothelin-1 application is clearly 
apparent. Although there was some variation between animals with respect to the
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topographical distribution and magnitude of the reductions in local CBF following transient 
MCA occlusion, this same basic pattern of temporal change in CBF was apparent to some 
extent for all animals studied. In contrast, for the animal subjected to permanent MCA 
occlusion, blood flow was still very low and not appreciably altered from the 5 min time 
point 2 h post-MCA occlusion (Figure 14c-d).
The mean values for local CBF 5 min and 2 h post-MCA occlusion are shown in Table 3. 
Since local CBF measured by the HMPAO technique can not be expressed in absolute units 
(i.e. ml/100 g/min) both the HMPAO-derived values (5 min time point) and the IAP- 
derived values (2 h time point) are shown normalised to the cerebellum to allow direct 
comparison of local CBF at the 2 time points (mean absolute blood flow for the cerebellar 
cortex was 146 ± 50 ml/100 g/min).
5 min post-endothelin-1 application to the MCA the greatest reductions in local CBF were 
observed in the frontal and sensorimotor cortices (11 - 16% of contralateral value) and 
dorsolateral caudate nucleus (29% of contralateral value) (Table 3). Moderate reductions 
in local CBF were found in the parietal cortex, ventromedial caudate nucleus, globus 
pallidus and genu (38 - 57% of contralateral value) while small, but statistically significant, 
reductions in flow were present in the thalamus and nucleus accumbens (87 - 91% of 
contralateral value). Due to heterogeneity in the distribution of the areas of 
endothelin-1-induced ischaemia, the averaged local CBF values masked more severe 
reductions in local CBF in a substantial proportion of the animals. For example inspection 
of the individual data for the dorsolateral caudate nucleus revealed that for 7 of the 12 
animals blood flow was reduced to less than 25% of the contralateral value.
By 2 h post-endothelin-1 application local CBF in the core MCA territory had increased - to 
29 - 30% of the contralateral value in the frontal and sensorimotor cortices, and 50% of the 
contralateral value in the dorsolateral caudate nucleus (Table 3). In contrast for regions 
such as the nucleus accumbens and thalamus which exhibited only minor reductions in 
local CBF at the 5 min time point, local CBF (expressed as a percentage of the contralateral 
value) was not appreciably altered at the 2 h time point.
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Table 2 Physiological variables for autoradiographical determination of 
local cerebral blood flow following transient MCA occlusion
Pre-MCAO Post-MCAO
pH 7.401 ±0.047 7.386 ±0.054
Pa CO2 (mmHg) 38.6 ±1.8 39.6 ±2.8
PaO^mmHg) 174.1 ±36.7 190.8 ±27.6
Rectal Temp (°C) 37.11 ±0.22 36.82 ±0.34
Glucose (mmol/1) 10.82 ±2.36 9.89 ±1.88
Temporalis 
TemD (°C) 36.70 ±0.45
------
Physiological variables were determined immediately prior to and 2 h 
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In contrast to the reductions in local CBF induced by endothelin-1, the sham procedure 
(saline applied to the MCA) resulted in minimal alterations in local CBF. For example the 
mean values (n = 2) for local CBF 5 min post-saline application to the MCA (expressed as 
percentages of the blood flow in the cerebellum) were 127 ± 8 and 140 ± 5 for the frontal 
cortex (ipsilateral and contralateral to the sham procedure) and 134 ± 4 and 137 ± 4 for the 
dorsolateral caudate nucleus (ipsilateral and contralateral to the sham procedure).
3.4. D iscussion
In this study double label autoradiography was used to measured local CBF at 2 time points 
following constriction of the MCA induced by endothelin-1. The results demonstrate that 
there were severe reductions in local CBF in regions such as the frontal cortex and 
dorsolateral caudate nucleus that receive their blood supply primarily from the MCA 5 min 
post-application of endothelin-1 to the artery. The magnitude of the reductions in flow in 
the frontal and sensorimotor cortices (expressed as percentages of the contralateral values) 
were similar to those previously reported for both permanent MCA occlusion (Tamura et al. 
1981b) and topical application of endothelin-1 to the MCA (Robinson et al. 1990) where 
local CBF was measured 30 and 10 min post-onset of ischaemia respectively using the LAP 
technique. Thus the dose of endothelin-1 (25 |il x 1(HM) used in the present study causes 
reductions in CBF in the MCA territory to levels that have previously been demonstrated to 
induce ischaemic damage (Tamura et al. 1981 a,b). However the present study has also 
shown that local CBF values in the core MCA territory increase approximately 2-3 fold 2 h 
post-endothelin-1 application, indicating that a significant degree of reperfusion is present 
by this time point. The demonstration of reperfusion 2 h following endothelin-1 
application to the MCA is in good agreement with the temporal restoration of flow 
previously reported in this model using the hydrogen clearance technique (Macrae et al. 
1993). In summary this study has established that application of endothelin-1 to the MCA 
(as described in Section 2.3.) results in a period of profound ischaemia followed by partial 
restoration of blood flow by 2 h post-endothelin-1 application, thereby validating this 
approach as a model of transient focal ischaemia.
Although local CBF in the core MCA territory was still reduced at the 2 h time point 
compared with the corresponding contralateral regions, the observed absolute values for 
local CBF were well above the flow threshold for irreversible ischaemic damage in the 
normotensive rat (see Section 5.3.1.). For example the minimum mean absolute value for 
local CBF (derived from the IAP autoradiograms) obtained at the 2 h time point was 50 
ml/100 g/min in the sensorimotor cortex which is approximately twice the ischaemic 
threshold. Thus although restoration of blood flow was by no means complete at the 2 h
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time point, CBF had probably been sufficiently increased to prevent further direct 
ischaemic damage to the tissue. The demonstration of a significant degree of reperfusion, 
present as early as 2 h post-onset of ischaemia, lends support to the hypothesis that the 
dramatic increase in lesion volume that occurs from 4 h to 24 h post-onset of ischaemia in 
this model (see Section 4.2.) is due to pathological processes associated with reperfusion 
rather than continued severe ischaemia.
Comparison with alternative models of transient MCA occlusion in the rat
In the present study local CBF (measured by [99mTc]HMPAO uptake) was reduced to 11 - 
16% of the actual contralateral value in core MCA territory such as the frontal and 
sensorimotor cortices 5 min post-endothelin-1 application. Similar reductions in flow are 
achieved with MCA occlusion induced by the intraluminal thread method (10 - 15% of 
contralateral values measured by [14C]IAP autoradiography, Memesawa et al. 1992a) or 
extravascular occlusion with clips (10% of baseline measured by laser Doppler flowmetry, 
Buchan et al. 1992b) or ligatures (21% of baseline measured by laser Doppler flowmetry, 
Kaplan et al. 1991) in tandem with carotid artery occlusion.
2 h following application of endothelin-1 local CBF in the previously ischaemic regions 
(frontal and sensorimotor cortices and dorsolateral caudate nucleus) had increased to 29 - 
50% of the contralateral value demonstrating reperfusion had been initiated. For 
comparison, in the intraluminal thread model local CBF returns to 32% (cortex) and 47% 
(caudate) of contralateral values with a 15 min period of reperfusion following 1 h MCA 
occlusion (Memesawa et al. 1992b), and 68% (cortex) and 58% (caudate) after 2 h 
recirculation (Nagasawa & Kogure 1989). Thus although it may have been surmised that 
reperfusion in the endothelin-1 model of MCA occlusion would be slower and more 
progressive than reperfusion following removal of an intraluminal filament this does not 
appear to be the case. Nagasawa and Kogure suggest the comparatively slow reperfusion 
in their model is due to marked oedema formation on reperfusion that tends to reduce CBF 
throughout the brain (Nagasawa & Kogure 1989). In contrast reperfusion following 
removal of clips or ligatures is associated with an immediate transient hyperaemia (CBF 
greater than 200% of baseline, Kaplan et al. 1991) which is followed by return to baseline 
flows (Buchan et al. 1992b; Kaplan et al. 1991). The different haemodynamic patterns of 
reperfusion observed in the different rat models of transient MCA occlusion will be 
discussed further in Section 8.2.
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It is difficult to relate the CBF changes following experimental transient focal ischaemia to 
the clinical situation since there is very little data available concerning CBF in the first few 
hours following resolution of MCA occlusion in man. However it is known that 
hyperaemia within the previously ischaemic region can frequently occur (44 - 87% of all 
cases showing reperfusion (Olsen & Lassen 1984; Ringelstein et al. 1992) within the first 
few days following stroke onset and can persist for approximately 2 weeks (Olsen & 
Lassen 1984; Ringelstein et al. 1992). The cause of this prolonged hyperperfusion is 
unclear - lactate accumulation during the ischaemic phase (Lassen 1966) may contribute to 
immediate hyperaemia on reperfusion, but is not likely to sustain the hyperaemic state for 2 
weeks (Olsen 1986). It is more likely that the hyperperfusion reflects ischaemic damage to 
the vasculature resulting in loss of the normal vascular reactivity to vasoconstrictive stimuli 
(Olsen 1986).
The temporal progression of reperfusion in the endothelin-1 model has not yet been studied 
beyond 4 h post-onset of ischaemia in the anaesthetised rat (Macrae et al. 1993). 
Measurement of local CBF at later time points (e.g. 24 and 72 h post-endothelin-1) may 
yield further information that is pertinent both to the temporal evolution of lesion size 
within this model and also to clinical stroke.
Methodological considerations for the determination of cerebral blood flow using HMPAO
1) In normal rat brain there is an excellent linear relationship between relative CBF 
measured by the HMPAO technique and absolute CBF determined by other methods (e.g. 
IAP) up to flows of approximately 100 ml/100 g/min (Bullock et al. 1991; Lear 1988). 
However above this level the HMPAO method can underestimate CBF due to back 
diffusion of the lipophilic tracer from the brain to the blood. Several authors (Bullock et al. 
1991; Lear 1988) have utilised the correction algorithm derived by Lassen and colleagues 
(Lassen et al. 1988) to compensate for this phenomenon but we chose not to use this 
correction factor in the present study for 2 reasons. Firstly, the Lassen correction was 
originally devised to 'enhance(s) the contrast between high and low flow regions' on an 
HMPAO image (Lassen et al. 1988). Although the correction factor does achieve this aim, 
and thereby improves the linearisation between CBF measured by HMPAO uptake and 
other techniques (Lassen et al. 1988; Lear 1988), it also increases the spread of the data so 
that the correlation between the 2 data sets may actually be weaker once the correction 
factor has been applied (Heiss et al. 1990). Therefore we saw no advantage in applying the 
Lassen correction to quantitative analysis of blood flow data. Secondly, in this study 
HMPAO uptake was used to assess the ischaemia invoked by endothelin-1-induced
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constriction of the MCA. Thus we were primarily concerned with measuring CBF in 
regions exhibiting pathologically low levels of blood flow. As stated above the HMPAO 
method accurately reflects CBF up to 100 ml/100 g/min, thus no correction factor was 
necessary for assessment of blood flow in ischaemic regions.
2) The problem of cross-contamination between the autoradiographic images produced by 
the 2 radio-isotopes (14C and 99mTc) must be considered. Contamination of the 
14C-image by 99mTc was prevented by allowing virtual complete decay of 99mTc before the 
tissue sections were apposed to 14C-sensitive film. However the possible contamination of 
the " “ Tc-image by 14C must be addressed. This is of particular importance to the present 
study since, due to the presence of reperfusion, blood flow in certain regions would be 
higher at the time of 14C-uptake compared with 99mTc-uptake and thus the relatively high 
tissue concentrations of 14C may have resulted in overestimation of CBF on the HMPAO 
image i.e. the severity of the ischaemia induced by endothelin-1 may have been 
underestimated in regions which were subsequently well reperfused. To assess the degree 
of contamination, a 'worst-case' analysis was performed using CBF data derived from the 
HMPAO autoradiogram with the longest exposure time (5.5 h). For this animal the 
contribution of 14C to the optical density of the regions with densest ischaemia was found 
to amount to less than the equivalent of 1 ml/100 g/min CBF. Therefore we can conclude 
that cross-contamination was minimal and that the values of CBF in the ischaemic regions 
derived from the HMPAO autoradiograms are a true reflection of CBF at the time of 
HMPAO uptake.
3) Once lipophilic HMPAO has been taken up by brain tissue and converted to the 
hydrophilic form it is assumed that the tracer is entrapped within the brain. Although 
conversion of the hydrophilic form of HMPAO back to the lipophilic form is negligible, a 
small amount of hydrophilic HMPAO may be lost from the brain resulting in 
underestimation of CBF. Loss of hydrophilic HMPAO may be of particular importance to 
CBF studies of cerebral ischaemia since it may be surmised that ischaemia induced damage 
to the blood-brain barrier and cellular membranes could potentially increase the rate of loss 
of hydrophilic HMPAO. However it has been reported that HMPAO uptake accurately 
reflects CBF (measured by [14C]IAP) 72 h post-permanent MCA occlusion in the rat 
(Bullock et al. 1991) when blood-brain barrier permeability is increased. Thus loss of 
hydrophilic HMPAO through a damaged blood-brain barrier does not appear to influence 
CBF measurement within the sub-acute phase of experimental cerebral ischaemia.
While hypofixation of [99mTc]HMPAO may be expected in regions of tissue damage, 
paradoxically increased [99mTc]HMPAO uptake has been reported in infarcts from patients 
with sub-acute stroke and evidence of reperfusion (Sperling & Lassen 1993).
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[99mTc]HMPAO uptake in these patients overestimated CBF as measured by 133Xe 
tomography at the same time point. Thus the actual degree of reperfusion in these patients 
was more modest than the overt hyperemia suggested by the [ " mTc]HMPAO image. The 
reasons for hyperfixation of [99mTc]HMPAO in a reperfused infarct are at present 
unknown but again may be related to redistribution of the hydrophilic form of the tracer as 
a consequence of blood-brain barrier damage (Heiss et al. 1990). In the present study 
[99mTc]HMPAO was used to assess the degree of ischaemia rather than reperfusion, and 
the tracer was administered within 5 min of endothelin-1 application at a time when the 
blood-brain barrier is likely to be intact, thus hyperfixation of [99mTc]HMPAO is not likely 
to be a confounding influence on the results presented herein.
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4. HISTOLOGICAL CHARACTERISATION OF ISCHAEMIC DAMAGE FOLLOWING 
TRANSIENT AND PERMANENT MCA OCCLUSION
4.1. Assessment of acute ischaemic damage following MCA occlusion
4.1.1. Introduction
The ischaemic damage induced by transient MCA occlusion was first quantified 
histopathologically in the anaesthetised rat, 4 h following application of endothelin-1 to the 
MCA. For comparison, the volumes of ischaemic damage following permanent MCA 
occlusion (4 h duration) or the sham procedure were also determined. The 4 h time point 
was chosen because: a) maintenance of artificially-ventilated rats under anaesthesia allows 
physiological parameters (blood pressure, blood gases, body temperature) to be rigorously 
controlled within strict limits throughout the 4 h period. The impact of these variables on 
outcome is thus comparable for all animals and b) 4 h is the earliest time point at which the 
bonder between viable and ischaemically-damaged tissue can be reliably delineated using 
the specified histopathological techniques.
4.1.2. Experimental protocol
Rats, maintained under halothane anaesthesia, were subjected to permanent or transient 
MCA occlusion or the sham procedure as described in Section 2.3.1. Blood pressure was 
monitored continuously throughout the experiments and rats were killed 4 h post-onset of 
ischaemia by perfusion fixation. Quantitative histopathology was then used to determine 
the volumes of ischaemic damage for each group.
4.1.3. Results
4.1.3.1. Physiological Variables
The physiological variables for the 3 separate procedures (permanent, transient and sham 
MCA occlusion) are shown in Table 4 and were within normal physiological limits for all 
groups.
Mean values for mean arterial blood pressure (MABP) prior to exposure of the MCA were 
88 ± 21, 86 ± 9 and 86 ± 6 mmHg for permanent MCA occlusion, transient MCA 
occlusion and sham procedure respectively. MABP was not appreciably affected by the 
surgical procedure (see also Figures 26-27).
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Table 4 Physiological variables for 4 h MCA occlusion in the anaesthetised rat
PERMANENT MCAO (n = 6)
Pre-MCAO + 1 HOUR + 4 HOUR
PH 7.495 ± 0.042 7.497 ± 0.036 7.442 ± 0.040
Pa CO2 (mmHg) 37.5 ± 3.2 36.0 ±1.6 36.7 ± 1.4
Pa 0 2 (mmHg) 165.0± 23.0 166.8 ±12.5 164.7 ± 11.3
Glucose (mmol/1) 9.22 ± 1.04 8.97 ±0.48 8.63 ±0.58
Rectal Temp (°C) 36.90 ±0.55 36.92 ±0.26 36.88 ±0.10
TRANSIENT MCAO (n = 12)
Pre-MCAO + 1 HOUR + 4 HOUR
pH 7.453 ±0.040 7.443 ±0.041 7.425 ±0.047
Pa CO2 (mmHg) 37.7 ±3.1 37.4 ±3.0 37.8 ±1.7
Pa 0 2 (mmHg) 137.4 ±23.0 145.3 ±26.3 154.3 ±20.1
Glucose (mmol/1) 11.09 ± 1.09 10.27 ±1.39 9.21 ±1.12
Rectal Temp (°C) 36.91 ±0.34 36.97 ±0.24 37.06 ±0.23
SHAM PROCEDURE (n = 3)
Pre-saline + 1 HOUR + 4 HOUR
pH 7.417 ±0.040 7.423 ± 0.025 7.437 ±0.012
Pa a >2 (mmHg) 36.7 ± 1.5 36.3 ±3.1 37.0 ±2.0
Pa 0 2 (mmHg) 158.7 ±8.5 181.3 ± 11.1 174.3 ±14.6
Glucose (mmol/1) 10.00 ± 1.41 10.37 ±0.83 9.97 ±0.57
Rectal Temp (°C) 36.67 ±0.58 37.23 ±0.21 37.37 ± 0.32
Physiological variables were measured immediately prior to MCA 
occlusion (MCAO), and 1 h and 4 h post-MCA occlusion.
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4.1.3.2. Quantification of ischaemic damage
Permanent MCA occlusion
Permanent MCA occlusion resulted in a large lesion that extended from the frontal to 
parietal cortices and also included a large portion of the lateral caudate nucleus (see Figure 
15a). The total volumes of ischaemic damage (mean ± S.D.) for hemisphere, cortex and 
caudate nucleus were 106.6 ± 14.7, 68.5 ± 13.6 and 30.2 ± 4.6 mm3 respectively.
Neurones within the lesion exhibited the classical signs of ischaemic cell change. The 
nuclei were shrunken, densely stained and triangular in shape, while the cytoplasm was 
intensely eosinophillic. The surrounding neuropil was palely stained and spongy in 
appearance (see Figure 16a).
Transient MCA occlusion
At the 4 h time point the lesion following transient MCA occlusion was smaller than for 
permanent MCA occlusion but the topographic distribution within the brain was similar for 
both models (see Figure 15b). The mean volumes of ischaemic damage for hemisphere, 
cortex and caudate nucleus following transient MCA occlusion were 48.0 ± 26.4, 31.9 ± 
22.9 and 12.7 ± 9.6 mm3 respectively. The histological appearance of neurones and 
neuropil within the region of ischaemic cell damage following transient MCA occlusion 
was indistinguishable from permanent MCA occlusion (Figure 16b). Although the mean 
area of damage at each stereotactic level tended to be less following transient MCA 
occlusion (particularly in the centre of the lesion), the rostro-caudal extent of ischaemic 
damage following both permanent and transient MCA occlusion were comparable (see 
Figure 17).
Sham procedure
The sham operation (involving application of saline to the exposed MCA) resulted in either 
no apparent lesion, or veiy minor damage located in the cerebral cortex ventral to the rhinal 
fissure and corresponding to the site of craniectomy. The mean volumes of ischaemic 
damage for hemisphere, cortex and caudate nucleus were 0.4 ± 0.7, 0.4 ± 0.7 and 0.0 ± 
0.0 mm3 respectively.
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Figure 15 Distribution of tissue damage assessed 4 h following onset of permanent or 
transient MCA occlusion in the anaesthetised rat
a) Permanent MCA occlusion b) Transient MCA occlusion
Diagramatic representation of regions showing ischaemic cell change (shaded black) at each 
of 8 pre-selected stereotactic levels. The figure shows the extent of histological damage for 
2 representative animals subjected to a) permanent MCA occlusion or b) transient MCA 
occlusion. For both models ischaemic damage was located predominantly in frontal and 
parietal cortices and lateral caudate nucleus.
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F ig u r e  16 Isch aem ic  c e ll ch a n g e  4 h fo llo w in g  perm anent or transient M C A  o cc lu s io n  in 
the anaesthetised  rat
T he fig u re  sh o w s high p o w er  m icrograp h s o f  the ipsila teral frontal co r tex  (sta in ed  w ith  
h aem atoxy lin  and eosin ) for 2 representative rats subjected to a) perm anent and b) transient 
M C A  occ lu sio n . In each ca se  the border b etw een  the isch aem ic  lesion  and m orp h o log ica lly  
norm al tissu e  is clearly  v is ib le . W ith in  the les io n  neurones that have undergone isch a em ic  
ce ll ch a n g e  are triangular in shape w ith  in ten se ly  stained nu cle i. T he neuropil surrounding  
th ese  n eu ron es is p ale  and sp o n g y  in ap pearance. In contrast n eu ron es w ith in  the in tact 
















































































4.2. Timecourse for evolution of ischaemic damage following transient and 
permanent MCA occlusion
4.2.1. Introduction
Having established that transient MCA occlusion induced by endothelin-1 results in a 
quantifiable lesion 4 h post-application of the peptide, the evolution of ischaemic damage 
beyond the 4 h time point was then determined. Our hypothesis was that the volume of 
ischaemic damage following transient MCA occlusion would continue to increase beyond 
4 h due to the introduction of additional, as yet undefined, pathological factors during the 
reperfusion phase. For comparison, separate experiments were again conducted for 
permanent and sham MCA occlusion at the same time points (4, 24 and 72 h). Rats were 
allowed to recover consciousness following surgery for the longer survival times (24 and 
72 h). Therefore to permit valid comparisons between the 3 time points anaesthetics were 
also withdrawn following surgery from the 4 h groups. Control of physiological 
parameters is not possible to the same extent in conscious animals compared to animals 
maintained in the anaesthetised state. However physiological variables were monitored 
throughout the survival period so that any observable differences between groups could be 
taken into account in the interpretation of apparent changes in lesion size over time.
4.2.2. Experimental protocol
Rats were anaesthetised and the right femoral artery cannulated as described in Section 2.2. 
A permanent, transient (endothelin-1) or sham (saline) MCA occlusion was then 
performed. Approximately 10-15 min following surgery anaesthetics were withdrawn and 
the animals allowed to regain consciousness. The rats were killed 4 h, 24 h or 72 h 
following induction of ischaemia (or application of saline for the sham group). Blood 
pressure in the 4 h groups was monitored continuously. For the 24 h and 72 h groups 
blood pressure was monitored for 1 h post-surgery and then for 10-15 min (in conscious 
animals) at 24 h, 48 h and 72 h post-MCA occlusion where applicable. Blood gases, 
plasma glucose and rectal temperature were also measured at the 1 h, 24 h, 48 h and 72 h 
time points. After completion of physiological monitoring rats were returned to the 
post-operative recovery room. In some animals the cannula did become blocked (inspite of 
the use of heparin and antibiotics) and hence no physiological data could be obtained for 
these rats at certain time points. At the end of the specified survival period rats were 
reanaesthetised and perfusion fixed as described in Section 2.3.2. Quantitative 




Physiological variables for rats allowed to survive for 4, 24 or 72 h post-transient, 
permanent or sham MCA occlusion are shown in Tables 5, 6 and 7 respectively. For 
transient MCA occlusion physiological variables immediately prior to MCA occlusion 
(when rats were anaesthetised) were comparable between the 3 groups. Although the rats 
were breathing spontaneously under anaesthesia, hypercapnia was not apparent and arterial 
blood C 0 2 levels were similar to those for artificially ventilated rats in other studies.
Arterial blood 0 2 levels decreased following withdrawal of anaesthetics due to the lower 0 2 
concentration of atmospheric air. In the 24 h and 72 h groups plasma glucose 
concentrations were decreased at the 24 h and 48 h time points along with the observed 
weight loss in the animals, however by 72 h feeding had been resumed and the plasma 
glucose concentration began to recover. A small increase in rectal temperature was 
apparent that peaked at 24 h post-MCA occlusion and then subsequently began to decline. 
Similar changes in physiological variables were noted for both permanent and sham MCA 
occlusion (see Tables 6 and 7).
The changes in blood pressure following transient MCA occlusion are illustrated in Figure 
18. At the time of MCA occlusion (under anaesthesia) mean MABP was similar for the 4 
h, 24 h and 72 h groups. Anaesthetics were withdrawn approximately 10-15 min 
following MCA occlusion. In response to the withdrawal of anaesthetics blood pressure in 
all 3 groups began to increase, returning to the normal range for the conscious rat by 1 h 
post-MCA occlusion. MABP was then well maintained at this level throughout the 
remainder of the survival periods and did not differ appreciably between groups at any 
comparable time point Similar patterns of blood pressure response following withdrawal 
of anaesthetics were observed for permanent (Figure 19) and sham (Figure 20) MCA 
occlusion and mean values for MABP were comparable between the 4 h, 24 h and 72 h 
groups in each study.
4.2.3.2. Post-operative behaviour
During the first 24 hours post-MCA occlusion hunching and piloerection were commonly 
observed in survival animals, but these features resolved themselves with longer survival 
times. The rats were reluctant to eat and lost weight in the first 2 days post-operatively 
(probably partly due to impairment of mastication resulting from surgical section of the 
temporalis muscle), but began to recover weight by the third day. Neither overt 
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4 Hour (n = 10) 
24 Hour (n = 9) 
72 Hour (n = 12)
1 0 0 -
0 1 2  3 4 24 481 72
j  Time (h)
MCAO
Transient MCA occlusion (MCAO) was performed under halothane 
anaesthesia. 10-15 min post-MCA occlusion anaesthetics were withdrawn 
and the rats allowed to recover consciousness. Rats were reanaesthetised 
and killed by perfusion fixation 4,24 or 72 h post-MCA occlusion.
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4 Hour (n = 6) 
24 Hour (n = 6) 















Permanent MCA occlusion (MCAO) was performed under halothane 
anaesthesia. 10-15 min post-MCA occlusion anaesthetics were withdrawn and 
the rats allowed to recover consciousness. Rats were reanaesthetised and killed 

























#  4 Hour (n = 3)
O —  24 Hour (n = 4) 




The sham procedure (saline applied to MCA) was performed under 
halothane anaesthesia. 10-15 min post-saline application anaesthetics 
were withdrawn and the rats regained consciousness. The animals were 
reanaesthetised and killed 4,24 or 72 h post-saline application.
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neurological examination was performed. The rats appeared generally apathetic and 
reluctant to move either spontaneously or in response to touch. A similar response pattern 
has been reported following selective lesion of the dorsolateral caudate nucleus in humans 
(Mendez et al. 1989). In general symptom severity appeared related to the extent of 
ischaemic damage so that rats subjected to permanent MCA occlusion were most affected.
4 2 3 3 .  Evolution of ischaemic damage 
Permanent MCA occlusion
Permanent MCA occlusion resulted in a large lesion located predominantly in the frontal, 
sensorimotor and parietal cortices and the dorsolateral caudate nucleus. The total volume of 
damage in the 4 h recovery group was 131.1 ± 37.0 mm3. No further increase in damage 
was apparent at 24 h or 72 h and there were no significant differences between the volumes 
of ischaemic damage following permanent MCA occlusion of 4 h, 24 h or 72 h duration for 
whole hemisphere, cortex or caudate nucleus (see Figure 21). Therefore in this model the 
volume of ischaemic damage does not increase beyond the 4 h time point The areas of 
ischaemic damage at each stereotactic level were also comparable for each time point 
Areas of damage following 4 h or 24 h permanent MCA occlusion are shown in Figure 22 
(the values for the 72 h group, which were numerically similar to the 4 and 24 h groups, 
were omitted to improve the clarity of the figure).
Transient MCA occlusion
In contrast to permanent MCA occlusion, the volumes of ischaemic damage in whole 
hemisphere, cortex and caudate nucleus increased markedly (3 to 4-fold) from 4 h to 24 h 
post-onset of transient MCA occlusion (see Figure 23). However the volumes of damage 
at the 72 h time point were smaller than at the 24 h time point, although still increased 
compared to the volumes of damage 4 h post-onset of transient MCA occlusion. Statistical 
analysis by one-way ANOVA revealed a significant effect of time on the volumes of 
ischaemic damage. Subsequent pairwise comparisons showed the volume of damage 
increased significantly from the 4 h to the 24 h time point The areas of damage 4 h or 24 h 
following onset of transient MCA occlusion are shown in Figure 24. These graphs 
demonstrate that ischaemic damage increased from 4 h to 24 h throughout the rostrocaudal 























f^ l  Caudate Nucleus
4 Hour 24 Hour 72 Hour
Mean volumes of ischaemic damage in the hemisphere, cerebral cortex and 
caudate nucleus assessed 4 (n = 6), 24 (n = 6) and 72 (n = 4) h post-permanent 
MCA occlusion. There were no significant differences between the volumes 
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Figure 23 Evolution of the volume of ischaemic damage following
transient MCA occlusion
125 1





4 Hour 72 Hour
Mean volumes of ischaemic damage in the hemisphere, cerebral cortex and 
caudate nucleus assessed 4 (n = 10), 24 (n = 9) and 72 (n = 12) h following the 
onset of transient MCA occlusion. The volumes of damage increased 
significantly from 4 to 24 h in the hemisphere, cortex and caudate nucleus 
(one-way ANOVA followed by unpaired Student's t-tests *p < 0.05, **p < 0.01 









































































































































































































































Apart from variations in overall size, there were no gross differences between the 
morphological appearance of lesions following either transient MCA occlusion (4 h and 24 
h groups) or permanent MCA occlusion (4 h, 24 h and 72 h groups). In all these animals 
the lesions exhibited classical ischaemic cell change: shrunken, densely stained cell bodies 
containing pyknotic nuclei, and spongiform, palely stained neuropil. However the 
morphological appearance of the lesions in the 72 h transient MCA occlusion group 
differed in 2 important aspects from all other groups. Firstly pronounced oedema was 
observed within these brains (despite the fixation procedure), manifested as uniform pallor 
of the neuropil (which otherwise appeared morphologically normal) surrounding, but 
outwith, the ischaemic infarct. Secondly in 9 of the 12 animals discrete areas of blood 
were present, located within the infarct in either the dorsolateral cortex or dorsolateral 
caudate nucleus {i.e. distant from the surgical site). In contrast blood was only observed in 
1 of the brains from the 24 h transient MCA occlusion group and in no other animals 
subjected to either permanent or transient MCA occlusion.
Various physiological factors which have an influence on outcome were examined in an 
attempt to account for the variability in the results for the 24 h and 72 h time points 
following transient MCA occlusion. Individual data points were analysed to determine if 
there was any obvious relationship between blood pressure and/or the degree of initial 
MCA constriction induced by endothelin-1, and the final volume of ischaemic damage. 
Rats from the 24 h and 72 h groups were subdivided into those in which endothelin-1 
induced only a moderate constriction of the MCA and those in which there was a severe 
constriction of the artery. Individual volumes of hemispheric damage were then plotted 
against a) MABP at the time of MCA occlusion and b) MABP 1 h post-MCA occlusion - 
when blood pressure was increasing following withdrawal of anaesthetics (Figure 25). 
Firstly these graphs show that, iiTespective of blood pressure, there was a tendency for the 
final volume of ischaemic damage to be greater following a severe constriction in response 
to endothelin-1 compared to a moderate constriction (mean volumes of damage 73 ± 44 
mm3 and 46 ± 33 mm3 respectively). Secondly, although the scatterplots revealed no 
obvious relationship between final lesion volume and MABP at the time of MCA occlusion 
(anaesthetised MABP, Figure 25a), there was an apparent inverse correlation between 
blood pressure 1 h post-MCA occlusion (conscious MABP) and final lesion size for rats in 
which endothelin-1 induced only a moderate constriction (Figure 25b). In these animals 
higher MABP during recovery resulted in lower volumes of ischaemic damage. No such 
relationship was apparent for rats with severe MCA constrictions in response to 
endothelin-1 (Figure 25b).
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Figure 25 Transient MCA Occlusion: relationship between ischaemic damage, severity of 
vasoconstriction and blood pressure.
Scatterplots of individual volumes of hemispheric damage for rats killed 24 h (filled 
symbols) and 72 h (open symbols) following onset of transient MCA occlusion plotted 
against individual mean arterial blood pressure (MABP) at a) time of application of 
endothelin-1 to MCA and b) 1 h post-onset of MCA occlusion. Data is subdivided into 
moderate (25 % of original diameter) and severe (< 20 % of original diameter) constrictions 
of the MCA in response to endothelin-1.
There was no obvious relationship between volume of ischaemic damage and MABP at the 
time of MCA occlusion for either moderate or severe constrictions. In contrast there was a 
significant inverse correlation between volumes of damage and MABP 1 h post-MCA 
occlusion for moderate vasoconstriction (p < 0.01, Pearson product moment correlation), 
but no significant relationship for severe vasoconstriction. The dotted lines on the graphs 
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The sham procedure (saline applied to the MCA) resulted in a very small region of 
ischaemic damage in less than 40% of the animals located in the cerebral cortex ventral to 
the rhinal fissure and corresponding to the site of craniectomy. The remainder of the rats 
showed no ischaemic damage at all. The total volumes of ischaemic damage at the 4 h, 24 
h and 72 h time points following sham occlusion were 0 ± 0 mm3, 0.55 ±1.1 mm3 and 1.2 
± 0.85 mm3 respectively.
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4.3. Effect of recovery from anaesthesia on acute outcome following
transient and permanent MCA occlusion
4.3.1. Introduction
Comparison of the volumes of ischaemic damage 4 h following transient MCA occlusion 
revealed the volume of damage was greater for the group maintained under anaesthesia 
compared to the group allowed to recover consciousness following surgery. This result 
suggests that some factor associated with the maintenance or withdrawal of anaesthetics 
directly influences lesion size. Data from the 4 h anaesthetised and recovery groups (for 
both transient and permanent MCA occlusion) were therefore compared in more detail to 
further assess the relationship between lesion size and recovery from anaesthesia.
4.3.2. Results
4.3.2.1. Effect of anaesthetic withdrawal on blood pressure
Mean arterial blood pressures at the time of MCA occlusion (when all rats were 
anaesthetised) were comparable between groups being 91 ± 8 mmHg and 89 ± 4 mmHg 
for permanent MCA occlusion, anaesthetised and recovery groups respectively and 86 ± 3 
mmHg and 84 ± 4 mmHg for transient MCA occlusion, anaesthetised and recovery groups 
respectively. In the anaesthetised groups MABP remained relatively stable throughout the 
experimental period (see Figure 26 and 27), while in the recovery groups MABP increased 
rapidly following withdrawal of anaesthetics. In these groups MABP returned to the 
normal range for the conscious rat within 1 to 1.5 h of anaesthetic withdrawal. Blood 
pressure was then well maintained throughout the remainder of the survival period. 4 h 
post-MCA occlusion the MABP in the recovery groups was 35 mmHg and 45 mmHg 
higher than the corresponding anaesthetised groups, for permanent and transient MCA 
occlusion respectively.
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Mean arterial blood pressure pre- and post-permanent MCA occlusion 
(MCAO) of 4 h duration. Blood pressure for the group maintained under 
halothane anaesthesia remained relatively stable throughout. In contrast, 
following withdrawal of anaesthetics (approximately 10-15 min post-MCA 
occlusion), blood pressure in the recovery group rapidly returned to the normal 
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Mean arterial blood pressure pre- and 4 h post-transient MCA occlusion 
(MCAO). Blood pressure for the group maintained under halothane 
anaesthesia remained relatively stable, while blood pressure in the recovery 
group rapidly increased following withdrawal of anaesthetics 
(approximately 10-15 min post-MCA occlusion).
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4.3.2.2. Effect of anaesthetic withdrawal on ischaemic damage
The volumes of ischaemic damage following permanent and transient MCA occlusion of 4 
h duration are illustrated in Figure 28 and 29. For permanent MCA occlusion the volumes 
of ischaemic damage for whole hemisphere, cortex and caudate nucleus were not 
significantly different between the anaesthetised and recovery groups (Figure 28). In 
contrast following transient MCA occlusion the total volume of ischaemic damage in the 
recovery group was reduced by 52% compared to the anaesthetised group (Figure 29). 
The reduction in volume of ischaemic damage reached significance (p<0.05) for the whole 
hemisphere and caudate nucleus, but not the cerebral cortex.
The areas of hemispheric ischaemic damage in anaesthetised and recovery groups following 
permanent MCA occlusion were similar at each stereotactic level (Figure 30). In contrast 
the greater volume of ischaemic damage in the anaesthetised group compared to the 
recovery group following transient MCA occlusion was reflected in higher mean areas of 
hemispheric damage, particularly in the centre of the lesion (Figure 31).
I l l
Figure 28 Effect of anaesthetic withdrawal on volumes of ischaemic
damage following permanent MCA occlusion
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a  100








Mean volumes of ischaemic damage (mm3) in the hemisphere, cerebral 
cortex and caudate nucleus following permanent MCA occlusion of 4 h 
duration. The volumes of damage were not significandy different between 
the anaesthetised (n = 6) and recovery (n = 6) groups (p > 0.05 unpaired 
Student's t-tests).
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Figure 29 Effect of anaesthetic withdrawal on volumes of 
ischaemic damage following transient MCA occlusion







Mean volumes of ischaemic damage (mm3) in the hemisphere, cerebral 
cortex and caudate nucleus measured 4 h following the onset of transient 
MCA occlusion. The volumes of damage were significantly reduced in 
the recovery group (n = 10) compared with the group maintained under 
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4.4.1. Evolution of ischaemic damage
The results of the time course study show that following permanent MCA occlusion, the 
volume of ischaemic damage remains relatively constant between 4 h and 72 h. This 
volume of damage does not necessarily represent the absolute maximum amount of tissue 
that can be recruited to the lesion following permanent MCA occlusion because 
manipulation of several physiological parameters can influence lesion size e.g. transient 
hypotension further increases the volume of ischaemic damage in this model (Osborne et al.
1987). However, under the physiological conditions used in the present study, it can be 
concluded that the volume of ischaemic damage is already maximal 4 h post-permanent 
MCA occlusion. In contrast following transient MCA occlusion the volume of damage 
significandy increased from 4 h to 24 h demonstrating that in this model pathological 
processes are continuing following the onset of reperfusion.
Permanent MCA occlusion
Several studies have purported to evaluate the development of ischaemic damage following 
permanent MCA occlusion in the rat (Garcia et al. 1993; Hakim et al. 1992; Nedergaard 
1987; Persson et al. 1989) but the strength of the conclusions of these studies (with regards 
to this point only) is questionable due to problems of methodology. Firsdy, investigations 
of the change in volume of ischaemic damage over time should use a method of 
quantification that compensates for the contribution of oedema to total infarct volume. 
Direct measurement of infarct volume (e.g. from the area of pallor on TTC or cresyl violet 
stained sections) will include a component of tissue swelling due to brain oedema that can 
overestimate infarct volume by 20% (Brint et al. 1988; Lin et al. 1993). Brain oedema 
(assessed by hemispheric water content) increases progressively after the onset of 
permanent MCA occlusion reaching its maximum level at 3 days (Gotoh et al. 1985). This 
time course differs from the temporal evolution of ischaemic damage so that apparent 
fluctuations in infarct volume (measured directly from stained sections) can be the direct 
result of variations in oedema content of the tissue (Lin et al. 1993). The method of 
quantification used in the present study addresses this problem by measuring the areas of 
damage from scale drawings rather than directly from the sections so that the confounding 
influence of tissue swelling is avoided. Secondly, studies of the temporal evolution of 
ischaemic damage that only analyse selected sections at the centre of the infarct (Garcia et 
al. 1993; Hakim et al. 1992) may incompletely characterise the lesion and over- or 
underestimate changes in total lesion volume. Previous studies have shown that a 
minimum of 8 stereotactic levels must be analysed to give an accurate asssessment of total
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lesion volume (Duverger & Mackenzie 1988; Osborne et al. 1987) and therefore this was 
the number of levels used in the present study.
Persson et al. 1989 have reported that infarct area does not reach maximal size until 18 h to 
2 days following permanent MCA occlusion. The lesion was then constant until day 7 
when a progressive reduction in size was observed due to resorption of oedema and tissue 
atrophy. However given the small group size (n = 3) and wide time-scale (1 h - 8 h) of the 
only group of animals killed earlier than 18 h post-MCA occlusion no real conclusions can 
be drawn from this study concerning the early evolution of ischaemic damage. Nedergaard 
(1987) found that infarction was clearly demarcated only in the striatum at 4 h and was not 
obvious in the cortex until 24 h post-MCA occlusion. However this report was primarily 
directed towards studying selective neuronal necrosis outwith the borders of the main 
infarct and no real attempt was made to quantify temporal changes in infarct size.
Hakim et al. 1992 reported that the area of damage increased in size from 4 to 24 h 
post-MCA occlusion, but the method of assessing ischaemic damage used in this study - 
area of pallor on cresyl violet stained sections - can only detect 'frank infarction'. This 
method is therefore much less sensitive than the morphological assessment used to 
delineate ischaemic damage in the present study and may have failed to detect early 
evidence of necrosis. Finally Garcia et al. 1993 found the area of ischaemic damage 
(expressed as percentage of ipsilateral hemispheric area) did not change markedly from 3 to 
48 h post-MCA occlusion. In this study there was a late increase in lesion size apparent at 
72 h and 96 h that may have reflected changes in hemispheric area due to alterations in 
oedema content.
In summary none of these published studies was particularly well suited for volumetric 
assessment of the temporal changes in ischaemic damage following permanent MCA 
occlusion. However our results have received confirmation from the work of Gill 1992 
who has shown, using a similar system of quantitative analysis to our own, that following 
permanent MCA occlusion the lesion volume is maximal at 4 h and 'the size of the lesion 
does not change between 4 h and 7 days' (Gill 1992).
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Transient MCA occlusion
The majority of studies of the temporal evolution of ischaemic damage following transient 
focal ischaemia have approached the problem by varying the duration of the initial 
ischaemic insult and keeping the kill time constant. This approach is directed towards 
assessing the therapeutic time window in which re-establishment of CBF may be beneficial 
to patient outcome by salvaging tissue otherwise destined to die. However we were 
interested in the more fundamental question of whether lesion size increases with time 
following a period of transient focal ischaemia. Therefore we kept the procedure for 
induction of ischaemia constant and looked at outcome following increasing periods of 
reperfusion. We found that the volume of ischaemic damage continued to increase from 4 
to 24 h in the endothelin-1 model of transient focal ischaemia. In this model restoration of 
CBF begins before the 4 h time point (Macrae et al. 1993 and see Section 3.3.). Thus the 
volume of damage is increasing during the reperfusion phase. This result suggests, but can 
not prove, that secondary mechanisms occuring within the reperfusion phase are 
contributing to the maturation of lesion size. In the 72 h group the lesion size was smaller, 
although still numerically greater than at the 4 h time point. Examination of the 
physiological data revealed no obvious explanation for the difference in lesion size between 
the 24 h and 72 h groups since blood gases, plasma glucose, body temperature and MABP 
were similar for both groups (see Table 5 and Figure 18). From studies of permanent 
MCA occlusion it is known that resorption of the lesion does not become apparent until 7 
days post-ischaemia (Persson et al. 1989). Thus 72 h is probably too early a time point for 
actual resorption of the lesion to be occuring and the apparent reduction in lesion size may 
merely reflect the inherent variability present in this, and indeed all, models of transient 
focal ischaemia (Macrae 1992 and see Section 8.1.). Despite the fact that mean lesion 
volume was smaller at 72 h compared to 24 h there was qualitative evidence from the 
morphological appearance of these lesions that reperfusion injury was continuing from 24 h 
to 72 h post-transient MCA occlusion. The pronounced oedema in the 72 h group together 
with the appearance of blood within a substantial proportion of the infarcts, suggestive of 
haemorrhagic transformation, points to secondary vascular damage occuring late within the 
reperfusion phase that may be further evidence of reperfusion injury within this model.
To the best of our knowledge there is only one published study directly comparable to the 
present work in which the period of ischaemia (90 min MCA occlusion (ligature) in tandem 
with bilateral carotid occlusion (clips)) was kept constant while the reperfusion period was 
increased (Lin et al. 1993). In this study the volume of ischaemic damage (corrected for 
influence of oedema) did not change with periods of reperfusion of 6,24, and 72 h, while 
oedema (assessed as hemispheric water content) increased from 6 to 24 h reperfusion and 
then subsequently decreased. This result may at first appear to contradict our study in
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which the volume of ischaemic damage increased from 4 to 24 h post-MCA occlusion. 
However our results suggest that the volume of damage reaches its maximal level at some 
unspecified time between 4 and 24 h post-MCA occlusion which compares well with Lin et 
al. whose earliest time point was 7.5 h post-onset of ischaemia.
In studies where the duration of the initial ischaemia is varied, the final volume of 
ischaemic damage, as would be expected, is proportional to the length of the ischaemic 
insult. Studies utilising models of distal MCA occlusion together with unilateral or bilateral 
carotid artery occlusion have found that the volume of ischaemic damage increases 
progressively with periods of MCA occlusion from 1 to 3 h duration when outcome is 
assessed at 24 h (Buchan et al. 1992b; Kaplan et al. 1991) or 7 days (Hiramatsu et al. 
1993) post-onset of ischaemia. The volume of damage is maximal after 3-4 h of transient 
MCA occlusion (with 21-20 h reperfusion), at which point it is equivalent to the volume of 
damage following 24 h permanent MCA occlusion (Buchan et al. 1992b; Kaplan et al. 
1991). Oedema formation (assessed by the difference in hemispheric volumes) also 
increases with increased duration of ischaemia (Hiramatsu et al. 1993) being equivalent to 
that observed with 24 h permanent MCA occlusion after 3 h of transient ischaemia (plus 21 
h reperfusion) (Kaplan et al. 1991). In a study using Koizumi's intraluminal thread 
technique the volume of ischaemic damage was found to increase with increasing lengths of 
ischaemia of up to 2 h duration (plus 7 days reperfusion) at which point lesion size was 
comparable to that for 24 h permanent MCA occlusion (Memezawa et al. 1992b). The 
shorter time frame in this model (2 h versus 3-4 h for extravascular occlusion models) 
probably reflects the 'massive brain edema' that results in very high mortality rates for rats 
subjected to ischaemic intervals of 90 min or longer (Memezawa et al. 1992b).
4.4.2. Factors influencing outcome in the endothelin-1 model of transient focal ischaemia
Analysis of the individual data from the transient ischaemia time course study revealed 2 
important factors that can influence final lesion volume in this model. Firstly, the degree of 
vasoconstriction induced by endothelin-1 influenced lesion size with severe 
vasoconstriction of the MCA tending to be associated with larger lesions than moderate 
vasoconstriction. If it is assumed that the degree of ischaemia induced by endothelin-1 is 
proportional to the severity of the observed vasoconstriction then this result suggests that 
the severity of the initial ischaemic insult can directly influence final lesion volume. 
Similarly, in a cat model of transient MCA occlusion the extent of cortical damage was 
found to be directly related to the degree of reduction in CBF during the ischaemic period 
(Tamura et al. 1980). Secondly, the MABP 1 h following application of endothelin-1 to 
the MCA was found to be inversely related to lesion volume in rats with a moderate initial
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ischaemia. The increase in arterial blood pressure following withdrawal of anaesthetics in 
these experiments occurs at approximately the same time as the vasoconstrictive action of 
endothelin-1 is beginning to wane and CBF in the ischaemic region is recovering (Macrae 
et al. 1993). Thus increased MABP at this time may help to re-open the previously 
constricted artery and improve the quality of reperfusion of the MCA territory. Following a 
moderate ischaemic insult the net effect of improved reperfusion appears beneficial and 
reduces the volume of ischaemic damage. However following severe vasoconstriction no 
such relationship was apparent, suggesting that either reperfusion is not improved by this 
level of hypertension or that improved reperfusion is not beneficial to outcome following a 
severe ischaemic insult
4.4.3. Effect of recovery from anaesthesia on acute outcome following transient and 
permanent MCA occlusion
Comparison of the volumes of ischaemic damage at the 4 h time point showed that recovery 
from anaesthesia, concomitant with an increase in MABP of 35-45 mmHg, did not improve 
acute outcome following permanent MCA occlusion but was of benefit in the endothelin-1 
model of transient MCA occlusion.
In the context of permanent focal ischaemia hypertension has been proposed as a possible 
treatment strategy to increase collateral perfusion of the ischaemic region (Yatsu 1982). 
Phenylephrine-induced hypertension (30-35 mmHg) has been demonstrated to improve 
cerebral blood flow via the collateral circulation 15 min following permanent MCA 
occlusion in normotensive rats (Drummond et al. 1989). However increasing the 
hydrostatic pressure gradient to a region where the cerebrovasculature is already 
compromised by ischaemic damage carries the risks of increased oedema formation 
(Hatashita & Hoff 1986) and haemorrhagic transformation of the infarct (Olsen 1983). In 
the present study, despite the elevated MABP in the recovery group, the volumes of 
ischaemic damage following permanent MCA occlusion did not differ significantly between 
the anaesthetised and recovery groups. In fact there was a trend for the volume of 
ischaemic damage to be greater in the recovery group (volumes of hemispheric damage 131 
± 15 vs 107 ± 5 mm3 for recovery and anaesthetised groups respectively) suggesting that 
the continued presence of halothane anaesthesia may be neuroprotective and that removal of 
anaesthesia opposes any beneficial effect of the resultant rise in blood pressure. This result 
is in contrast to Drummond's group who have found, using a different model of permanent 
MCA occlusion, that hypertension instituted immediately following MCA occlusion, or 
delayed in onset for 2 hours, significantly reduces the area of ischaemic damage (measured 
by TTC staining) 4 h post-MCA occlusion in the SHR (Patel et al. 1991b). There are 2
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possible explanations for this apparent discrepancy. Firstly in the Drummond study rats 
were maintained under isoflurane anaesthesia while blood pressure was increased with 
phenylephrine. In our study anaesthesia was withdrawn resulting in a spontaneous rise in 
blood pressure. Thus the confounding influence of isoflurane anaesthesia, which itself 
may be neuroprotective, makes direct comparison between the 2 studies difficult. 
Secondly, the method of inducing MCA occlusion (2 separate ligatures) may have 
improved the possibility of collateral supply to the ischaemic region compared to the more 
complete occlusion used in our permanent ischaemia model.
With regards to transient MCA occlusion, phenylephrine-induced hypertension (30 mmHg) 
initiated during the reperfusion phase following 2 h MCA occlusion (ligatures) in SHR, 
also improves CBF in the MCA territory (Cole et al. 1992) and reduces the area of 
ischaemic damage following 2 h of reperfusion without aggravation of oedema formation 
(Patel et al. 1991a). These results agree with the present findings where a relative increase 
in blood pressure reduced the volume of ischaemic damage following transient MCA 
occlusion. However differences in the mechanism of inducing hypertension, as for 
permanent MCA occlusion, probably precludes direct comparison of the 2 studies. 
Drummond's group attribute the beneficial effect of hypertension to reopening of collapsed 
vessels in the microvasculature thereby improving the quality of reperfusion. It may be 
however that their method of inducing MCA occlusion (by ligatures) provoked mechanical 
damage to the MCA so that an increase in intraluminal hydrostatic pressure (induced by the 
hypertension) was necessary to regain adequate reperfusion through the main MCA itself, 
and this was the reason for the observed beneficial effect of hypertension. It is interesting 
to note that the same group have found hypertension induced at the onset of reperfusion 
following a longer period of ischaemia (3 h) was associated with an increase in blood-brain 
barrier permeability and hence aggravated oedema formation (Cole et al. 1991).
In the present study the rise in blood pressure began within 15 min of endothelin-1 
application. Therefore the increase in arterial pressure may have reduced the volume of 
ischaemic damage by increasing the intraluminal pressure within the MCA, firstly opposing 
the vasoconstriction induced by endothelin-1 and secondly improving the quality of 
reperfusion either through the previously constricted MCA and/or by reopening collapsed 
capillaries. Future studies aimed at measuring local CBF at early and late time points 
following withdrawal of anaesthetics post-MCA occlusion could address this issue.
In this discussion it has been assumed that the difference in volumes of ischaemic damage 
between the anaesthetised and recovery groups following transient MCA occlusion is a 
result of the difference in blood pressure between the 2 groups. An alternative explanation 
is that continued halothane anaesthesia is detrimental to outcome compared with rats from
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which halothane is withdrawn. This explanation appears unlikely since halothane 
anaesthesia maintained during the ischaemic phase of transient global (Baughman et al.
1988) or transient focal (Warner et al. 1993) ischaemia markedly reduces neuronal damage 
compared to nitrous oxide or 'awake' controls.
Combining the information gained from the acute (4 h) study and the time course study it 
appears that increased blood pressure (and therefore it is proposed improved reperfusion) is 
beneficial to outcome when volumes of damage are assessed at a relatively early time point 
(4 h) following transient MCA occlusion when the ischaemic phase is the major contributor 
to lesion size. However at later time points, when the reperfusion phase may also be 
contributing to maturation of the lesion (as evidenced by the marked increase in volume of 
ischaemic damage from 4 h to 24 h), improved reperfusion may not be beneficial to 
outcome (providing the initial ischaemic insult was relatively severe). Thus secondary 
pathological mechanisms associated with improved early reperfusion {e.g. increased free 
radical production) may be the causative factor leading to the delayed increase in damage 
observed at the 24 h time point.
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5. ALTERATIONS IN FORSKOLIN AND Di RECEPTOR BINDING FOLLOWING 
PERMANENT FOCAL AND GLOBAL CEREBRAL ISCHAEMIA IN THE RAT
5.1. Forskolin and Dj receptor binding following permanent focal cerebral 
ischaemia, and relationship with cerebral blood flow
5.1.1. Introduction
Post-ischaemic alterations in second messenger systems have been widely studied using 
models of global ischaemia (e.g. Daval et al. 1989; Onodera & Kogure 1989), in contrast 
there is a paucity of data available for focal ischaemia. This study was therefore designed 
to assess the effects of focal reductions in CBF (induced by permanent MCA occlusion) on 
the adenylate cyclase second messenger system utilising in vitro autoradiographical 
techniques and the ligands pHjforskolin (to map adenylate cyclase) and pH]SCH23390 
(to map Dj dopamine receptors that are coupled to adenylate cyclase via a stimulatory G 
protein). Ligand binding was assessed at 2 time points following MCA occlusion to 
determine whether significant alterations in binding could be detected at an earlier time point 
than irreversible damage to neurones: 1) 2 h - i.e. before the border between normal and 
abnormal tissue can be reliably defined using standard histopathological techniques and 
2) 24 h - when gross infarction is present
The changes in local CBF following permanent MCA occlusion are well characterised 
(Tamura et al. 1981b; Bolander et al. 1989). In these models the continued presence of 
collateral blood supply maintains a range of blood flows (Hakim et al. 1992) that is in 
contrast to the uniform severity of a global ischaemic insult. This range of flows gives the 
opportunity to study the relationship between CBF and alterations in binding sites in more 
detail. To do this, in the present study in vivo autoradiographical determination of local 
CBF 2 h post-MCA occlusion was combined with in vitro autoradiography to obtain 
measurements of CBF and ligand binding within the same animals.
5.1.2. Experimental protocol
Rats underwent permanent MCA occlusion of 2 or 24 h duration. The general surgical 
preparation and induction of MCA occlusion were as described in Sections 2.2. and 2.3.1., 
with the exception that the femoral artery was not cannulated in the 24 h survival group. 
Local CBF was measured immediately prior to sacrifice in the 2 h group using a 30 s 
ramped infusion of [14C]IAP as described in Section 2.4.2.1. The brains were then
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rapidly removed, frozen in isopentane (-42°C) and sectioned in a cryostat Consecutive 
sections (20 pm) were taken for [3H]forskolin binding, [3H]SCH23390 binding and 
determination of local CBF. For the 24 h group rats were reanaesthetised 24 h post-MCA 
occlusion, decapitated and the brains processed as for the 2 h group except that sections 
were taken for histology rather than CBF determination. These sections were fixed in 10% 
formaldehyde then stained with cresyl violet Forskolin and SCH23390 binding protocols 
were performed as described in Section 2.4.1. Optical densities of regions of interest on 
die autoradiograms were measured using computer-assisted densitometry (Section 2.4.3.).
For qualitative assessment of the relationship between loss of ligand binding and 
histological evidence of infarction at 24 h, areas of infarcted tissue were drawn from the 
cresyl violet stained sections using a light microscope with a drawing tube attachment and 
compared to the areas of forskolin and Dj receptor loss (for 24 h group) traced from the 
densitometer screen.
Flow threshold for loss of forskolin binding
The relationship between local CBF and forskolin binding 2 h post-permanent MCA 
occlusion was investigated in the ipsilateral dorsolateral caudate nucleus. Six individual 
measurements of optical density, corresponding to a range of blood flows, were made for 
each rat. [3H]Forskolin and [14C]IAP autoradiograms were superimposed to ensure 
optical density was measured at exactly the same point on each section. A graph of 
forskolin binding (represented as a percentage of the binding in the contralateral caudate 
nucleus for each individual animal) versus caudate blood flow was then constructed to 
obtain the blood flow threshold for loss of forskolin binding sites.
5.1.3. Results
Physiological variables measured immediately prior to MCA occlusion and 2 h post-MCA 
occlusion are shown in Table 8 and were comparable for the 2 time points.
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Table 8 Physiological variables for autoradiographical determination of 
cerebral blood flow and ligand binding following permanent MCA occlusion
Pre-MCAO Post-MCAO
PH 7.473 ±0.019 7.532 ±0.014
Pa COi (mmHg) 35.0 ± 1.5 34.9 ±1.0
Pa (>2 (mmHg) 148.3 ±11.2 137.2 ±6.8
Rectal Temp (°C) 37.05 ±0.23 37.08 ±0.30
MABP (mmHg) 102 ± 8 102 ± 7
Physiological variables were determined immediately prior to and 
2 h following MCA occlusion (n = 6).
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Cerebral blood flow following permanent MCA occlusion
Local CBF was reduced throughout the hemisphere ipsilateral to the occluded MCA (Table 
9). The greatest reductions in CBF were seen in frontal, sensorimotor and parietal cortices 
(19 - 26% of contralateral values) and dorsolateral caudate nucleus (6% of contralateral 
value). Moderate reductions in CBF were observed in the ipsilateral anterior cingulate 
cortex, ventromedial caudate nucleus and nucleus accumbens (60 - 71% of contralateral 
values), while small, but still statistically significant, reductions in CBF were found in the 
ipsilateral septum, globus pallidus, thalamus and hypothalamus. No areas of 
hyperperfusion were observed at this time point following permanent MCA occlusion.
Forskolin binding sites
Representative autoradiograms, at the level of the caudate nucleus, of [3H]forskolin 
binding 2 and 24 h post-permanent MCA occlusion are shown in Figure 32. In the 
hemisphere contralateral to the occluded MCA, the highest levels of binding sites were 
located in the caudate nucleus and olfactory tubercle, while binding in the cerebral cortex 
was lower. The level of non-specific binding was less than 5% of the total for both cortex 
and caudate nucleus. In the ipsilateral hemisphere a reduction in forskolin binding sites in 
the dorsolateral caudate nucleus was clearly visible to the naked eye 2 h post-MCA 
occlusion (Figure 32a). By 24 h post-MCA occlusion forskolin binding was clearly 
reduced in both the caudate nucleus and overlying cerebral cortex (Figure 32c).
The mean values for forskolin binding sites 2 and 24 h post-permanent MCA occlusion are 
shown in Tables 10 and 11. Forskolin binding was significantly reduced only in the 
ipsilateral dorsolateral caudate nucleus 2 h post-occlusion (60% reduction compared with 
contralateral value) and was further reduced at 24 h post-MCA occlusion in this region 
(94% reduction). Forskolin binding was also significantly reduced in the frontal and 
sensorimotor cortices (by 74 and 63% respectively) at the 24 h time point.
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Table 9 Local cerebral blood flow 2 h post-permanent MCA occlusion
REGION
Local cerebral blood flow 
(ml/100 g/min)
Ipsilateral Contralateral
Frontal Cortex 37 ± 10** 156 ±57
Sensorimotor Cortex 32 ±11*** 171 ±46
Parietal Cortex 47 ± 15** 183 ±35
Anterior Cingulate Cortex 111 ±34** 186 ±35
Caudate Nucleus
Dorsolateral 10 ±4*** 166±66
Ventromedial 102 ±13** 159 ±31
Globus Pallidus 99 ±25* 119 ± 32
Septum 90 ±12* 99 ±11
Nucleus Accumbens 107 ±7** 150 ±23
Thalamus
Medial 109 ±14** 142 ±15
Ventral 113 ±14* 135 ± 9
Hypothalamus 91 ± 11* 99±  13
Internal Capsule 65 ±15 62 ±14
Genu of Corpus Callosum 43 ± 15*** 62 ±13
Local cerebral blood flow in hemispheres ipsilateral and contralateral to MCA 
occlusion. *p < 0.05, **p < 0.01, ***p < 0.001 comparison with contralateral 
































































































































































































































































































in c s t
wo ,-4 On On cn oo _ | wo OO CS
“d"* CS* CO d - CO NO to cd cd c s CS* c s
-H -H -H -H -H -H -H -H -H -H -H -H -H +1
O n On oo «n On d ; oo NO d ; O r-H oo O n CO





c s1 4 d -* O n CS* d-’
*
« o o oo
NO c s T f CS d - OO wo c s




-H -H ■H -H +1
00 o VO CO O n CO f-H wo








cs* cd cd cs*
-H -H -H -H
wo c s CS c s





wo O n v q  O n
cs’ c d  
c s  c o  c s  c o
-H -H -H -H
wo On r f  T f 
^  <s n  in 
NO VO On










-H -H -H -H -H -H +1 -H -H -H
















CO NO O  COM W  h  OO 
CO CO CS
-H -H -H -H
no o  ^  






c s O n C"; O n \q WO CS. H 00
00 WOCO WOCS
O nr- d-*CS d-* r-Hcs
r*H
^H
-H -H -H +1 -H -H -H -H -Hr- wo d- c s O n d; wo vq
ONr-Hcs






























































































































OO ^  ON
Tt Tt CO
-H -H -H(S rH
tj- in <h
rH  t—<
•0 * 0  Tf
On (S ^  ® 'O W
CO Tj- T j- OO r - '
-H -H -H -H -H -|_j
v q  NO <S CO f ;
cd ov co ov qo m tj- ts n  <s w
v n
*cs w-> 0 0 O n
cs’ cs* c d cs CO c d OO
-H +1 -H cs-H -H -H -HT"H «q oo w-> H






















'<fr ON cs in Ov VO wo cs
*ri OvOO vdr-" 0 o▼■H
vdwo dcs
-H -H +1 -H -H ■H -H -H -H
VO wo © wn vq CS cs V O
Ov cd dK . v d CS c d ON



















** COc d O On
cs
CS CO t>* r--H -H -H -H
0 0 o © VO
c d o VO









































Dj receptor binding sites
Representative autoradiograms, at the level of the caudate nucleus, of [3H]SCH23390 
binding 2 and 24 h post-permanent MCA occlusion are shown in Figure 33. In the 
contralateral hemisphere the highest levels of binding were observed in the caudate nucleus 
and nucleus accumbens, while binding throughout the cerebral cortices was relatively low. 
The level of specific binding in the caudate nucleus was approximately 90% of the total 
amount bound. In contrast to the reductions in forskolin binding, alterations in SCH23390 
binding in the ipsilateral hemisphere were not obvious to the naked eye but were present in 
the dorsolateral caudate nucleus.
The mean values for Dj receptor binding sites 2 and 24 h post-permanent MCA occlusion 
are shown in Tables 10 and 11. 2 h post-MCA occlusion there was a small, but 
significant, reduction in the level of Dj dopamine receptor binding in the dorsolateral 
caudate nucleus (20% reduction). This reduction was smaller in magnitude than the 60% 
reduction in forskolin binding in the same region at the same time point. 24 h 
post-occlusion the dorsolateral caudate nucleus was still the only region to show a 
significant reduction in Dj dopamine receptor binding. Unlike the progressive reduction in 
forskolin binding, there was no significant difference between the levels of dopamine 
receptor binding at 2 and 24 h post-MCA occlusion. These comparative changes in 
forskolin and Di receptor binding in the frontal cortex and dorsolateral caudate nucleus are 
illustrated in Figures 34 and 35.
24 h post-MCA occlusion the boundary between normal tissue and the area of infarction 
was clearly demarcated on cresyl violet stained sections. The infarct appeared as an area of 
pallor that included the dorsolateral caudate nucleus and overlying cerebral cortex. The 
areas of reduced forskolin and D{ receptor binding sites in the dorsolateral caudate nucleus 
24 h post-occlusion were found to match this area of pallor, while the area of reduced 














































































































































Figure 34 [3H]Forskolin binding in the frontal cortex and caudate nucleus
2 and 24 h post-permanent MCA occlusion
300n
H  Contralateral 
□  Ipsilateral
2h  24 h 
Dorsolateral 
Caudate Nucleus
2 h 24 h 
Frontal Cortex
[3H]Forskolin binding was substantially reduced in the dorsolateral caudate 
nucleus 2 h post-MCA occlusion, and was further reduced to only 6% of 
contralateral value by 24 h. In contrast [3H]forskolin binding in the frontal cortex 
was only significantly reduced 24 h post-MCA occlusion. **p<0.01, ***p<0.001 
comparison with contralateral region (paired Student's t-tests).
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Figure 35 [3H]SCH23390 binding in the frontal cortex and caudate nucleus
2 and 24 h post-permanent MCA occlusion
H  Contralateral 
[H Ipsilateral
in
2 h 24 h 
Frontal Cortex
[3H]SCH23390 binding in the dorsolateral caudate nucleus was decreased by 
20% 2 h post-MCA occlusion. Unlike forskolin binding there was no 
progressive reduction in binding from 2 to 24 h. There was no significant 
alteration in the level of [3H]SCH23390 binding in the frontal cortex either 2 or 
24 h post-MCA occlusion. **p < 0.01 comparison with contralateral region 
(paired Student's t-tests).
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Relationship between blood flow and forskolin binding in the caudate nucleus
Visual inspection of the CBF and [3H]forskolin autoradiograms revealed that forskolin 
binding in some parts of the dorsolateral caudate nucleus was preserved despite marked 
reductions in blood flow in the corresponding [14C]IAP autoradiogram (Figure 36). The 
subsequent analysis of the relationship between blood flow and forskolin binding in the 
caudate nucleus is shown in Figure 37. Forskolin binding was represented as a percentage 
of the corresponding contralateral value because of the heterogeneous distribution of 
forskolin binding sites within the caudate nucleus. Inspection of Figure 37 reveals that 
blood flows well below the mean contralateral value of 166 ml/100 g/min could be tolerated 
without significant loss of forskolin binding sites at the 2 h time point. However when 
blood flow fell below approximately 34 ml/100 g/min reductions in forskolin binding 
began to occur, and blood flows below 25 ml/100 g/min (with one exception) were 
associated with at least a 20% reduction in forskolin binding sites.
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Figure 36 Autoradiograms showing conservation of [3H]forskolin binding sites in
regions of less severe hypoperfusion
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Autoradiograms of consecutive sections from an animal 2 h post-permanent MCA 
occlusion showing a) local cerebral blood flow measured by [14C]iodoantipyrine and b) 
[3H]forskolin binding. Note the area of conserved forskolin binding sites corresponding to 
an area of less profound hypoperfusion (arrowheads on a and b). Scale 8:1.
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Figure 37 Blood flow threshold for loss of [3H]forskolin binding sites
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The graph shows the relationship between forskolin binding sites and 
blood flow in the ipsilateral dorsolateral caudate nucleus 2 h 
post-permanent MCA occlusion. Each point represents an individual pair 
of measurements for forskolin binding and blood flow made at 
corresponding locations on consecutive autoradiograms.
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5.2. Forskolin and Dt receptor binding following permanent global
ischaemia
5.2.1. Introduction
In this study the impact of a permanent global ischaemic insult on cortical and striatal 
second messenger associated binding sites was investigated using in vitro autoradiography. 
The aim of this work was to assess the effect of a complete absence of cerebral blood flow 
on forskolin and Dj receptor binding sites, and also to gain more information on the relative 
time courses for reductions in these binding sites following cerebral ischaemia.
5.2.2. Experimental protocol
Rats (n = 5 per group) were subjected to irreversible global ischaemia of 0 to 4 h duration 
(see Section 2.3.3.). Consecutive cryostat sections (20 |im) from the level of the caudate 
nucleus were processed for pHJforskolin and [3H]SCH23390 binding as described in 
Section 2.4.1. In addition saturation analysis was performed using sections from a control 
brain and a brain subjected to 4 h ischaemia. Sections were incubated with pHJforskolin 
over the concentration range 2 - 150 nM or pH]SCH23390 over the range 0.25 - 20 nM 
and processed for autoradiography as described above.
5.2.3. Results 
Forskolin binding sites
Representative autoradiograms, at the level of the caudate nucleus, of pHJforskolin 
binding following decapitation and incubation of the head at 37°C for 0,1 or 4 h are shown 
in Figure 38. pHJForskolin binding in the caudate nucleus decreased rapidly after the 
onset of global ischaemia, being reduced by 35% (compared with control) after 15 min and 
87% after 4 h (Figure 39). At the 4 h time point pHJforskolin binding in the caudate 
nucleus had reached a level similar to that observed in the frontal cortex (see Figures 38 and 
39). The rate of reduction in pHJforskolin binding in the frontal cortex was much slower 
with a significant reduction only observed 4 h post-onset of ischaemia, when the level of 
binding was reduced by 53% compared with control (Figure 39).
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Autoradiograms of [3H]forskolin binding 0 h (a), 1 h (b) and 4 h (c) following onset of 
global (decapitation) ischaemia. Note the progressive, bilateral loss of forskolin binding 
sites in the caudate nucleus with increasing duration of ischaemia, so that by 4 h the level of 
binding in the caudate nucleus is comparable to that in the cerebral cortex. Scale 5:1.
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Duration of Ischaemia (hours)
Forskolin binding in the caudate nucleus decreased rapidly and progressively 
with increasing durations of global ischaemia so that by 4 h the level of 
binding in the caudate nucleus was comparable to that in the frontal cortex. 
**p < 0.01, ***p < 0.001 comparison with time 0 (unpaired Student's t-tests).
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Saturation data and Scatchard analysis for control and 4 h ischaemic brain are shown in 
Figures 40 and 41. There was a 52% reduction in the number of high affinity forskolin 
binding sites in the caudate nucleus 4 h post-ischaemia (control Bmax = 849 pmol/g, 4 h 
ischaemia Bmax = 414 pmol/g), while in the frontal cortex ischaemia had a minimal effect 
on the number of binding sites (control Bmax = 289 pmol/g, 4 h ischaemia Bmax = 284 
pmol/g). IQ values for both caudate nucleus and frontal cortex were increased following 4 
h ischaemia indicating a decrease in affinity for forskolin binding sites in both regions 
(caudate nucleus: control IQ = 23 nM, 4 h ischaemia IQ = 83 nM; frontal cortex: control IQ 
= 38 nM, 4 h ischaemia IQ = 67 nM).
Dj  receptor binding sites
Representative autoradiograms, at the level of the caudate nucleus, of pH]SCH23390 
binding following 0, 1 and 4 h of global ischaemia are shown in Figure 42. 
pH]SCH23390 binding in the caudate nucleus had significantly decreased by 23% 15 min 
following onset of global ischaemia (Figure 43). However, unlike forskolin binding, there 
was no further decrease in the level of [3H]SCH23390 binding which remained at 
approximately 80% of control value throughout the 4 h of the experiment. The level of 
pH]SCH23390 binding in the frontal cortex was very low (compared to forskolin) and did 
not show any significant changes over time.
Saturation data and Scatchard analysis for SCH23390 binding to Dx dopamine receptors in 
the caudate nucleus are shown in Figures 44 and 45. There was a small (15%) reduction in 
the number of Dj dopamine receptors following 4 h ischaemia (control Bmax = 192 pmol/g, 
4 h ischaemia Bmax =163 pmol/g), but no appreciable change in affinity (control IQ = 1.4 
nM, 4 h ischaemia IQ = 1.3 nM). The level of pH]SCH23390 specific binding in the 
frontal cortex was too low to enable Scatchard analysis to be performed on this data.
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Figure 40 Saturation analysis of [3H]forskolin binding sites in the caudate nucleus and 
frontal cortex following permanent global ischaemia
Sections from control (n = 1) and 4 h ischaemic (n = 1) brain were incubated with 
increasing concentrations of [3H]forskolin (2 - 150 nM). Non-specific binding was 
assessed in adjacent sections by the addition of unlabelled forskolin (20 |iM). Specific 
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Figure 41 Scatchard analysis of saturation data for [3 H]forskolin binding in 
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Sections from control and 4 h ischaemic brain were incubated with increasing 
concentrations of [3H]forskolin (2 - 150 nM). Bmax and were determined 
using linear regression analysis and are shown in main text.
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Autoradiograms of [3H]SCH23390 binding 0 h (a), 1 h (b) and 4 h (c) following onset of 
global (decapitation) ischaemia. Note that SCH23390 binding is bilaterally reduced in the 
caudate nucleus 1 h post-onset of ischaemia but that there was no further loss of binding 
sites at the 4 h time point. Scale 6:1.
145
Figure 43 Reduction in [3H]SCH23390 binding sites
following permanent global ischaemia
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[ 3H]SCH23390 binding in the caudate nucleus was reduced by approximately 20% 
following 15 min global ischaemia. No further reduction in binding was apparent 
with increasing periods of ischaemia. The lower level of binding in the frontal 
cortex was not significantly altered by up to 4 h of global ischaemia. **p < 0.01, 
***p < 0.001 comparison with time 0 (unpaired Student's t-tests).
146
Figure 44 Saturation analysis of [3 H]SCH23390 binding sites 
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Sections from a control brain (a) and one subjected to 4 h ischaemia (b) 
were incubated with increasing concentrations of [3H]SCH23390 (0.25 - 20 
nM). Non-specific binding was assessed in adjacent sections by addition of 
piflutixol (10 pM). Specific binding was determined by subtraction of 
non-specific binding from total binding.
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Figure 45 Scatchard analysis for [3H]SCH23390 binding sites in the 
caudate nucleus following permanent global ischaemia
■ #  ■ Control 
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Sections from control and 4 h ischaemic brain were incubated with increasing 
concentrations of pH]SCH23390 (0.25 - 20 nM). Bmax and Kd were determined 
using linear regression analysis, and values are given in the main text.
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5.3. Discussion
5.3.1. Post-ischaemic reductions in second messenger-associated binding sites and 
neurotransmitter receptors
The present study was one of the first in the literature to examine second messenger 
systems in a model of focal cerebral ischaemia. The use of 2 separate ligands (forskolin and 
SCH23390) allowed us to assess the effect of permanent focal ischaemia at 2 distinct levels 
within the neurotransmitter-adenylate cyclase system. Although forskolin also binds, 
independently of adenylate cyclase, to several other membrane proteins including glucose 
transporters and ion channels (Laurenza et al. 1989), it has low affinity for these alternative 
sites (Laurenza et al. 1989). Furthermore it has been reported (Gerhart et al. 1991) that the 
glucose transporter site in rat brain is unaffected by ischaemia. Therefore it can be assumed 
that the observed post-ischaemic alterations in forskolin binding do reflect changes in the 
adenylate cyclase system.
Changes in ligand binding have been widely studied following transient global ischaemia in 
rats and gerbils (Daval et al. 1989; Hara et al. 1991; Onodera & Kogure 1989; Onodera et 
al. 1989). In these models selective neuronal necrosis becomes apparent in specific brain 
regions (e.g. CA1 region of the hippocampus) 3-7 days following recirculation (Kirino et 
al. 1982). The time course for reduction in forskolin binding sites in these models appears 
to parallel this neuronal loss since very small (Hara etal. 1991; Onodera & Kogure 1989) 
or no (Araki et al. 1991) reductions in binding are apparent within 2 h of the onset of 
reperfusion, while appreciable reductions (36 - 50%) only occur after 3-7 days (Araki et al. 
1991; Hara et al. 1991; Onodera & Kogure 1989). In contrast in the present study a 60% 
reduction in striatal forskolin binding sites was observed only 2 h post-onset of focal 
ischaemia, while a recent study has reported significant reductions in striatal forskolin 
binding as early as 30 min post-permanent MCA occlusion (Wallace et al. 1991). These 
early reductions in forskolin binding sites are greater in magnitude than any change 
reported up to 7 days following transient global ischaemia. Thus reductions in forskolin 
binding sites (in certain regions) following permanent focal ischaemia appear to proceed 
much faster than for any neuroanatomical region following transient global ischaemia. 
However in the present study no significant reductions in forskolin binding sites were 
apparent in the frontal or sensorimotor cortices at the 2 h time point. This suggests that 
changes in forskolin binding could be used as a reliable early indicator of tissue likely to 
proceed to irreversible ischaemic damage within the caudate nucleus, but not the cerebral 
cortex. However by 24 h post-permanent MCA occlusion the areas of reduced forskolin 
binding sites matched the areas of cell damage assessed by histological staining in both the
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caudate nucleus and cerebral cortex. Thus at this late time point assay of forskolin binding 
sites could be used as an alternative indicator of tissue infarction than the more traditional 
histological methods.
The decapitation model of global ischaemia was included in this study to investigate in 
more detail the time course for reductions in forskolin and Dj dopamine receptor binding 
following cerebral ischaemia. The global ischaemia study confirmed the major findings of 
the focal ischaemia work and has given insight into the interpretation of those results. 
Firstly, reductions in forskolin binding sites proceeded more quickly than reductions in Dj 
dopamine receptor binding sites following both global and focal ischaemia. Forskolin 
binding in the caudate nucleus was significantly reduced at the earliest time point in both 
studies (15 min or 2 h) and continued to decrease over time. In contrast to forskolin, Dj 
dopamine receptor binding did not show a progressive reduction over time. Dj dopamine 
receptor binding was reduced at the earliest time points but did not decrease further at the 4 
h or 24 h time point respectively. Thus Dj dopamine receptor binding appears more 
resistant to cerebral ischaemia than forskolin binding. This may reflect the subcellular 
localisation of the binding sites: the intracellular second messenger site (forskolin) appears 
to be more vulnerable than the neurotransmitter receptor site ( Dj dopamine) located on the 
outside of the plasma membrane. The majority of the dopamine receptor sites 
maintained their integrity even after 24 h of permanent focal ischaemia when neuronal 
necrosis must be present. This suggests that Dj dopamine binding will only show 
appreciable reductions when neurones undergo lysis and the membrane structure 
disintegrates. Our results have been confirmed by a study of post-mortem delay in which 
rat brains, subjected to a controlled cooling curve, showed only a 20 % reduction in Dj 
dopamine receptor binding levels in the caudate nucleus after 24 h (Gilmore et al. 1991).
Secondly, reductions in both forskolin and Dx dopamine receptor binding proceed faster in 
the caudate nucleus than the frontal cortex. From the focal cerebral ischaemia studies it 
may be surmised that the vulnerability of striatal forskolin binding sites reflects the more 
severe reduction in CBF observed in this region compared to the frontal cortex. However 
the results of the global ischaemia study demonstrate that this can not be the entire 
explanation since both frontal cortex and caudate nucleus are exposed to the same degree of 
ischaemia (i.e. total absence of blood flow) in this model. It is possible that striatal 
forskolin binding sites differ functionally and/or structurally from cortical forskolin binding 
sites, and this difference renders them more vulnerable to ischaemic damage. The 
differential sensitivity of forskolin binding sites to ischaemia may reflect regional 
differences in the expression of G protein-subtypes. Within the rat brain high levels of
150
mRNA controlling the expression of the Gs-like protein Golf are found in the caudate 
nucleus while other brain regions, including the cortex, exhibit much lower expression of 
this mRNA (Drinnan et al. 1991). This molecular variation may underlie observed 
differences between high affinity forskolin binding sites in the caudate nucleus and other 
brain regions (Poat et al. 1988) and their vulnerability to cerebral ischaemia. Alternatively 
the caudate nucleus may contain the same relatively resistant forskolin binding sites as the 
cortex, and an additional population of sites which are peculiarly vulnerable to ischaemia. 
However the Scatchard analysis showed no clear evidence of 2 distinct populations of 
forskolin binding sites in the caudate nucleus.
5.3.2. Cerebral blood flow following permanent MCA occlusion, and relationship with 
loss of forskolin binding sites
The hypoperfusion observed following permanent MCA occlusion in this study is 
qualitatively and quantitatively similar to previous reports in this model (Tamura et al. 
1981b). The regions with the most profound reductions in blood flow were located in core 
MCA territory e.g. frontal and sensorimotor cortices and dorsolateral caudate nucleus. 
Structures that receive blood supply from the anterior cerebral artery as well as the MCA 
e.g. ventromedial caudate nucleus and anterior cingulate cortex showed smaller reductions 
in flow. In contrast to the original study (Tamura et al. 1981b) no hyperperfusion was 
observed in the ipsilateral globus pallidus. This may reflect the different time points at 
which local CBF was measured in the 2 studies (30 min compared with 2 h post-MCA 
occlusion in the present study). The values for regions contralateral to the occlusion were 
similar to those obtained previously for sham operated rats (Tamura et al. 1981b) validating 
the use of the contralateral hemisphere as a control group in the present study.
Flow thresholds for focal cerebral ischaemic damage
The CBF threshold for development of irreversible ischaemic damage is dependent not only 
on the severity of the ischaemic insult, but also on its duration (Jones et al. 1981; Hakim et 
al. 1992). Thus severe reductions in blood flow produce minimal damage if the ischaemia 
is of very short duration, while comparatively mild reductions in flow can cause 
irreversible damage if sustained for a sufficient length of time. Therefore direct comparison 
of thresholds obtained in different studies is strictly only valid when comparing identical 
models at the same time point. However because the volume of ischaemic damage 
following permanent MCA occlusion is maximal by 3 to 4 h post-onset of ischaemia (see 
Section 4.2.) studies assessing infarction at, or beyond, this time point can be compared.
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In primates the critical CBF threshold for irreversible damage is approximately 17 ml/100 
g/min (Jones et al. 1981) while in normotensive rats the threshold is considerably higher at 
24-25 ml/100 g/min (Bolander et al. 1989; Tyson et al. 1984). The higher CBF threshold 
in rats reflects the 3-fold higher basal CBF in this species compared with primates. This 
high basal CBF is dictated by the higher cerebral metabolic rate necessary to sustain the 
3-fold greater neuronal density in the rat brain (Jacewicz et al. 1992).
In the present study detailed analysis of the relationship between forskolin binding and 
blood flow in the caudate nucleus revealed that flow must fall below 34 ml/100 g/min 
before reductions in forskolin binding become apparent. In addition blood flow below 25 
ml/100 g/min is always associated with at least a 15% loss of forskolin binding sites. 
These values are in good agreement with the thresholds for irreversible tissue damage in the 
rat discussed above. In particular Tyson et al. (1984) reported some histologically 
abnormal areas in the caudate nucleus when blood flow was less than 35 ml/100 g/min, 
whereas flows below 25 ml/100 g/min were always associated with histological damage. 
Bearing in mind the different time points of these 2 studies, it appears that the flow 
threshold for loss of striatal forskolin binding sites at 2 h post-MCA occlusion is a good 
predictor of irreversible damage at 4 h in the same model.
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6. THE CEREBROVASCULAR EFFECTS OF L-NAME IN THE INTACT RAT
6.1. Introduction
The aim of this study was to assess the importance of endogenous NO in cerebral 
circulatory control. In order to do this NO production was inhibited by systemic 
adminstration of the NOS inhibitor L-NAME, and the resultant reductions in local CBF 
were determined using the in vivo [14C]IAP technique. Firstly a dose-response curve (0.3 
- 30 mg/kg) for L-NAME-induced reductions in CBF was obtained in conscious rats. The 
duration of action of the highest dose (30 mg/kg) was then followed over the course of 3 h. 
Finally the comparative effect of L-NAME on blood presure and CBF in conscious and 
anaesthetised rats was assessed. In addition to the primary aim of this study, a fuller 
understanding of the cerebrovascular effects of the NO synthase inhibitor L-NAME 
obtained from this work will aid interpretation of the observed effects of L-NAME against 
cerebral ischaemic damage in vivo (see Section 7).
6.2. Dose-dependency of response to L-NAME
6.2.1. Experimental protocol
L-NAME (0.3, 3, 30 mg/kg i.v.) or saline (1 ml/kg i.v.) was administered to conscious 
rats 30 min prior to [14C]IAP determination of local CBF. [14C]IAP was administered as a 
ramped infusion over 30 s during which time approximately 18 timed samples of arterial 
blood were collected as described in Section 2.4.2. The arterial concentration curve for 
[14C]IAP was determined from the timed blood samples as described previously, but the 
tissue content of [14C]IAP was measured using liquid scintillation analysis of 
micro-dissected tissue samples instead of autoradiography. Following decapitation the 
brain was removed from the skull onto an ice-cooled glass plate and 13 neuroanatomical 
regions were rapidly dissected out. The regions studied were cerebellum, medulla 
oblongata, inferior colliculus, superior coQiciilus, thalamus, hypothalamus, hippocampus, 
caudate nucleus, nucleus accumbens, frontal cortex, parietal cortex, occipital cortex and 
olfactory bulbs. The tissue samples were placed in preweighed glass vials which were 
immediately capped and re weighed. Soluene 350 (1 ml) was added to each vial prior to 
placement in a water bath (50°C) for approximately 12 h to dissolve the tissue samples. 0.5 
ml acetic acid (2N) in toluene and 10 ml scindllant were then added to each vial and the 





Physiological variables pre-L-NAME or saline administration are shown in Table 12. 
Arterial blood gases and plasma glucose were comparable between groups.
L-NAME (0.3,3 30 mg/kg i.v.) induced a dose-related hypertensive response as shown in 
Figure 46. All 3 doses elicited a significant increase in MABP, the magnitude of which 
increased with increasing dose. At the 30 mg/kg dose of L-NAME rats appeared sedated 
and less sensitive to external stimuli.
6.2.2.2. Dose-dependency of reductions in cerebral blood flow
The reductions in CBF induced by L-NAME were also found to be dose-related and are 
represented in Table 13 as a percentage of each contemporaneous saline control group. For 
the 0.3 mg/kg dose of L-NAME there was a trend to reduce CBF, but this did not reach 
significance for any of the 13 regions studied. With 3 mg/kg L-NAME the reductions in 
CBF attained significance in 6 of the 13 regions (cerebellum, inferior colliculus, superior 
colliculus, hypothalamus, occipital cortex and olfactory bulbs), while for 30 mg/kg 
L-NAME significant reductions in CBF were achieved for 11 of the 13 regions. The data 
for 5 selected regions is illustrated in Figure 47. From this graph the dose-dependency of 
the hypoperfusion induced by L-NAME can be clearly seen in regions such as the 
cerebellum and medulla oblongata. In addition the statistical significance of the reductions 
in flow, for all 5 regions, was greater for the 30 mg/kg dose of L-NAME than for the lower 
doses. However for the frontal cortex and caudate nucleus the magnitude of the observed 
reductions in flow were comparable between the 3 and 30 mg/kg doses of L-NAME.
154
Table 12 Physiological variables for the dose-dependency












PH 7.435 ±0.016 7.426 ±0.035 7.436 ±0.017 7.399 ±0.027
Pa CC>2 (mmHg) 39.4 ±2.9 40.0 ±2.9 39.4 ±1.5 42.0 ± 3 .0
Pa 0 2 (mmHg) 84.6 ±3.9 92.2 ±6.8 85.4 ±6.4 87.2 ±4.3
Glucose (mmol/1) 9.00± 1.13 8.82 ±2.01 8.28 ±1.39 8.26 ±0.57
Rectal Temp (°C) 37.13 ±0.40 36.90 ±0.22 37.18 ±0.85 37.08 ±0.24
Physiological variables were measured immediately prior to administration of 
L-NAME (0.3, 3 or 30 mg/kg i.v.) or saline (1 ml/kg i.v.). Local cerebral blood 
flow was subsequently determined 30 min post-drug administration.
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Figure 46 Dose-dependency of the pressor response to L-NAME in the conscious rat
Saline L-NAME L-NAME L-NAME 
0.3 mg/kg 3 mk/kg 30 mg/kg
Change in mean arterial blood pressure measured 30 min following L-NAME 
(0.3 - 30 mg/kg i.v.) or saline administration in conscious rats. ***p < 0.001 
compared with saline control (unpaired Student's t-tests). Base-line mean arterial 
blood pressures prior to drug or vehicle administration were 135 ± 6, 135 ± 4, 
134 ± 1 and 131 ± 6 (mean ± S.D.) for saline and 0.3, 3 and 30 mg/kg L-NAME 
groups respectively.
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Table 13 Dose-dependency of the effect of L-NAME on local cerebral blood 




0.3 mg/kg 3 mg/kg 30 mg/kg
Cerebellum 92 ± 8 7 6 ± 6  * 70 ±  8 ***
Medulla 96 ± 9 86 ± 8 7 6 ± 5  **
Inferior Colliculus 91 ±15 73 ± 1 0 * 80 ±  8 **
Superior Colliculus 86 ±12 68 ±11 * 85 ±  19 *
Hypothalamus 87 ±12 68 ±11 * 67 ±  16 **
Thalamus 80 ±13 73 ± 16 7 0 ± 8  **
Hippocampus 91 ±13 80 ±21 7 6 ± 6  *
Caudate Nucleus 86 ±11 78 ±12 81 ± 1 4 *
Nucleus Accumbens 79 ±18 74 ±24 63 ± 5 * *
Frontal Cortex 87 ±11 75 ±13 74 ±  11 *
Parietal Cortex 86 ±12 75 ±12 84 ±  16
Occipital Cortex 74 ± 9 6 0 ± 9  * 83 ± 1 2
Olfactory Bulbs 88 ± 9 75 ± 8 * 79 ± 9 * *
Local cerebral blood flow was measured 30 min following 
administration of L-NAME (0.3, 3 and 30 mg/kg i.v.) or saline (n = 5-6 
per group) in the conscious rat. Data is represented as percentages of 
the mean CBF values for individual saline control groups.
***p < 0.001, **p < 0.01, *p < 0.05 compared with relevant saline 
control group (unpaired Student's t-tests).
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Figure 47 Dose-dependency of the cerebrovascular









Cerebellum Medulla Hypothalamus Frontal Caudate
Cortex Nucleus
-50 -J
■  0.3 mg/kg 
□  3 mg/kg 
0  30 mg/kg
Percentage reduction in cerebral blood flow in selected neuroanatomically defined 
regions of the brain measured 30 min following 0.3, 3 or 30 mg/kg L-NAME i.v. 
Data was compared to individual saline control groups by unpaired Student's 
t-tests. *p < 0.05, **p < 0.02, ***p < 0.001.
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6.3. Time course for effect of L-NAME on cerebral blood flow
6.3.1. Experimental Protocol
Local CBF was measured, in separate groups of conscious rats, 15, 30, 60 and 180 min 
after injection of L-NAME (30 mg/kg i.v.) or saline (1 ml/kg i.v.). The whole tissue 
method described in Section 6.2. was used to determine the tissue concentrations of 




Physiological variables pre-drug administration were within the normal ranges and are 
shown in Table 14.
As in the previous study (Section 6.2.), L-NAME induced a rapid and highly significant 
increase in MABP compared with the relevant saline control group. For experiments of 
180 min duration subsequent pairwise comparisons showed this difference was significant 
at all timepoints studied (Figure 48a). MABP declined slightly bom its maximal value 60 
min post-drug, but was still elevated (by over 30 mmHg) 180 min following administration 
of the single dose of L-NAME.
In the conscious rat L-NAME (30 mg/kg) induced a significant hypothermic response, even 
with the presence of heating lamps, exhibited as a slow progressive reduction in rectal 
temperature that was most marked at the 60 min and 180 min time points (e.g. mean rectal 
temperatures were 35.5 ± 0.17 and 37.1 ± 0.3 in L-NAME and saline groups respectively, 
60 min post-drug or saline administration).
6.3.2.2. Time course for reductions in cerebral blood flow
CBF was significandy reduced by L-NAME in the majority of regions at each time point 
post-drug administration (15-180 min, see Table 15). The reductions in CBF did not 
decrease in magnitude over time, and CBF was still significantly reduced in all 13 regions 
at the 180 min time point (see Table 15 and Figure 48b). The reductions in CBF were 
similar in magnitude for all regions of interest (e.g. 37-43% for 180 min group).
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Table 14 Physiological variables for the time course of the effect of L-NAME
on local cerebral blood flow in the conscious rat









pH 7.424 ±0.007 7.377 ±0.042 7.418 ±0.026 7.399 ±0.027
PaCO^mmHg) 41.7 ±0.6 40.6 ±3.1 41.0 ±2.9 42.0 ±3.0
Pa O2 (mmHg) 80.1 ±3.3 84.5 ±6.7 83.1 ±1.8 87.2 ±4.3
Glucose (mmol/1) 9.06 ±0.48 9.58 ±1.42 7.95 ±0.55 8.26 ±0.57
Rectal Temp (°C) 37.17 ±0.72 36.95 ±0.33 37.30 ±0.35 37.08 ±0.24









pH 7.423 ±0.026 7.431 ±0.052 7.429 ±0.022 7.435 ±0.051
Pa CO2 (mmHg) 42.3 ±2.4 41.0 ±6.2 37.7 ±5.6 40.0 ±2.4
Pa O2 (mmHg) 88.3 ±8.0 86.0 ±8.6 92.5 ±6.6 92.7 ±8.0
Glucose (mmol/1) 9.90 ±2.35 8.47 ±1.38 9.50 ±2.05 9.05 ± 1.76
Rectal Temp (°Q 37.05 ±0.25 36.93 ±0.48 36.75 ±0.79 37.12 ±0.65
Physiological variables were measured immediately prior to administration of 
L-NAME (30 mg/kg i.v.) or saline (1 ml/kg i.v.). Local cerebral blood flow was 
determined 15 min, 30 min, 1 h or 3 h following drug treatment.
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Figure 48 Prolonged maintenance of the pressor and
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Temporal profile of peripheral and central responses following 
administration of L-NAME (30 mg/kg i.v. at time 0): a) Change in mean 
arterial blood pressure (MABP) and b) Reductions in cerebral blood flow 
(CBF) expressed as percentage of relevant saline control.
*p<0.05, **p<0.01, ***p<0.001 compared with appropriate saline control 
group (statistical analysis by a) two-way repeated measure ANOVA 
followed by unpaired Student's t-tests with Bonferroni correction for 
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6.4. C om parison of the effect of L-NAME on cerebra l blood flow in 
anaesthetised and conscious rats
6.4.1. Experimental Protocol
Conscious and halothane-anaesthetised rats were prepared for [14C]IAP measurement of 
local CBF as described in Section 2.4.2.1. Local CBF was measured 30 min after 
administration of L-NAME (30 mg/kg) or 1 ml/kg saline i.v. using a 30 s ramped infusion 
of [14C]LAP. Following decapitation the brains were processed for autoradiography.
6.4.2. Results
6.4.2.1. Physiological variables
Physiological variables measured immediately prior to administration of L-NAME (30 
mg/kg i.v.) or saline are shown in Table 16. Values for all animals were within the normal 
ranges for conscious and halothane-anaesthetised rats.
The changes in MABP following administration of L-NAME (30 mg/kg) or saline in 
conscious and halothane-anaesthetised rats are shown in Figure 49. In the conscious rat 
L-NAME induced a rapid and significant elevation in MABP (p < 0.001) compared to the 
saline control group. Subsequent pairwise comparisons revealed significant differences (p 
< 0.05) between L-NAME and saline treated rats at all time points following drug 
administration, and MABP at the 30 min time point was 32 ± 12 mmHg (mean ± S.D.) 
greater than the pre-drug value. In contrast under halothane anaesthesia the pressor 
response to L-NAME was markedly reduced so that MABP did not differ significantly (p > 
0.05) between the L-NAME and saline groups. MABP at the 30 min time point was only 
12 ± 11 mmHg above the pre-L-NAME level. This represents approximately one-third of 
the pressor response observed with the same dose of L-NAME in conscious rats.
6.4.2.2. Cerebrovascular effect of L-NAME
L-NAME significantly reduced CBF in all 16 of the neuroanatomical regions studied in 
both conscious and halothane-anaesthetised rats (Table 17). The hypoperfusion induced by 
L-NAME was rather uniform throughout the brain. Reductions in CBF for the conscious 
group ranged between 21 and 41%, while for halothane anaesthetised rats L-NAME 
reduced CBF by 36 to 50%. The cerebrovascular conductance values for all 16 regions of 
interest were similarly significantly reduced following L-NAME treatment in both 
conscious and halothane-anaesthetised rats (Table 17).
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Table 16 Physiological variables for the effect of L-NAME on
cerebral blood flow in conscious and anaesthetised rats
CONSCIOUS
SALINE (n = 7) L-NAME (n = 6)
pH 7.43510.030 7.43110.037
PaCC>2(mmHg) 39.112.9 39.113.2
Pa O2 (mmHg) 85.616.2 82.413.4
Glucose (mmol/1) 9.0011.41 9.3610.93
Rectal Temp (°C) 36.7710.48 37.0710.52
HALOTHANE
SALINE ( n = 6) L-NAME (n = 6)
pH 7.41010.044 7.9610.088
PaCC>2(mmHg) 39.011.8 37 .811.9
Pa O2 (mmHg) 166.2116.7 160.6116.2
Glucose (mmol/1) 9.4210.65 9.2810.87
Rectal Temp (°C) 37.3010.25 37.0810.38
Physiological variables were measured immediately 
prior to administration of L-NAME (30 mg/kg i.v.) or 
saline (1 ml/kg i.v.).
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6.5.1. Peripheral vascular response to nitric oxide synthase inhibition
In the conscious rat L-NAME elicited a dose-related hypertensive response. The magnitude 
of this response is in agreement with previous studies (Gardiner et al. 1990a; Rees et al. 
1990) and demonstrates that NO maintains the basal vasodilatory tone of the peripheral 
vasculature. In addition we have shown that halothane anaesthesia significantly attenuates 
the pressor response to L-NAME. This phenomenon was also observed in other studies 
designed to investigate the effect of L-NAME on ischaemic damage in anaesthetised rats 
(see Section 7). The influence of anaesthetic agents on the pressor response to NOS 
inhibitors has also been reported by other groups (Aisaka et al. 1991; Greenblatt et al. 
1992; Wang et al. 1991). These studies have confirmed that halothane anaesthesia reduces 
the elevation in MABP induced by NOS inhibition, and also shown that other anaesthetic 
agents (e.g. pentobarbital) can increase the pressor response to L-NAME. The mechanism 
by which halothane reduces the pressor response is not known, but can not be wholly 
dependent on its inherent vasodilator properties since other volatile anaesthetics which 
produce a similar degree of hypotension to halothane actually potentiate the hypertensive 
action of NOS inhibitors (Wang et al. 1991). In addition this effect appears selective for 
NOS inhibitors as halothane only minimally reduces the pressor response to noradrenaline 
and angiotensin II (Pang et al. 1992). Interestingly halothane has also been reported to 
reduce the vasodilation induced by NO in isolated large conductance vessels (Muldoon et 
al. 1988). Thus halothane appears to reduce the physiological response to both NO and 
NOS inhibitors. However regional variations in the vascular response to NOS inhibition 
(Greenblatt et al. 1992) cautions against direct comparison of in vitro studies with in vivo 
control mechanisms in the whole animal.
6.5.2. Central vascular response to nitric oxide synthase inhibition
Prior to the initiation of this study no detailed report concerning the regional distribution, 
dose-dependency and duration of action of NOS inhibition on local CBF had been 
published. Before the identification of EDRF as NO, an endothelium derived factor was 
known to control the relaxation of central vessels (Rosenblum 1986). This fact together 
with the subsequent demonstration that NOS inhibitors could constrict cerebral vessels in 
vivo (Faraci 1990; Gotoh et al. 1991; Rosenblum et al. 1990) suggested that NO may 
mediate regulation of vascular tone centrally as well as peripherally. The results of the 
present study have shown that this is indeed the case.
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In the conscious rat, L-NAME elicited sustained, dose-dependent reductions in CBF 
throughout the brain. Reductions in CBF of the same magnitude have subsequently been 
reported for both conscious (Tanaka et al. 1991) and anaesthetised (Kozniewska et a l  
1992; Prado et a l  1992) rats using similar doses of NOS inhibitors. If NOS inhibitors had 
no effect on the cerebrovasculature, the increase in arterial blood pressure induced by NOS 
inhibition would lead to autoregulatory constriction of cerebral blood vessels in an attempt 
to maintain constant CBF. The fact that CBF is actually decreased following NOS 
inhibition demonstrates that these drugs have a direct constrictive action on cerebral vessels 
and confirms that basal NO production is involved in the maintenance of resting CBF in the 
rat.
NOS is located within all cellular elements of the CNS including endothelium (Bredt et a l 
1990), vascular smooth muscle (Katusic 1991), intrinsic and extrinsic peri-vascular 
neurones (Regidor et a l  1993; Iadecola et a l  1993) and glia (Murphy et a l  1990). All of 
these sources of NO could potentially influence cerebrovascular tone. However the 
hetergeneous distribution of neuronal NOS (highest in cerebellum, lowest in medulla 
oblongata (Bredt et a l  1990; Forstermann et a l  1990)) does not match the homogeneity of 
the observed reductions in local CBF suggesting that endothelial NOS may be of greater 
importance than intraparenchymal NOS in controlling the basal tone of the cerebral 
circulation. Furthermore the response to NOS inhibition is dependent on vessel size, being 
greater in large arteries than arterioles regardless of brain region (Faraci 1991), suggesting 
the reductions in CBF observed following administration of NOS inhibitors are mediated 
primarily by constriction of the main cerebral vessels rather than the microcirculation. In 
this regard the NOS-containing neurones that originate in the sphenopalantine ganglion and 
innervate the cerebral arteries (Iadecola et a l  1993; Nozaki et al. 1993) may also be an 
important regulator of global CBF. The intrinsic NOS-containing neurones within the 
brain (Regidor et al. 1993) may be more involved in the control of localised changes in 
blood flow in response to stimulation of particular neuronal pathways.
In the anaesthetised cat a heterogeneous reduction in regional CBF following L-nitro- 
arginine has been reported (Kovach et al. 1992) leading the authors to suggest involvement 
of neuronal NO in the control of basal cerebrovascular tone in this species. However this 
argument is not supported by the regional distribution of neuronal NOS which does not 
match the reported reductions in rCBF in the cat. However some species differences do 
appear to exist with regards to the relative importance of NO for control of basal tone since 
L-nitroarginine has no significant effect on CBF in the rabbit (Faraci & Heistad 1992).
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In the present study the time course for L-NAME-induced reductions in local CBF was 
monitored for 3 h following administration of a single dose of L-NAME (30 mg/kg). The 
reductions in CBF were still maximal at the 3 h time point accentuating the prolonged 
inhibition of NO production achieved by treatment with NOS inhibitors. Other studies 
have demonstrated similarly prolonged cerebrovascular responses to NOS inhibition 
(Kovach et al. 1992; Prado et al. 1992) with reports of reduced CBF 24 h post-infusion of 
L-nitroarginine in the rat (quoted in Prado et al. 1992) and 48 h post-infusion of L-NAME 
in the goat (Fernandez et al. 1993). In addition subsequent ex vivo assay of cerebral vessel 
reactivity following systemic administration of L-nitroarginine has shown NO-dependent 
relaxations to be impaired (Kovach et al. 1992). All of this data is consistent with the 
irreversible inhibition of central NOS activity that has been reported to occur following 
systemic administration of NOS inhibitors (Dwyer et al. 1991).
6.5.3. Halothane anaesthesia and cerebrovascular effect of L-NAME
Halothane anaesthesia did not dramatically alter the cerebral hypoperfusion induced by 
L-NAME since significant reductions in local CBF were observed in both conscious and 
halothane-anaesthetised rats. However the hypertension induced by L-NAME in conscious 
rats makes direct comparison of CBF between conscious and anaesthetised rats difficult. 
Therefore conductance values were calculated to compensate for the difference in blood 
pressure between L-NAME treated rats in the conscious and halothane groups. These 
results showed that, following L-NAME treatment, there were no significant differences in 
the cerebrovascular conductances for conscious and halothane-anaesthetised rats. Therefore 
the degree of cerebral vasoconstriction induced by L-NAME is equivalent in the 2 groups.
The results of this study have demonstrated that halothane anaesthesia reduces the 
peripheral vasoconstrictive action of the NOS inhibitor L-NAME but does not affect the 
central response. This differential action may reflect the different subcellular localisations 
of NOS in the brain and periphery. Within peripheral endothelial cells NOS is located in 
both the plasma membrane and cytoplasm (Forstermann et al. 1991), while in the brain 
NOS is predominantly cytosolic (Matsumoto et al. 1993). Halothane, like other general 
anaesthetics, induces membrane perturbations that may prevent interaction of L-NAME 
with membrane NOS while leaving cytosolic NOS unaffected, resulting in attenuation of 
the peripheral rather than the central response to L-NAME.
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6.5.4. The choice of L-NAME as the inhibitor of nitric oxide synthase
L-NAME was chosen as the in vivo inhibitor of central NOS in these studies in preference 
to NG-monomethyl-L-arginine (L-NMMA), the first widely available NOS inhibitor, for 
several reasons. L-NMMA acts in part indirectly by inhibiting L-arginine uptake into 
neurones and endothelium (Bogle et al. 1992; Westergaard et al. 1993). This compound is 
also metabolised to L-arginine (Hecker et al. 1990) and can therefore actually promote NO 
synthesis (Archer & Hampl 1992). Furthermore L-NMMA is a more potent inhibitor of 
inducible NOS than constitutive NOS (Gross et al. 1990; Lambert et al. 1991) so is not 
ideally suited to studies of constitutive NOS in neuronal or endothelial cells. In contrast 
N^nitro-L-arginine (L-NA) is a more potent inhibitor of constitutive NOS than L-NMMA 
(Moore et al. 1990), and is not metabolised to L-arginine (Hecker et al. 1990). However 
because L-NA has low solubility in saline, its methyl ester derivative L-NAME was instead 
used in the present studies. L-NA and L-NAME are similar in potency, and are more 
potent inhibitors of neuronal and endothelial NOS than L-NMMA in vitro (East & 
Garthwaite 1990; Moore et al. 1990) and in vivo (Babbedge et al. 1993; Rees et al. 1990). 
In vivo L-NAME is rapidly converted to L-NA (Schwarzacher & Raberger 1992) by an 
esterase, so the actions of L-NAME are probably mediated by L-NA which itself does not 
undergo further metabolism (Krejcy et al. 1993). The presence of a guanidino-nitro group 
means L-NA and L-NAME can cross the blood-brain barrier more easily than other 
arginine analogs such as L-NMMA, and systemic administration of L-NA has been 
demonstrated to inhibit brain NOS activity in rats (Dwyer et al. 1991).
6.5.5. The putative role of nitric oxide as an endogenous vasodilator in the 
cerebrovasculature
The identification of NO as the EDRF controlling the response to acetyl choline in the CNS 
has been disputed (Rosenblum 1992), and it may be that EDRFACh is actually a 
NO-containing compound such as a nitrosothiol rather than NO itself (Myers et al. 1990; 
Rosenblum 1992). The mode of action of 'NOS inhibitors', particularly L-NMMA, has 
also been questioned. In the mouse cerebral circulation L-NMMA may act by activating 
arachidonic acid metabolism thereby generating superoxide which scavenges NO resulting 
in vasoconstriction (Rosenblum et al. 1992). However this response appears to be 
species-specific for the mouse since 'NOS inhibitors' in the presence of cyclooxygenase 
inhibitors or superoxide dismutase still produce significant vasoconstriction in both rats and 
cats (Rees et al. 1990; Wei et al. 1992). This fact together with the demonstration that 
coadministration of L-arginine and L-NAME reverses the cerebrovascular response to 
L-NAME (Prado et al. 1992) justifies our conclusion that L-NAME reduces CBF by 
inhibiting basal production of NO.
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7. THE CONTRIBUTIONS OF GLUTAMATE AND NITRIC OXIDE TO ISCHAEMIC 
AND EXCITOTOXIC DAMAGE
7.1. Effect of MK-801 p re - tre a tm e n t on ischaem ic dam age following 
transient MCA occlusion
7.1.1. Introduction
The role of glutamate in the pathophysiology of permanent focal cerebral ischaemia is well 
established (see Section 1.4.3.), but its role in transient ischaemia-reperfusion injury 
remains to be as fully defined. As a first step towards elucidation of the role of glutamate 
in focal ischaemia-reperfusion injury the neuroprotective efficacy of the non-competitive 
NMD A receptor antagonist MK-801 was assessed on acute outcome (4 h) following 
transient MCA occlusion in the anaesthetised ra t The 4 h, anaesthetised paradigm was 
chosen because it allows monitoring and control of physiological variables (including blood 
pressure) which can influence outcome in the endothelin-1 model of transient ischaemia 
(see Section 4.1.4.).
7.1.2. Experimental protocol
A bolus injection of MK-801 (0.12 mg/kg i.v.) was administered either 1 h or 2.5 h prior 
to transient MCA occlusion induced by application of endothelin-1 to the MCA. The bolus 
was immediately followed by an infusion of MK-801 (108 pg/kg/h at 0.6 ml/h i.v.) that 
continued throughout the experimental period. The control group received a bolus injection 
of saline (1 ml/kg i.v.) 1 h prior to endothelin-1 application that was followed by 
continuous infusion of saline (0.6 ml/h i.v.). Blood pressure and rectal temperature were 
monitored throughout. Temporalis muscle temperature was measured at the time of 
endothelin-1 application. Blood gases and plasma glucose were measured at one hourly 
intervals following MCA occlusion. 4 h post-MCA occlusion the rats were perfusion fixed 
and the volumes of ischaemic damage in the 3 groups assessed by quantitative 




Physiological variables prior to drug or vehicle administration, and pre- and post-MCA 
occlusion arc shown in Table 18. There were no major differences between groups for any 
variable tested. In particular temporalis muscle temperatures at the time of endothelin-1 
application to the MCA were similar in all groups. Plasma glucose levels tended to decline 
with time probably reflecting the relatively long duration of these experiments.
Immediately following administration of the bolus dose of MK-801 there was a rapid and 
significant reduction in mean arterial blood pressure in both MK-801 groups (Figure 50). 
MABP returned to basal level 30 min before MCA occlusion for the group in which 
MK-801 treatment was initiated 2.5 h pre-MCA occlusion. In contrast significant 
hypotension persisted until 30 min after MCA occlusion for the group in which MK-801 
treatment was initiated only 1 h before the onset of ischaemia.
7.1.3.2. Effect of MK-801 on ischaemic damage
MK-801 treatment initiated 2.5 h pre-transient MCA occlusion markedly, and significantly, 
reduced the volumes of ischaemic damage in the whole hemisphere and caudate nucleus by 
71 and 85% respectively (Figure 51). The volume of ischaemic damage in the cerebral 
cortex was reduced by 61% but this just failed to reach statistical significance at the 5% 
level. In contrast MK-801 treatment initiated 1 h pre-MCA occlusion did not significantly 
alter the volume of ischaemic damage in the whole hemisphere or cortex. There was a 
trend for reduction in the volume of damage in the caudate nucleus, but this was also not 
statistically significant
MK-801 treatment initiated 2.5 h pre-MCA occlusion reduced the areas of ischaemic 
damage in hemisphere, cortex and caudate nucleus throughout the rostrocaudal extent of the 
lesion (Figure 52). The areas of damage in the caudate nucleus following the 1 h MK-801 
pre-treatment were intermediate between the control and 2.5.h MK-801 group reflecting the 
trend for reduced volume of damage in this region following 1 h MK-801 pre-treatment In 
contrast the 1 h MK-801 treatment tended to increase the cortical areas of damage towards 
the caudal part of the lesion compared with the saline control group (Figure 52).
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Table 18 Physiological variables for effect of MK-801 against 
ischaemic damage induced by transient MCA occlusion
CONTROL (n = 10)____________ _____________ _____________
PRE-SALINE MCAO +1 HOUR + 4 HOUR
pH 7.432 ±0.045 7.401 ±0.064 7.400 ±0.032 7.392 ±0.052
PaCC>2(mmHg) 34.4 ±2.1 39.1 ±3.2 37.1 ±3.6 37.8 ±2.7
Pa O2 (mmHg) 170.3 ±18.3 176.5 ±25.2 173.9 ± 14.5 184.2 ±23.6
Glucose (mmol/1) 9.25 ±1.86 9.05 ±1.61 9.16 ±1.48 8.17 ±1.25
Rectal Temp (°C) 36.98 ± 0.25 37.01 ±0.19 37.00 ±0.19 36.99 ±0.17
Temporalis 
Temp (00 36.67 ±0.29
MK-801 lhpre-MICAO (n = 9)
PRE-MK-801 MCAO + 1 HOUR + 4 HOUR
pH 7.444 ±0.059 7.404 ±0.053 7.420 ±0.039 7.413 ±0.054
PaCCVjOnmHg) 36.2 ±3.4 37.1 ±2.7 36.6 ±3.5 37.1 ±2.5
Pa (>2 (mmHg) 176.9 ±20.6 176.0 ±21.7 180.2 ±27.1 184.9 ±14.9
Glucose (mmol/1) 9.10 ±1.23 8.40 ±1.73 8.03 ±1.17 6.92 ± 1.02
Rectal Temp (°C) 36.92 ±0.29 37.11 ±0.29 36.92 ±0.48 37.14 ±0.14
Temporalis 
Temn (°C) 36.68 ±0.29
MK-801 2.5 h pre-MCAO (n = 9)
PRE-MK-801 MCAO + 1 HOUR + 4 HOUR
pH 7.428 ±0.035 7.403 ±0.025 7.392 ±0.032 7.406 ±0.048
PaCO^mmHg) 36.9 ±2.5 38.2 ±2.6 35.7 ±3.0 37.3 ±2.9
Pa O2 (mmHg) 181.8 ±39.4 179.1 ±29.1 176.7± 26.7 173.8 ±21.6
Glucose (mmol/1) 8.70 ±0.97 7.57 ±1.00 7.20 ±1.01 6.94 ±0.62
Rectal Temp (°C) 36.94 ±0.24 37.01 ±0.08 36.99 ±0.15 36.96 ±0.10
Temporalis
ls?pp (°Q. 36.41 ±0.28
Treatment with MK-801 (0.12 mg/kg bolus then 108 pg/kg/h at 0.6 ml/h i.v.) or an 
equivalent volume of saline was initiated either 1 h or 2.5 h pre-MCA occlusion. 
Physiological variables were measured immediately prior to drug administration, 
immediately prior to MCA occlusion and 1 h and 4 h post-MCA occlusion.
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Figure 50 Effect of MK-801 on mean arterial blood pressure
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MK-801 was administered as a bolus (0.12 mg/kg i.v.) followed by continuous 
infusion (108 pg/kg/h at 0.6 ml/h). Treatment was started either 2.5 h or 1 h 
pre-MCA occlusion (MCAO). Both dosing schedules resulted in significant 
reductions in mean arterial blood pressure (MABP), but while MABP had 
returned to pre-drug levels by the time of MCAO for the 2.5 h group it was still
significantly reduced for the 1 h pre-treatment group. *p < 0.05, t p  < 0.05 



















Figure 51 Effect of MK-801 on volume of ischaemic damage
induced by transient MCA occlusion
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MK-801 pre-treatment (0.12 mg/kg bolus followed by 108 pg/kg/h at 0.6 
ml/h i.v.) initiated 2.5 h pre-MCA occlusion significantly reduced the 
mean volumes of ischaemic damage in the whole hemisphere and 
caudate nucleus. In contrast MK-801 treatment initiated only 1 h 
pre-MCA occlusion did not significantly alter the mean volumes of 
ischaemic damage in hemisphere, cortex or caudate nucleus. *p < 0.05, 
***p < 0.001 compared with saline control group respectively (unpaired 
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In halothane-anaesthetised rats bolus injection of 0.5 mg/kg MK-801 (a dose that 
significantly reduces the volume of ischaemic damage following permanent MCA 
occlusion, Park et al. 1988; Roussel et al. 1992a) induces an immediate and relatively 
prolonged hypotension where MABP falls below 60 mmHg (Park et al. 1988; Park et al. 
1989). Transient hypotension of this magnitude can significantly increase the volume of 
ischaemic damage (Osborne et al. 1987) and blood-brain barrier permeability (Tyson et al. 
1982) following permanent MCA occlusion. In view of this, and the apparent relationship 
between outcome and MABP following transient MCA occlusion (see Section 4.1.4.), we 
wished to avoid the confounding influence of MK-801-induced hypotension in the present 
study. MK-801 was therefore administered as a low bolus dose followed by a continuous 
intravenous infusion using a dosing schedule previously demonstrated to transiently reduce 
MABP below 75 mmHg for less than 15 min while providing significant neuroprotection 
against permanent MCA occlusion (Gill et al. 1991). However despite the use of this 
dosing schedule a relatively prolonged hypotension was still observed in the present study. 
This result was in contrast to the Gill et al. study where MK-801 treatment was initiated 
immediately following MCA occlusion. This suggests an interaction between MK-801 and 
the surgical procedure involved in exposing the MCA prolongs the hypotensive action of 
the drug. A similar phenomenon has been observed with bolus administration of MK-801: 
MABP remains significantly depressed (below 75 mmHg for 3.5 h) when MK-801 is 
administered pre-MCA occlusion whereas MABP returns to control level within 60 min 
when the drug is given post-MCA occlusion (Park et al. 1988). To compensate for the 
prolonged hypotensive response a second group of animals was included in the study in 
which MK-801 infusion was started 2.5 h pre-MCA occlusion to ensure that MABP had 
returned to control levels by the time of MCA occlusion. The infusion rate employed in the 
current study attains steady state plasma levels of MK-801 (18.9 ng/ml) within 60 min (Gill 
et al. 1991; Willis et al. 1991), therefore the plasma concentrations of MK-801 at the time 
of MCA occlusion should have been equivalent in both MK-801 groups, the only 
difference being the relative MABP.
In this study the MK-801 infusion initiated 2.5 h prior to MCA occlusion significantly 
reduced the volume of ischaemic damage while the 1 h pre-MCA occlusion infusion did 
not. Thus the lower MABP at the onset of ischaemia in the 1 h group (68 ± 6 mmHg 
compared to 84 ± 4 mmHg) appears to have increased the severity of the ischaemic insult 
(as for permanent MCA occlusion, Osborne et al. 1987) and directly counteracted the 
neuroprotective action of the drug. Significant neuroprotection was demonstrated in the 
caudate nucleus following the 2.5 h pre-treatment with MK-801. In contrast to this result
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ischaemic damage in the caudate nucleus following permanent MCA occlusion in the rat is 
usually resistant to MK-801 (Gill et al. 1991; Roussel et al. 1992a) although a very small 
neuroprotective effect has been reported (Park et al. 1990). The lack of efficacy of 
MK-801 against striatal damage following permanent focal ischaemia is usually attributed 
to the absence of collateral supply to this region (Gill et al. 1991). In the context of 
transient MCA occlusion the restoration of blood supply to the caudate nucleus allows the 
potential salvage of the tissue as demonstrated in the present study.
In addition to its peripheral action on blood pressure MK-801 has marked effects on 
cerebral glucose metabolism and CBF, which differ in conscious and anesthetised rats 
(Kurumaji & McCulloch 1989; Nehls et al. 1990; Park et al. 1989; Roussel et al. 1992b), 
and which could potentially influence outcome following cerebral ischaemia. In conscious 
rats MK-801 increases local CBF in specific regions including the neocortex and caudate 
nucleus while minimally affecting other regions (Nehls et al. 1990; Roussel et al. 1992b). 
In contrast under halothane anaesthesia MK-801 induces widespread homogeneous 
reductions in local CBF (of approximately 37%) in the majority of brain regions including 
cortex and caudate nucleus (Park et al. 1989). However following MCA occlusion in 
halothane-anaesthetised rats and cats, MK-801 does not invoke further reductions in CBF 
in the MCA territory beyond the control level of ischaemia (Dezsi et al. 1992; Greenberg et 
al. 1991; Park et al. 1989). Therefore the cerebrovascular effects of MK-801 are likely to 
have less impact on outcome following experimental ischaemia in which halothane 
anaesthesia is maintained (as in the present study) compared with studies in which animals 
are allowed to regain consciousness.
MK-801 administered either during ischaemia and reperfusion, or immediately prior to 
onset of ischaemia, significantly reduces the amount of damage following 2-3 h transient 
MCA occlusion combined with 22 or 3 h reperfusion in normotensive rats (Buchan et al. 
1992a; Yang et al. 1991 respectively). However in these models the animals were 
conscious for most of the ischaemic period and all of the reperfusion phase, and the 
beneficial action of MK-801 has been attributed to the observed increase in blood flow in 
the ischaemic core region (Buchan et al. 1992a). To the best of our knowledge the present 
study is the first (for normotensive rats) in which halothane anaesthesia was maintained 
throughout both the ischaemic and reperfusion periods and in which therefore MK-801 
probably does not significantly influence CBF in the MCA territory. Therefore the present 
results represent the first study of transient focal cerebral ischaemia in the normotensive rat 
to demonstrate a beneficial effect of MK-801 pre-treatment that is independent of the 
cerebrovascular effects of the drug and probably mediated by its antiexcitotoxic action. 
This result has been confirmed by studies in halothane-anaesthetised cats. MK-801 (1
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mg/kg), administered during a 2 h period of MCA occlusion, significantly reduces the 
volume of hemispheric damage (by 29%) assessed after 4 h reperfusion, without altering 
CBF in the peripheral MCA territory during either the ischaemic or reperfusion phases 
(Dezsi et al. 1992). Similar results have been obtained (2mg/kg MK-801) with a 1 h period 
of MCA occlusion followed by 3 h reperfusion (Greenberg et al. 1991).
In SHR, where MK-801 does not improve CBF in the ischaemic core of conscious rats 
(Buchan et al. 1992a), pre-treatment with MK-801 or the alternative non-competitive 
NMDA antagonist ketamine, does not significantly alter ischaemic damage assessed 24 or 
96 h following a 2 h period of transient MCA occlusion (Buchan et al. 1992a; Panetta et al. 
1989; Ridenour et al. 1991). However it is also more difficult to demonstrate significant 
neuroprotection with MK-801 against permanent MCA occlusion in this strain (Roussel et 
al. 1992a) due to the inefficient collateral circulation. In contrast to MK-801, the AMPA 
antagonist NBQX has been reported to reduce the volume of ischaemic damage at 24 h 
following 2 h transient MCA occlusion in SHR (Buchan et al. 1991b), apparently without 
altering CBF. A more dramatic, long term protective effect of the non-selective 
AMPA/kainate antagonist DNQX has also been reported in which DNQX administered 
prior to, and immediately following, onset of ischaemia significantly reduced brain atrophy 
measured 1 month following 60 min transient MCA occlusion induced by the intraluminal 
thread technique (Hara et al. 1993).
Glutamate-induced excitotoxic mechanisms are one of the main mediators of ischaemic 
injury following permanent focal ischaemia as evidenced by the marked increase in 
extracellular glutamate (Butcher et al. 1990) and the repeated demonstration of efficacy of a 
wide range of glutamate receptor antagonists in animal models of permanent MCA 
occlusion (Bullock et al. 1990; Gill et al. 1991; Park etal. 1988; Simon & Shiraishi 1990). 
However following transient MCA occlusion the volume of ischaemic damage continues to 
increase after the onset of reperfusion (see Section 4.1.2.) suggesting that secondary 
mechanisms, other than glutamate, contribute to outcome in these models. However 
glutamate released during the ischaemic phase may indirectly lead to reperfusion injury by 
’priming’ the brain to increase oxygen radical and NO production at the onset of 
reperfusion. Thus the observed beneficial effect of MK-801 pre-treatment in the 
endothelin-1 model of transient focal ischaemia may be due to direct antagonism of 
glutamate-induced excitotoxicity in the ischaemic phase and consequential prevention of 
glutamate-induced production of free radicals and other potentially neurotoxic molecules in 
the reperfusion phase.
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Following MCA occlusion extracellular glutamate levels in the cortex rapidly increase 
reaching a peak approximately 30-60 min post-onset of ischaemia with subsequent decline 
towards basal levels despite the persistence of the occlusion (Butcher et al. 1990; Ginsberg 
et al. 1992; Graham et al. 1990). With the onset of reperfusion only a small, very 
transient, increase in the extracellular concentration of glutamate occurs (Ginsberg et al. 
1992), thus the direct contribution of glutamate to injury is likely to be less during the 
reperfusion phase compared with the ischaemic phase of the insult. Consequently 
glutamate receptor antagonists may be less efficacious when administered post-onset of 
reperfusion compared to the pre-ischaemic dosing schedule used in the present experiment 
Future studies using the endothelin-1 model of transient ischaemia could address this issue, 
although the effects of MK-801 on blood pressure and CBF in the conscious rat discussed 
above will make experimental design and interpretation difficult
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7.2. Effect of L-NAME pre-treatment on ischaemic damage following
transient and permanent MCA occlusion
7.2.1. Introduction
The demonstration that under certain conditions NO synthase inhibitors can antagonise 
glutamate toxicity in vitro (see Section 1.6) raised the possibility that these drugs would be 
efficacious against ischaemic damage in vivo. The potential neuroprotective action of the 
NO synthase inhibitor L-NAME was therefore assessed in a series of experiments in 
anaesthetised rats killed 4 h post-onset of transient or permanent MCA occlusion.
7.2.2. Experimental protocol
In the first series a relatively high dose of L-NAME (30 mg/kg s.c.) was administered 30 
min pre- and 30 min post-permanent MCA occlusion only. Control rats received an 
equivalent volume of saline (1 ml/kg s.c.). Blood pressure and rectal temperature were 
monitored throughout, while blood gases and plasma glucose were measured at one hourly 
intervals. 4 h post-MCA occlusion rats were killed by perfusion fixation and volumes of 
ischaemic damage determined using quantitative histopathology.
In the second series of experiments a lower dose of L-NAME (3 mg/kg i.v.), or an 
equivalent volume of saline (1 ml/kg i.v.), was adminstered 30 min prior to induction of 
permanent or transient MCA occlusion. Physiological variables were monitored as above 
and in addition temporalis muscle temperature was measured at the time of MCA occlusion. 




Physiological variables for the 3 separate studies are shown in Tables 19, 20 and 21 and 
were within the normal ranges for all groups.
181
Table 19 Physiological variables for effect of L-NAME (30 mg/kg)
against ischaemic damage induced by permanent MCA occlusion
CONTROL (n  = 9)
PRE-SALINE MCAO + 1 HOUR + 4 HOUR
PH 7.433 ±0.037 7.452 ±0.036 7.470 ±0.045 7.443 ±0.045
Pa CO2 (mmHg) 37.4 ±2.7 37.0 ±0.4 37.0 ±4.1 37.6 ±2.5
Pa O2 (mmHg) 144.1 ±22.1 136.0 ±17.0 153.3 ±27.6 167.8 ±21.0
Rectal Temp (°C) 37.05 ±0.14 36.98 ±0.42 36.90 ±0.18 36.91 ±0.18
Glucose (mmol/1) 10.78 ±1.05 10.53 ±2.10 9.75 ±1.98 10.25 ±1.35
L-NAME (n = 9)
PRE-L-NAME MCAO + 1 HOUR + 4 HOUR
PH 7.460 ±0.064 7.448± 0.078 7.421 ±0.063 7.383 ±0.045
Pa CO2 (mmHg) 37.2 ±1.6 36.8 ±1.4 36.3 ±3.0 38.3 ±2.4
Pa O2 (mmHg) 149.4 ± 19.4 155.2 ±17.8 152.8 ±16.4 147.1 ±12.8
Rectal Temp (°C) 37.15 ±0.24 37.06 ±0.57 37.21 ±0.33 37.06 ±0.36
Glucose (mmol/1) 10.52 ±2.10 9.91 ± 1.17 9.65 ±1.04 8.32 ±2.04
L-NAME (30 mg/kg s.c.) or saline was administered 30 min pre- and 30 min 
post-permanent MCA occlusion (MCAO) in the anaesthetised rat.
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Table 20 Physiological variables for effect of L-NAME (3 mg/kg)
against ischaemic damage induced by permanent MCA occlusion
CONTROL ( n = 5)
PRE-SALINE MCAO + 1 HOUR + 4 HOUR
pH 7.392 ±0.056 7.395 ±0.028 7.387 ±0.027 7.405 ±0.041
Pa CC>2 (mmHg) 35.2 ±2.7 36.7 ±2.2 39.7 ±5.3 37.0 ±2.6
Pa02(mmHg) 201.3 ±24.9 212.3 ±32.1 209.3 ±20.9 220.5 ±32.0
Glucose (mmol/1) 8.90 ±1.38 8.60± 1.10 8.12 ±0.73 8.17 ±0.95
Rectal Temp (°C) 37.1 ±0.11 37.02 ±0.28 37.12 ±0.21 37.00 ±0.00
Temporalis 
Temp (°C) 36.72 ±0.34 36.52 ±0.66
L-NAME (n = 6)
PRE-L-NAME MCAO +1 HOUR + 4 HOUR
PH 7.393 ±0.051 7.390± 0.037 7.368 ±0.048 7.387 ±0.062
PaCQ 2(mmHg) 37.2 ±1.7 36.0 ±4.1 35.0 ±4.2 34.8 ±2.0
Pa O2 (mmHg) 203.5 ±26.6 204.0 ±25.0 198.7 ±31.2 208.0 ±24.9
Glucose (mmol/1) 8.37 ±0.76 9.02 ±0.36 8.70 ±0.70 8.15 ±0.72
Rectal Temp (°C) 37.15 ±0.27 37.27 ±0.27 37.07 ±0.23 37.03 ±0.08
Temporalis 
Temp (°C) 36.40 ±0.13 36.78 ±0.39
L-NAME (3 mg/kg i.v.) or saline was administered 30 min prior to permanent 
MCA occlusion (MCAO) in the anaesthetised rat.
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Table 21 Physiological variables for effect of L-NAME (3 mg/kg)
against ischaemic damage induced by transient MCA occlusion
CONTROL (n = 14)
PRE-SALINE MCAO + 1 HOUR + 4 HOUR
pH 7.417 ±0.024 7.391 ±0.027 7.391 ±0.033 7.409 ±0.035
PaCOjCmmHg) 37.6 ±3.2 39.0 ±3.8 37.1 ±3.7 37.0 ±2.8
Pa02(mmHg) 175.2 ±27.9 171.3 ±30.1 176.6 ±24.6 183.6 ±21.5
Glucose (mmol/1) 9.47 ±1.13 9.58 ±1.42 8.74 ±1.06 8.00 ±1.00
Rectal Temp (°Q 36.86 ±0.23 37.16 ±0.30 37.11 ±0.41 37.04 ±0.17
Temporalis 
Temp (°C) 36.63 ±0.40
L-NAME (n = 14)
PRE-L-NAME MCAO + 1 HOUR + 4 HOUR
pH 7.415 ±0.051 7.384 ±0.046 7.379 ±0.021 7.384 ±0.043
PaCQ2(mmHg) 36.1 ±3.5 35.2 ±2.4 38.4 ±2.3 36.8 ±3.1
PaO^mmHg) 168.5 ±23.7 166.9 ±19.7 173.9 ±25.9 177.6 ±25.5
Glucose (mmol/1) 9.31 ±0.99 8.71 ±1.12 7.94 ±0.80 7.60 ±1.06
Rectal Temp (°C) 37.05 ±0.37 37.06 ±0.39 37.00 ±0.32 37.04 ±0.12
Temporalis 
Temp (°C) 36.54 ±0.24
L-NAME (3 mg/kg i.v.) or saline was administered 30 min prior to transient MCA 
occlusion (MCAO) in the anaesthetised rat.
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In the first series of experiments repeat dosing of the higher dose of L-NAME (30 mg/kg 
30 min pre- and post-permanent MCA occlusion) resulted in a moderate hypertensive effect 
(see Figure 53). Statistical analysis revealed a significant drug-time interaction (p = 0.01) 
for this study that resulted in significant differences in MABP between the L-NAME and 
saline groups at 4 time points following the second dose of L-NAME (2-way repeated 
measure ANOVA followed by unpaired Student's t-tests with Bonfemoni correction). In 
contrast the lower dose of L-NAME (3 mg/kg administered 30 min pre-MCA occlusion 
only) did not significandy alter MABP in either the transient or permanent MCA occlusion 
model (Figures 54 and 55).
1.23.2. Effect of L-NAME on ischaemic damage
Permanent MCA occlusion
L-NAME (30 mg/kg 30 min pre- and post-permanent MCA occlusion) did not significantly 
alter the volume of ischaemic damage in whole hemisphere, cortex or caudate nucleus 
(Figure 56). In fact the total volume of ischaemic damage was marginally greater in the 
L-NAME group compared to the saline control. In contrast the lower dose of L-NAME (3 
mg/kg) significantly reduced the volume of ischaemic damage following permanent MCA 
occlusion in whole hemisphere and cortex (Figure 57) although the effect was relatively 
small (the total volume of tissue salvaged was 12 mm3 representing a 16% reduction in the 
total volume of ischaemic damage). The volume of ischaemic damage in the caudate 
nucleus was not significantly altered by L-NAME pre-treatment
The modest neuroprotective effect of L-NAME (3 mg/kg) in the volumetric assessment of 
ischaemic damage was paralled by only minor reductions in the areas of ischaemic damage 
in the hemisphere and cortex, while it had no effect on areas of damage in the caudate 
nucleus (Figure 58).
Transient MCA occlusion
The anti-ischaemic efficacy of L-NAME (3 mg/kg) in this model was similar in magnitude 
to that observed for permanent MCA occlusion. L-NAME reduced the volumes of 
ischaemic damage in the whole hemisphere, cortex and caudate nucleus by 29%, 26% and 
33% respectively following transient MCA occlusion (Figure 59), with the total volume of 
tissue salvaged being 16 mm3. However these reductions did not reach statistical 
significance because of the greater variability encountered in this model compared to the 
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L-NAME (3 mg/kg i.v.) or saline was administered 30 min prior to transient 
MCA occlusion (MCAO) in the anaesthetised rat. In this study L-NAME 



















Figure 56 Effect of L-NAME (30 mg/kg) on volume of ischaemic
damage induced by permanent MCA occlusion
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L-NAME (30 mg/kg s.c., n = 9) or saline (n = 9) was administered 30 
min pre- and 30 min post-MCA occlusion. This relatively high dose 
of L-NAME did not significantly alter the mean volumes of ischaemic 
damage in hemisphere, cortex or caudate nucleus (p > 0.05 unpaired 
Student's t-tests).
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Figure 57 Effect of L-NAME (3 mg/kg) on volume of ischaemic
damage induced by permanent MCA occlusion
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L-NAME (3 mg/kg i.v., n = 6) or saline (n = 5) was administered 30 
min prior to permanent MCA occlusion in the anaesthetised ra t This 
relatively low dose of L-NAME significantly reduced the mean 
volumes of ischaemic damage in the whole hemisphere and cerebral 







































































































































































































































Figure 59 Effect of L-NAME (3 mg/kg) on volume of
ischaemic damage induced by transient MCA occlusion
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L-NAME (3 mg/kg i.v., n = 14) or saline (n = 14) was 
administered 30 min prior to transient MCA occlusion in the 
anaesthetised rat. L-NAME did not significantly reduce the 
volume of ischaemic damage compared to the saline control (p 
> 0.05 unpaired Student's t-tests).
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7.2.4. Discussion
In the first pharmacoprotection study utilising permanent MCA occlusion L-NAME had no 
neuroprotective effect, whereas in the second series of experiments the drug had a 
signficant neuroprotective action. The difference between the 2 studies lies in the treatment 
paradigms employed: with 3 mg/kg L-NAME a significant, if comparatively moderate, 
reduction in ischaemic damage was achieved, but increasing the dose to 2 x 30 mg/kg 
resulted in the abolition of this beneficial effect.
The results presented in the preceding chapter demonstrated that the cerebral 
vasoconstrictive action of L-NAME is dose-dependent with 30 mg/kg producing 
significantly greater hypoperfusion than 3 mg/kg in the conscious rat (see Section 6.1.). 
Therefore the more severe vasoconstrictive response elicited by 2 x 30 mg/kg L-NAME in 
the current study (assuming a similar dose-response relationship is maintained in 
anaesthetised, ischaemic animals) may have further reduced blood flow to the MCA 
territory resulting in a more severe ischaemic insult that directly counteracted the 
neuroprotective action of the drug exhibited at the lower dose (3 mg/kg). However even at 
3mg/kg the degree of neuroprotection achieved with L-NAME (12 mm3 tissue salvaged) is 
smaller than that observed for MK-801 (0.5 mg/kg) pre-treatment in the same model (41 
mm3 of tissue salvaged, Park et al. 1988) suggesting that the contribution of NO to 
permanent focal ischaemic injury is less than that of glutamate. Following MCA occlusion 
there is an acute transient elevation in NO that reaches its peak within 5 minutes of the onset 
of ischaemia and declines to basal levels within one hour (Trifiletti et al. 1992; Malinski et 
al. 1993). Thus during severe ischaemia NO production can not be maintained despite the 
more prolonged elevation in extracellular glutamate (Butcher etal. 1990). This may reflect 
chronic depletion of oxygen and energy supplies since continued production of NO 
necessitates continued supply of adequate levels of oxygen (as substrate, see Rengasamy & 
Johns 1991) and ATP (to regenerate the cofactor NADPH). Therefore neuronal NO may 
not be a major contributor to ischaemic damage in the acute post-ischaemic period 
following permanent MCA occlusion and this, together with the vasoconstriction induced 
by L-NAME, may explain the very modest neuroprotective effect of L-NAME observed 
following 4 h permanent MCA occlusion in the present series of experiments.
With the onset of reperfusion (and the restoration of energy supplies) following transient 
MCA occlusion there is a slow, progressive increase in NO production that is maintained 
for at least 1 h (Malinski et al. 1993). Thus the potential for NO-mediated injury would 
appear greater in the context of transient MCA occlusion followed by reperfusion than for 
permanent MCA occlusion. However our results do not support this premise since in the
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present studies 3 mg/kg L-NAME had a broadly similar effect on ischaemic damage 
following both transient and permanent MCA occlusion (the volumes of tissue salvaged 
were 16 and 12 mm3 respectively). The only difference being that, due to the greater 
variability in the transient model relative to the permanent model (see Section 8.2), the 
comparable reduction in ischaemic damage did not attain statistical significance.
In addition, as for permanent MCA occlusion, the efficacy of L-NAME pre-treatment was 
smaller than that observed for MK-801 pre-treatment in the same model (16 and 42 mm3 of 
tissue salvaged by L-NAME and MK-801 respectively). Thus the cerebrohypoperfusion 
induced by L-NAME during the ischaemic phase may have again detracted from the direct 
anti-excitotoxic action of the drug in the transient MCA occlusion model. In addition 
several other factors may have contributed to the modest efficacy of L-NAME in this study. 
Firstly L-NAME pre-treatment was observed to facilitate the vasoconstriction of the MCA 
elicited by endothelin-1. L-NAME may therefore have increased the severity of the initial 
ischaemic insult compared to saline controls by removing a tonic basal NO-mediated 
vasodilatation. Enhancement of the vasomotor response to endothelin-1 by L-NAME has 
also been reported for other vascular beds (Gardiner et al. 1990b; Lerman et al. 1992). 
Secondly L-NAME may have adverse effects during the reperfusion phase that follows a 
period of transient ischaemia. NO synthase inhibitors enhance leucocyte adherence to 
vascular endothelium (Ma et al. 1993) and may therefore impair restoration of blood flow 
to ischaemic regions (see also Section 1.4.5). Furthermore it has recently been 
demonstrated that L-NAME pre-treatment results in prolonged elevation of extracellular 
glutamate levels in the reperfusion phase following transient global ischaemia (Zhang, J. et 
al. 1993). The mechanism behind this effect remains to be established, but it has been 
suggested that prevention of NO formation may prolong the half-life of superoxide and 
promote superoxide-induced glutamate release (Zhang, J. et al. 1993). The effect of NO 
synthase inhibition on glutamate levels during focal ischaemia/repexfusion has not yet been 
investigated, but enhancement of extracellular glutamate levels in the reperfusion phase 
may be another factor detracting from the inherent neuroprotective action of L-NAME in the 
endothelin-1 model of transient focal ischaemia.
In summary these experiments have demonstrated that the anti-ischaemic efficacy of 
L-NAME in both transient and permanent acute focal ischaemia is comparatively weak, and 
that careful choice of the dosing schedule is necessary to prevent loss of this small 
neuroprotective effect
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In the past 2 years several studies concerning the anti-ischaemic efficacy of L-NAME and 
other NOS inhibitors have been published in the scientific literature. The results of these 
studies have been diverse, ranging from marked beneficial effects of NOS inhibition on 
focal ischaemic damage to significant exacerbation of lesion size. In the following 
paragraphs I shall attempt to explain these discrepant findings and relate them to the 
moderate neuroprotective effect of L-NAME obtained in the current thesis.
The observation that inhibitors of NOS antagonise glutamate toxicity in vitro (Dawson et al.
1991) led directly to investigation of the possible role of NO in the pathophysiology of 
cerebral ischaemic damage. Elevated levels of extracellular glutamate observed during 
ischaemia in vivo (Butcher et al. 1990) were postulated to lead to an increase in neuronal 
NO production via an increase in intracellular Ca2+ and activation of constitutive NO 
synthase. The first published reports concerning the potential neuroprotective actions of 
NOS inhibitors were encouraging. Repeated dosing of L-nitroarginine or L-NAME 
throughout long survival periods was reported to dramatically reduce the volume of 
ischaemic damage following permanent MCA occlusion in mice (Nowicki et al. 1991) and 
rats (Buisson et al. 1992). However subsequent studies in which NOS inhibitors were 
dosed prior to and/or immediately following MCA occlusion have been unable to confirm 
these findings with NOS inhibition reported to have no effect (Xue et al. 1992a) or 
exacerbate (Yamamoto et al. 1992; Zhang, F. et al. 1993) ischaemic damage. The different 
dosing schedules employed by these 2 groups of studies may explain the discrepant results 
suggesting that late production of NO is detrimental to outcome while early NO production 
may be of benefit.
Although investigation of the role of NO in cerebral ischaemic damage was initiated by the 
hypothesis that excess glutamate stimulated neuronal production of NO, it now appears that 
endothelial and inducible NOS may be of greater importance than the neuronal form of the 
enzyme in dictating outcome following ischaemia. Endothelial-derived NO, produced 
immediately after onset of ischaemia (Tominaga et al. 1993), may be beneficial to outcome 
by inducing vasodilation and improving CBF to the ischaemic region. This effect can be 
augmented by exogenously-derived NO since administration of the NO donor sodium 
nitroprusside (Zhang, F. et al. 1993) or the NO precursor L-arginine (Morikawa et al. 
1992c) immediately following permanent MCA occlusion improve CBF in the ischaemic 
region and reduce infarct size 24 h post-onset of ischaemia (Morikawa et al. 1992b; Zhang, 
F. et al. 1993). As discussed above inhibition of endothelial NO production promotes 
cerebrovasoconstriction. Furthermore NOS inhibitors also potentiate platelet aggregation 
(Radomski et al. 1987) and induce red blood cell stasis in brain capillaries leading to 
'ischaemic microregions' (Prado et al. 1992). All of these responses may cause further
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reduction in flow through the MCA and also impair collateral blood flow to the ischaemic 
region. Thus non-selective inhibition of NO synthesis in the immediate post-ischaemic 
period appears detrimental to outcome. The consequences of such endothelial NOS 
inhibition may be greater in SHR than normotensive rat strains. It is known that cytokine 
production is increased in SHR compared to normotensive rats (Hallenbeck et al. 1991) 
and that elevated levels of cytokines can switch vessels from an active anti-coagulant state 
to a procoagulant state where introduction of any further anticoagulant factor can induce 
severe ischaemia (Hallenbeck et al. 1991). Inhibition of NOS may be such a factor and this 
may explain why L-nitroarginine has been reported to increase ischaemic damage following 
permanent MCA occlusion in the SHR (Yamamoto et al. 1992).
In contrast to the immediate increase in endothelial-derived NO which is of potential benefit 
in cerebral ischaemia, NO produced several hours or days following the onset of permanent 
focal ischaemia may directly contribute to ischaemic injury. A potential source of this late 
NO production may be iNOS in activated microglia (Boje & Arora 1992; Chao et al. 1992) 
and invading macrophages from the periphery (Fabian & Rea 1993) which first appear in 
appreciable numbers 1-7 days post-permanent MCA occlusion (Garcia & Kamijyo 1974; 
Morioka et al. 1993). In contrast to the transient increase in NO production that occurs 
following activation of cNOS, the release of NO from iNOS can be sustained over several 
days and occurs at approximately 500 times the rate of release of NO from endothelial NOS 
(reviewed in Nathan 1992). Thus this much larger source of NO may have greater 
cytotoxic potential than the comparatively small amount of NO produced by neurones and 
endothelial cells. NO released directly from macrophages is toxic to endothelial cells 
(Palmer et al. 1992) and can promote oedema formation through peroxidation of membrane 
lipids (See Section 1.6.8.). Therefore it is possible that prolonged inhibition of NO 
synthesis actually improves outcome following permanent focal ischaemia by reducing 
oedema formation rather than by directly affecting neuronal survival. The studies that 
reported beneficial effects of chronic NOS inhibition (Buisson et al. 1992; Nowicki et al.
1991) assessed infarct volume by measuring areas of damage on non-fixed tissue sections. 
As discussed in Section 4.4. tissue swelling due to brain oedema can significantly 
contribute to lesion size (Lin et al. 1993) and the apparent reductions in infarct volume 
achieved with NOS inhibition may actually reflect reductions in oedema content of the 
tissue. In support of this hypothesis repeated treatment with L-nitroarginine has been 
demonstrated to reduce oedema (assessed by hemispheric water content) 48 h 
post-permanent MCA occlusion (Nagafuji et al. 1992).
Another factor that may contribute to the dramatic efficacy of repeated dosing of NOS 
inhibitors in conscious animals following permanent MCA occlusion (Buisson et al. 1992;
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Nowicki et al. 1991) is drug-induced hypothermia. We have found that, even with heating 
lamps, L-NAME reduces body temperature in the conscious rat by approximately 2°C (see 
Section 6.2.). In the absence of an external heat source multiple dosing of NOS inhibitors 
may reduce body temperature sufficiently to give marked neuroprotection against focal 
ischaemic damage (see Section 8.1.). In our acute 4 h models of MCA occlusion body 
temperature was actively maintained around 37°C by means of heating blankets and, in 
addition, temporalis muscle temperature was not significantly altered by L-NAME (see 
Tables 20 and 21). Therefore the moderate neuroprotective action of L-NAME observed in 
the present studies is not due to hypothermia, whereas this variable can not be excluded as 
a causative factor for the more dramatic reductions in ischaemic damage previously reported 
in the conscious rat.
From the above discussion it is evident that NO synthase inhibitors induce a variety of 
physiological responses that can impact directly on final infarct size. The hypertension 
induced by low doses of NOS inhibitors in conscious animals and repeated dosing of 
higher doses in halothane-anaesthetised rats (as in the present study) might be expected to 
improve CBF to ischaemic regions and thereby reduce ischaemic damage. However the 
direct central vasoconstrictive action of NOS inhibitors reduces CBF in both conscious and 
halothane-anaesthetised rats (see Section 6.3.) so that hypertension is not likely to be an 
important factor. In contrast the cerebral hypoperfusion induced by inhibition of 
endothelial NOS is likely to be of critical importance to outcome since NOS inhibitors may 
reduce blood flow in the ischaemic penumbra to below the critical threshold for 
development of permanent neuronal damage, thereby negating any beneficial actions of 
these compounds. The potential therapeutic utility of NOS inhibitors as anti-ischaemic 
agents will therefore depend on the development of selective drugs that allow inhibition of 
neuronal and inducible NOS (potentially detrimental in ischaemia) while conserving 
endothelial NOS (potentially beneficial in ischaemia). This may prove possible in the near 
future as these 3 types of NOS are the products of separate genes (Bredt et al. 1991; Lamas 
et al. 1992; Xie et al. 1992) and more selective NOS inhibitors are already being developed 
(Moore et al. 1993). When available a selective neuronal NOS inhibitor, that does not 
facilitate endothelin-1 vasoconstriction, may prove more efficacious in both the 
endothelin-1 model of transient MCA occlusion and the permanent MCA occlusion model.
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7.3. Effect of L-NAME and MK-801 on glutamate toxicity in vivo
7.3.1. Introduction
The neuroprotective effect of L-NAME against ischaemic damage in our models of transient 
and permanent MCA occlusion was more modest than might have been expected from the 
results of in vitro studies of glutamate toxicity (Dawson et al. 1991). The lack of dramatic 
efficacy of L-NAME in vivo probably reflects the diverse physiological functions of the 
drug, particularly its cerebrovascular effects, discussed in Section 6.2.4. Therefore to 
directly assess the anti-excitotoxic effect of L-NAME in vivo required a model where 
cerebrohypoperfusion induced by the drug would have less impact on outcome. The 
neuroprotective effect of L-NAME was therefore investigated in the novel model of 
glutamate toxicity in vivo recently developed at the Wellcome Surgical Institute (Landolt et 
al. 1993), and directly compared to the efficacy of MK-801 in the same model.
7.3.2. Experimental protocol
The comparative neuroprotective efficacies of L-NAME and MK-801 against pure 
excitotoxic damage were evaluated using the glutamate toxicity model described in more 
detail in Section 2.3.4. L-NAME (lOmg/kg i.v.), MK-801 (0.5 mg/kg i.v.) or an 
equivalent volume of vehicle (5.5 % glucose solution, 1 ml/kg i.v.), were adminstered 30 
min prior to the start of the glutamate infusion. Blood pressure and rectal temperature were 
monitored continuously, while blood gases and plasma glucose were measured at regular 
intervals (lh) throughout the experiment. 4 h post-onset of glutamate infusion the rats 
were killed by decapitation and the volumes of neuronal damage quantified as described 
previously (Section 2.3.4).
The assessment of L-NAME in this model was part of a larger study (Fujisawa et al. 1993) 
comparing the relative efficacies of L-NAME, MK-801, the AMPA antagonist NBQX (30 
mg/kg 30 min pre- and 30 min post-onset of glutamate perfusion) and the kappa opioid 
agonist CI-977 (0.3 mg/kg 30 min pre- and 30 min post-onset of glutamate perfusion) 
against glutamate toxicity in vivo. The inclusion of NBQX in the study necessitated the use 




Physiological variables immediately prior to L-NAME (lOmg/kg i.v.) or MK-801 (0.5 
mg/kg i.v.) administration, glutamate infusion, and 1 and 4 h post-glutamate infusion are 
shown in Table 22 and were comparable between groups. L-NAME induced significant 
but moderate hypertension in this study (Figure 60), while MK-801 tended to reduce 
MABP, although this effect was not significant (Figure 60).
7.3.3.2. Neuroprotective effect of L-NAME and MK-801
In the vehicle control group the glutamate infusion induced neuronal injury in the parietal 
cortex that was clearly visible as an area of pallor on the haematoxylin and eosin stained 
sections (Fig 61a). At higher magnification neurones within the lesion neurones appeared 
shrunken and darkly stained with triangulated nuclei. The region of neuronal injury 
extended both rostrally and caudally from the probe site by approximately 1.5 mm in each 
direction (Figure 61b). Both L-NAME and MK-801 reduced the area of damage at each 
stereotactic level (Figure 61b) and significantly reduced the total volume of neuronal 
damage measured 4 h post-glutamate infusion compared with control (Figure 62). The 
magnitude of the reductions in lesion volume achieved with L-NAME and MK-801 were 
similar, being 27% and 30% respectively.
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Table 22 Physiological variables for effect of L-NAME and MK-801
against glutamate toxicity in vivo
CONTROL (n = 10)
VEHICLE OHOUR +1 HOUR + 4 HOUR
pH 7.4910.03 7.4810.03 7.4510.06 7.4410.03
PaC 0 2 (mmHg) 3 9 1 3 3 9 1 3 3 9 1 3 3 7 1 3
P a 0 2 (mmHg) 172119 181119 180122 171135
Glucose (mmol/1) 9 .8 1 1 2 9.410.95 9 .1 1 0 .6 10.011.3
Rectal Temp (°C) 37.010.3 37.210.3 37.210.3 37.210.3
L-NAME (n = 5)
L-NAME OHOUR + 1 HOUR + 4 HOUR
PH 7.4610.03 7.4610.03 7.4410.06 7.3810.09
PaC 0 2 (mmHg) 3 8 1 6 3 6 1 3 3 6 1 3 3 6 1 3
P a 0 2 (mmHg) 168150 175134 195125 189124
Glucose (mmol/1) 9 .310 .6 8.1 1 1 .2 8 .811 .0 10.0 1 1 .2
Rectal Temp (°C) 36.910.3 37.110.4 37.110.2 37.010.3
MK-801 (n = 5)
MK-801 OHOUR +1 HOUR + 4 HOUR
pH 7.4710.05 7.4710.03 7.4410.06 7.4410.05
PaC 0 2 (mmHg) 3 9 1 6 3 8 1 5 4 1 1 3 3 5 1 7
P a 0 2 (mmHg) 165141 174115 182123 173122
Glucose (mmol/1) 9 .811.2 8 .811.2 8 .810.9 9 .710 .8
Rectal Temp (°C) 37.010.2 37.210.3 37.010.3 37.010.4
L-NAME (lOmg/kg i.v.), MK-801 (0.5 mg/kg i.v.) or vehicle (5.5% 
glucose, 1 ml/kg i.v.) were administered 30 min pre-glutamate infusion. 
Physiological variables were measured immediately prior to drug or 
vehicle administration, immediately prior to start of glutamate infusion (0 
hours) and 1 and 4 h after start of glutamate infusion.
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Figure 60 Glutamate toxicity in vivo: effect of L-NAME and



















L-NAME (10 mg/kg i.v.f n = 5), MK-801 (0.5 mg/kg i.v., n = 5) or 
vehicle (5.5% glucose i.v., n = 10) were administered 30 min 
pre-glutamate infusion. L-NAME moderately and significantly 
increased blood pressure while MK-801 tended to decrease it although 
this response was not significant. *p < 0.05 compared with vehicle 
control at each time point (two-way, repeated measure ANOVA 
followed by unpaired Student's t-tests with Bonfenoni correction).
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Figure 61 Glutamate toxicity in vivo: histological appearance of lesion, and areas of
neuronal damage following pre-treatment with L-NAME, MK-801 or vehicle
a) Histological appearance of the lesion 4 h post-onset of glutamate infusion.
Representative coronal section demonstrating the lesion induced by perfusion of glutamate 
(0.5 M at 1.5 pl/min for 90 min) into the right parietal cortex. The section illustrated was 
taken from a control animal (5.5% glucose i.v., 30 min pre-glutamate infusion) and 
represents the area of neuronal damage at the centre of the lesion. The lesion is clearly 
defined as a region of pallor on the haematoxylin and eosin stained section. At higher 
magnification neurones within the lesion appeared shrunken and densely stained.
b) Areas of damage assessed 4 h post-onset of glutamate infusion.
Glutamate induced a reproducible lesion, that extended both rostrally and caudally from the 
probe site (assigned stereotactic co-ordinate 0 mm). L-NAME (10 mg/kg i.v., n = 5) or 
MK-801 (0.5 mg/kg i.v., n = 5) administered 30 min prior to the start of the glutamate 
infusion reduced the areas of damage throughout the rostral-caudal extent of the lesion 
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Figure 62 Glutamate toxicity in vivo: volumes of neuronal
damage following L-NAME or MK-801 pre-treatment
Saline L-NAME MK-801
L-NAME (10 mg/kg i.v.) administered 30 min pre-glutamate infusion 
(0.5 M at 1.5 pl/min for 90 min) reduced the volume of cortical 
damage assessed 4 h post-onset of glutamate infusion. In this model, 
the protection achieved with L-NAME was equivalent to that observed 
with MK-801 (0.5 mg/kg i.v., 30 min pre-glutamate). **p < 0.01 
compared with vehicle control (unpaired Student's t-tests).
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7.3.4. Discussion
In this study 30% of the tissue potentially at risk from the glutamate infusion was salvaged 
by pre-treatment with MK-801. This result is in concordance with in vitro studies of 
glutamate excitotoxicity (see Section 1.4.3) and demonstrates the expected involvement of 
the NMDA receptor in glutamate toxicity in vivo. However, also in agreement with in vitro 
work, this result shows that other glutamate receptor subtypes also partly mediate glutamate 
toxicity since 70% of the lesion was unaffected by MK-801 pre-treatment In this regard 
the AMPA receptor appears to be of equal importance to the NMDA receptor because, in a 
parallel experiment the AMPA antagonist NBQX also significantly reduced the volume of 
damage by approximately 30% compared with control (Fujisawa et al. 1993).
The direct pharmacological antagonism of glutamate-induced neuronal injury observed with 
MK-801 and NBQX is of minor importance in terms of advancement of our knowledge of 
the excitotoxic cascade of neuronal injury, but did serve to validate the glutamate toxicity 
model. Of greater theoretical importance was the demonstration that L-NAME also gave 
significant neuroprotection against glutamate toxicity in vivo and, furthermore, the dose 
chosen (lOmg/kg) was similar in efficacy to MK-801 (0.5 mg/kg). Thus in this model NO 
appears to be an important mediator of glutamate-induced neuronal injury. This result is of 
potential clinical importance because it shows that pharmacological intervention with NO 
synthase inhibitors can allow successful interruption of the excitotoxic cascade downstream 
from the post-synaptic glutamate receptors thereby leaving normal excitatory 
neurotransmission relatively intact and circumventing potential therapeutic disadvantages 
associated with antagonism of either the NMDA or AMPA receptor.
Although both NMDA and AMPA receptor-activated events contribute to glutamate-induced 
damage in this model, stimulation of NO production probably occurs predominantly via the 
NMDA receptor since, in a similar model, pre- and post-treatment with L-NAME has been 
demonstrated to reduce hippocampal damage induced by focal injection of NMDA but not 
AMPA (Moncada et al. 1992). Thus it is likely that influx of Ca2+ through the NMDA 
receptor-gated ion channel is primarily responsible for activation of NO synthase and 
increased NO production following the pathway illustrated in Figure 10 (Section 1.6.5).
The comparative neuroprotective efficacy of L-NAME in acute focal cerebral ischaemia and 
glutamate toxicity in vivo can be directly assessed in our models because the experiments 
were performed under broadly similar conditions (Sprague-Dawley rats maintained under 
halothane anaesthesia, physiological variables constantly monitored and controlled, rats
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killed 4 h post-glutamate administration/onset of MCA occlusion). The results of these 2 
studies have shown that L-NAME is equipotent with MK-801 in reducing neuronal damage 
in the glutamate toxicity model, but is much less efficacious than MK-801 against 
permanent focal ischaemic damage. There are 2 possible explanations for this discrepancy 
which may be associated with the conservation of CBF in the glutamate toxicity model and 
which have been addressed in the preceding section (Section 7.2.). Firstly NO is likely to 
be of greater importance as a mediator of neurotoxicity in situations where its synthesis is 
not compromised by reduced blood flow such as the reperfusion phase of transient MCA 
occlusion or the glutamate toxicity model, rather than permanent MCA occlusion where 
depletion of oxygen and ATP supplies preclude prolonged production of NO. Secondly, 
the contribution of cardiovascular and cerebrovascular parameters to final outcome is likely 
to be of less importance in the glutamate toxicity model compared with models of cerebral 
ischaemia. Thus the cerebral hypoperfusion induced by L-NAME, that may have tended to 
exacerbate neuronal damage following MCA occlusion, appears to have much less impact 
on outcome following glutamate infusion, allowing a significant neuroprotective effect of 
the drug to be demonstrated in the glutamate toxicity model.
In the glutamate toxicity study L-NAME induced a significant hypertensive response 
despite the presence of continued halothane anaesthesia. This result is in contrast to other 
experiments in which halothane anaesthesia markedly attenuated the pressor response to 
L-NAME (see Sections 6.3. and 7.2.3.) and is probably due to the lower concentration of 
halothane (0.5-0.7%) used by Dr Fujisawa.
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8. GENERAL DISCUSSION
8.1. Comparison of permanent and transient MCA occlusion in the rat
This thesis has been primarily concerned with the evaluation of a new model of transient 
MCA occlusion in the rat utilising the potent vasoconstrictor peptide endothelin-1. This 
model was specifically designed to investigate the pathophysiology of transient focal 
ischaemic damage since the more well established models of permanent MCA occlusion can 
not fully address the complexities of focal ischaemia-reperfusion injury. In the course of 
the completion of my investigations it has become increasingly apparent that outcome 
following transient MCA occlusion differs in many important aspects from outcome 
following permanent MCA occlusion. Some of the most important differences between 
transient and permanent MCA occlusion will be discussed below and are summarised in 
Table 23. The existence of these differences emphasises the importance of developing valid 
models of transient focal ischaemia in order that the pathophysiology of clinical embolic 
stroke, where reperfiision is more common than persistence of the occlusion (Mohr et al. 
1986), can be more fully investigated and understood.
The fundamental theoretical difference between transient and permanent MCA occlusion 
concerns the mechanisms of tissue damage in the 2 models. In both cases the ischaemic 
cascade mediates injury during the initial ischaemic insult This complex cascade involves 
the interaction of several different pathways that lead ultimately to cell death. However in 
addition to these mechanisms of injury the reperfusion phase that follows transient MCA 
occlusion introduces additional processes (e.g. free radical and leucocyte-mediated events) 
that can also contribute to cellular injury. Thus the mechanisms of tissue damage are more 
complex for a transient ischaemic insult compared to a permanent ischaemic insult
Differences in the temporal evolution of ischaemic damage following transient and 
permanent MCA occlusion lend support to the hypothesis that the reperfusion phase 
contributes to tissue damage in the transient MCA occlusion model. The results presented 
in Section 4 demonstrated that for permanent MCA occlusion the volume of damage was 
maximal 4 h post-onset of ischaemia whereas for transient MCA occlusion the volume of 
damage continued to increase from 4 h to 24 h post-onset of ischaemia.
It is also evident that key physiological variables such as blood pressure and brain 
temperature can influence the extent of tissue damage to a greater degree for transient 
compared to permanent MCA occlusion. For example with transient MCA occlusion the 
increase in blood pressure associated with anaesthetic withdrawal was found to reduce the 
volume of ischaemic damage, while the reduction in blood pressure induced by MK-801, if
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Table 23 Summary of the major differences between models of 











Permanent MCA Occlusion Transient MCA Occlusion 
Comparatively few More complex




Approximately 50 % 
Cerebral cortex




Up to 100 %
Cerebral cortex and 
caudate nucleus
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present at the time of MCA occlusion, inhibited the neuroprotective action of the drug. In 
contrast for permanent MCA occlusion anaesthetic withdrawal did not significantly alter the 
volume of damage, and previous studies have shown that MK-801 pre-treatment is highly 
neuroprotective in this model despite the presence of drug-induced hypotension at the time 
of MCA occlusion (Park et al. 1989).
In addition outcome following transient MCA occlusion is more sensitive to alterations in 
brain temperature than permanent MCA occlusion. Moderate hypothermia (30-33°C) 
maintained during the ischaemic phase and first hour of reperfusion has been shown to 
reduce the volume of ischaemic damage following transient MCA occlusion compared to 
normothermic or hyperthermic (39°C) controls (Chen et al. 1993; Morikawa et al. 1992a; 
Ridenour et al. 1992), whereas transient hypothermia of the same magnitude is not 
protective against permanent MCA occlusion (Morikawa et al. 1992a; Ridenour et al.
1992). More profound transient hypothermia (24°C, Onesti et al. 1991) or moderate 
hypothermia (32°C) maintained for the entire duration of the ischaemic insult (Xue et al. 
1992b) is normally necessary to demonstrate protection in models of permanent focal 
ischaemia. However one study has reported that transient hypothermia (33°C for 1 h) 
delayed up to 1 h post-permanent MCA occlusion can significantly reduce ischaemic 
damage (assessed by TTC staining, Kader et al. 1992).
The sensitivity of transient focal ischaemic damage to variations in brain temperature is 
further illustrated by reports that moderate hypothermia (30-32°C) initiated 1-3 h after the 
onset of reperfusion significantly reduces volume of ischaemic damage by approximately 
50 % (Xue et al. 1992b; Zhang, R.L. et al. 1993). The fact that delayed hypothermia 
initiated 3 h after the onset of reperfusion can give such dramatic protection further 
emphasises the importance of events occuring during the reperfusion phase to the evolution 
of tissue injury in models of transient focal ischaemia.
The long-standing assumption that the cerebroprotective effect of hypothermia is related to 
suppression of cerebral metabolic rate is questionable (Todd Sc Warner 1992). The 
protection achieved by progressively increasing levels of hypothermia does not parallel 
observed changes in metabolic rate, energy metabolite depletion or lactic acid accumulation 
(Dietrich 1992; Todd & Warner 1992). Instead recent evidence suggests the 
neuroprotective effect of intra-ischaemic hypothermia derives from inhibition of the 
ischaemia-induced elevation of extracellular glutamate (Busto et al. 1989; Graf et al. 1992). 
In contrast protection afforded by hypothermia initiated during reperfusion may be vascular 
in origin. Alterations in blood-brain barrier permeability and leucocyte accumulation 
following transient global ischaemia are temperature-dependent, being significantly 
increased at 39°C and attenuated at 33°C (Dietrich et al. 1990). The early deleterious
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increase in blood-brain barrier permeability following transient focal ischaemia is also 
suppressed by post-ischaemic hypothermia (28-30°C, Huang et al. 1993). This response 
may in turn be partly due to hypothermia-induced attenuation of post-ischaemic hyperaemia 
(Morikawa et al. 1992a) which is known to mediate the initial opening of the blood-brain 
barrier following resolution of arterial occlusion (Kuroiwa et al. 1989).
The well-documented protective action of hypothermia on outcome following transient 
focal ischaemia, coupled with the fact that both MK-801 and L-NAME induce hypothermia 
in conscious animals, made it imperative to monitor brain temperature in the 
pharmacoprotection studies included in this thesis to ensure that any observed beneficial 
effect was not due to drug-induced hypothermia. Therefore ipsilateral temporalis muscle 
temperature was continously measured during MCA exposure and occlusion. Unlike rectal 
temperature, temporalis muscle temperature correlates closely with intrapaienchymal brain 
temperature following MCA occlusion (Onesti et al. 1991) and therefore provides a good 
estimate of brain temperature. In our experiments, where rectal temperature was controlled 
by external heating, temporalis muscle temperature was not significantly altered by either 
L-NAME or MK-801 pre-treatment. In these studies intra- and inter-experimental 
temporalis muscle temperature was relatively consistent suggesting that variations in brain 
temperature were not a major contributor to overall variability in lesion size in the 
endothelin-1 model of transient focal ischaemia. However cerebral hypothermia may be of 
greater importance in dictating outcome in some alternative models of transient focal 
ischaemia. For example when ischaemia is induced by MCA occlusion in tandem with 
bilateral carotid artery occlusion, the interruption of carotid arterial blood flow causes a 
more profound reduction in brain temperature than that observed in our model (subdural 
temperature 2-3°C below rectal temperature, Moyer et al. 1992), which if not prevented, 
significantly reduces lesion size (Moyer et al. 1992).
Statistical power and variability in volumes of ischaemic damage
One of the most important criteria for the development of animal models of focal cerebral 
ischaemia (both permanent and transient) is that the model should achieve a reproducible 
lesion with an acceptable degree of variability so that different treatment strategies can be 
evaluated. The greater the degree of variability in a model the greater the possibility that a 
true difference between lesion size in control and drug groups will not be detected by 
statistical testing - a 'type IT error.
The presence of the collateral circulation in the rat introduces a certain level of variability 
into models of permanent focal ischaemia. Incorporation of a period of reperfusion into the 
design introduces additional variability, over and above that associated with the ischaemic
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phase, due to a whole series of physiological parameters (cerebral blood flow, blood 
pressure, temperature, biochemical mediators such as nitric oxide discussed above and in 
various parts of this thesis) that can directly influence neuronal damage and/or oedema 
formation following the restoration of blood flow. Therefore models of transient focal 
ischaemia are inherently associated with a greater degree of variability in lesion size than 
models of permanent focal ischaemia.
For any particular model power analysis can be used to estimate the number of animals per 
group necessary to avoid a type II error and detect a specified difference in lesion size 
between control and drug groups. Using the results for the 4 h paradigm in the 
anaesthetised rat, the group sizes necessary to detect a 50% reduction in lesion size, at the 
5% level of significance, with a power of 80% (i.e. 80% probability of detecting the true 
difference between the sample means and rejecting the null hypothesis o f equal means) 
were calculated for both transient and permanent MCA occlusion (Table 24a). The mean 
volumes of hemispheric damage for control rats from the 3 separate studies utilising this 
paradigm in the transient occlusion model were relatively consistent (Table 24a). However 
the variability in lesion size (estimated by the standard deviation) is rather high, particularly 
for the control group from the L-NAME study. This is reflected in the large group sizes 
estimated by power analysis to be necessary to detect a 50% reduction in lesion volume (n 
= 19-34) compared with n = 2 for the model of permanent MCA occlusion (Table 24a). As 
there was no significant difference between the volumes of ischaemic damage in the 3 
transient ischaemia studies they were combined to give an overall estimate of the variability 
in this model. This shows that, on average, groups of 26 would be required to 
demonstrate a statistically significant 50% reduction in lesion size utilising the 4 h paradigm 
in the anaesthetised rat (Table 24a). Furthermore power analysis predicts that groups with 
n = 78 would be necessary to statistically detect the observed 29% reduction in hemispheric 
damage achieved with L-NAME in the transient ischaemia study. The practicalities of 
conducting such a large experiment precluded its inclusion in the current thesis. However 
this analysis does not invalidate the present results achieved with smaller group sizes. In 
particular it can be concluded that pre-treatment with MK-801 is more efficacious than 
L-NAME pre-treatment (at the doses used) when volumes of ischaemic damage are 
assessed 4 h post-onset of transient MCA occlusion. Although the group sizes discussed 
above appear quite large it should be noted that power analysis gives conservative estimates 
of the number of animals required and that statistical significance can frequently be 
demonstrated with smaller experimental groups. For example the statistically significant 
70% reduction in lesion size observed with MK-801 in the transient ischaemia study was 
achieved with an average group size of only 9, while power analysis suggested n of 13 
would be required.
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Table 24 Power analysis for selected models of transient and permanent MCA occlusion
Sample sizes necessary to detect a 50% reduction in lesion volume were calculated for 80% 
power at the 0.05 level of significance (p = 0.2; a  = 0.05).
Volumes of hemispheric damage (mean ± S.D.) assessed 4 h or 24 h post-onset of 
transient MCA occlusion and sample sizes are shown for
a) Endothelin-1 model (4 h duration in the anaesthetised Sprague-Dawley (S-D) rat): i) 
untreated ii) saline control group from the MK-801 study iii) saline control group from the 
L-NAME study and iv) the overall mean of the 3 studies combined, compared with 
permanent MCA occlusion of 4 h duration.
b) and c) Endothelin-1 model ('ET-1', 24 h duration in the S-D rat) compared with 
representative studies from the published literature using normotensive and spontaneously 
hypertensive (SHR) rat strains.
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Table 24 Power analysis for selected models of transient
and permanent MCA occlusion
a) Volumes of ischaemic damage assessed 4 h post-onset of transient 
and permanent MCA occlusion in the anaesthetised rat
Transient MCA Occlusion




Volume of ischaemic 
damage (mm 3)
Sample size to detect 
50% reduction
48 ± 26 59 ± 37 54 ± 40  5 3 ± 34  
(n = 12) (n = 10) (n = 14) (n = 36)
n = 19 n = 25 n = 34 n = 26
107 ± 15 
(n = 6)
n = 2
b) Volumes of ischaemic damage assessed 24 h post-onset of transient 
MCA occlusion (normotensive strains)
ET-1
(S-D)
Buchan et al. 1992 
(Wistar, clip occlusion)




Volume of ischaemic 
damage (mm3)




60 120 180 
21 ±13 150± 29 211 ±34  
n = 25 n = 34 n = 26
60 120 180 
71 ±79  133 ±107 177 ±20 
n = 78 n = 41 n = 1
c) Volumes of ischaemic damage assessed 24 h post-onset of 
transient MCA occlusion (SHR)
Buchan et al. 1992 
(SHR; clip occlusion)




Volume of ischaemic 
damage (mm3)
Sample size to detect 
50% reduction
60 120 180 
15±25 93±65  217±28 
n = 180 n = 31 n = l
60 120 180 
33 ±21 100 ±23 183 ±29  
n = 25 n = 3 n = 12
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Although all models of transient focal ischaemia are more variable than their permanent 
counterparts, this comparative lack of power must be balanced against the maximum degree 
of pharamacoprotection that could potentially be demonstrated in the 2 types of model. For 
permanent MCA occlusion, tissue in the core ischaemic region will always be destined to 
die due to depletion of oxygen and energy supplies. Only the 'penumbral' region - the 
border zone between densely ischaemic and normally perfused tissue, where flow is less 
severely reduced - will be amenable to pharmacological intervention. This means that even 
the most efficacious of drugs such as MK-801 can only protect approximately 50% of the 
total tissue at risk. In contrast for transient MCA occlusion, the restoration of blood flow 
(providing it is initiated before ischaemic damage becomes irreversible) renders 100% of 
the affected tissue potentially salvagable. This is illustrated by the fact that tissue damage in 
the caudate nucleus, an end-artery region, can be successfully reduced by pharmacological 
intervention prior to transient MCA occlusion (e.g. with MK-801, Section 7.1.) whereas 
previous studies have shown that in the presence of permanent MCA occlusion this region 
is more resistant to neuroprotective agents. Therefore the 'ideal' drug is likely to reduce the 
total volume of tissue damage to a greater extent following transient compared with 
permanent MCA occlusion, and consequently the difference in power between the 2 models 
will be of less practical importance.
The results of the pharmacoprotection studies utilising L-NAME do not appear to support 
this view since the neuroprotective effect of the drug was broadly similar for both 
permanent and transient MCA occlusion. However in these studies outcome was only 
assessed in the acute post-ischaemic period. By extending the endpoint from 4 h to 24 h 
post-onset of transient ischaemia the contribution of reperfusion injury to the maturation of 
the lesion would be enhanced, and the volume of potentially salvagable tissue thereby 
increased. Thus it may prove more feasible to use 24 h as the endpoint for future studies of 
potential neuroprotective agents in the endothelin-1 model of transient focal ischaemia. 
From Table 24b it can be seen that, if damage is assessed at 24 h, a group size of only 15 is 
required to detect a 50% reduction in lesion size. In the present studies we did not use the 
24 h time point because 1) it is more difficult to control physiological variables over 24 h in 
the conscious rat compared with 4 h in the anaesthetised rat and 2) both drugs tested 
(L-NAME and MK-801) have significant effects on blood pressure and/or cerebral blood 
flow in the conscious rat that may contribute to apparent anti-ischaemic efficacy and make 
interpretation of the results difficult. However careful choice of dosing schedules and 
regular post-operative monitoring of physiological variables may make these problems 
surmountable in the future.
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8.2. Comparison of different models of transient MCA occlusion in the rat
In this section I shall compare the endothelin-1 model of transient MCA occlusion to the 
alternative models of transient focal ischaemia described in the literature. For most of these 
models lesion volume is assessed at least 24 h following the onset of the ischaemic insult 
(Buchan et al. 1992b; Kaplan et al. 1991). Table 24b-c shows the volumes of ischaemic 
damage and sample sizes necessary to detect a 50% reduction in lesion size for 
representative studies in which the MCA was transiently occluded (using clips, ligatures or 
hooks combined with unilateral or bilateral common carotid artery occlusion) for periods of 
60-240 min and volumes of ischaemic damage were assessed 24 h post-onset of occlusion. 
A previous analysis of the variability associated with different rat models of transient focal 
cerebral ischaemia concluded that a 3 h period of occlusion was necessary to reduce the 
variability to acceptable levels (Hiramatsu et al. 1993). From Table 24 it can be seen that 3 
h occlusion does dramatically reduce variability and required sample size. However the 
volume of ischaemic damage following 3 h of transient ischaemia in these models is 
equivalent to 24 h of permanent MCA occlusion (Buchan et al. 1992b; Kaplan et al. 1991). 
Thus the volume of damage is already maximal by the 3 h time point (purely due to the 
ischaemic insult) and the contribution of reperfusion injury can not be assessed. Therefore 
to study ischaemic-reperfusion injury an initial period of ischaemia of less than 3 h duration 
is advisable. When compared to models utilising normotensive rat strains and periods of 
ischaemia of less than 3 h duration, it can be seen from Table 24 that smaller group sizes 
are required for the endothelin-1 model than for the alternative models of transient focal 
cerebral ischaemia. Thus the variability associated with the endothelin-1 model (at the 24 h 
time point) compares favourably with that of other methods of transient MCA occlusion 
described in the literature.
One of the main advantages of the endothelin-1 model of transient MCA occlusion is that 
induction of ischaemia does not involve mechanical damage to the vasculature. In models 
utilising extravascular occlusion (Buchan et al. 1992b; Kaplan et al. 1991) the clips or 
ligatures used to induce occlusion may cause damage to the MCA resulting in variability in 
the degree of reflow through the vessel when the occluder is removed (Tamura et al. 1980). 
Models of intravascular occlusion may also cause vascular damage when the filament is 
advanced from the common carotid artery through the internal carotid artery to occlude the 
origin of the MCA. Insertion of a catheter into the common carotid artery is known to 
cause loss of endothelial cells and immediate reduction in NO-mediated vasodilation which 
is followed by a later increase in NO production 24 h post-insult due to induction of NO 
synthase in the vascular smoooth muscle (Joly et al. 1992). Thus occlusion of the MCA by 
insertion of a filament may cause initial loss of vasodilatory mechanisms that would
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normally be employed to counteract ischaemia, and secondly, following reperfusion, 
endothelial damage and/or increased NO production that may contribute to the massive 
cerebral oedema observed in these models (Koizumi et al. 1989; Memesawa et al. 1992b). 
An advantage of the intravascular models often cited is the fact that no craniectomy is 
necessary to induce MCA occlusion so that any increase in intracranial pressure in reponse 
to oedema formation will not be artificially ameliorated by the opening in the skull 
(Nagasawa & Kogure 1989). This is indeed the case, but the gross oedema induced by 
this method results in very high mortality rates (Koizumi et al. 1989; Memesawa et al.
1992) probably direcdy related to increased intracranial pressure. Thus the model is not 
ideally suited to long term studies of ischaemia-reperfusion injury. In contrast the 
endothelin-1 model is associated with very low mortality rates.
Models of extravascular occlusion normally utilise distal MCA occlusion resulting in a 
lesion located predominantly in the cerebral cortex with little striatal involvement. These 
models do not therefore closely mimic human stroke since, in man, the most common site 
for MCA occlusion is proximal to the lenticulo-striate branches resulting in consistent 
damage to the caudate nucleus (Ringelstein et al. 1992; Saito et al. 1987). The location of 
the lesion induced by MCA occlusion is of importance because recent evidence suggests 
the caudate nucleus responds differently to ischaemia-reperfusion injury than the cerebral 
cortex (Abe et al. 1988; Matsumiya et al. 1991). Models of transient distal MCA occlusion 
can not be used to elucidate the differential mechanisms underlying cortical and striatal 
damage, whereas the endothelin-1 model, which induces a lesion in both cortex and 
caudate nucleus, could be used for this purpose. In the present study both L-NAME and 
MK-801 had a greater neuroprotective effect on striatal damage compared with cortical 
damage following transient MCA occlusion lending support to the idea that the caudate 
nucleus is more susceptible to reperfusion injury and/or more amenable to pharmacological 
intervention than the cortex.
Another difference between the endothelin-1 model and other models of transient MCA 
occlusion concerns the dynamics of restoration of blood flow. In models where the MCA 
is mechanically occluded removal of the occluder can result in an immediate absolute 
hyperaemia in the previously ischaemic region in a substantial proportion of animals 
(Shigeno et al. 1985; Tamura et al. 1990). During ischaemia blood vessels are probably 
maximally dilated due to acidosis (Lassen 1966). Rapid re-opening of the occluded MCA 
causes a rush of blood through the dilated vessels resulting in "haemodynamic" damage to 
the blood-brain barrier and increased oedema formation (Kuroiwa et al. 1985; Kuroiwa et 
al. 1989; Tamura et al. 1980). Following subsidence of hyperaemia normal blood-brain
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barrier function is temporarily restored (Kuroiwa et al. 1985; Shigeno et al. 1985), until a 
second later opening of the blood-brain barrier occurs due to ischaemia-reperfusion injury 
to the vasculature (Kuroiwa et al. 1985). In the absence of hyperaemia, or when 
hyperaemia is actively suppressed by modulating the degree of arterial re-opening, the 
initial transient opening of the blood-brain barrier does not occur (Kuroiwa et al. 1989; 
Tamura et al. 1980). In contrast to other models, restoration of blood flow in the 
endothelin-1 model of transient MCA occlusion is slow and progressive (Macrae et al.
1993) so that the artifactual opening of the blood-brain banrier observed in other models 
will not influence outcome in the endothelin-1 model.
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8.3. Concluding remarks and future studies
In both experimental MCA occlusion and clinical stroke early reperfusion is essential if 
tissue is to be salvaged and functional recovery optimised. However the restoration of 
blood flow can invoke a further cascade of pathological events which, if not interrupted, 
may cause additional 'reperfusion injury' to the tissue. The fundamental premise that 
separate and/or additional pathological processes contribute to outcome following transient 
as opposed to permanent focal cerebral ischaemia has been repeatedly demonstrated within 
this thesis with the observation that outcome in the transient (endothelin-1) model differs in 
several important aspects from that in the permanent MCA occlusion model (reviewed in 
Section 8.1.).
To address the problem of reperfusion injury models of transient focal cerebral ischaemia 
are being increasingly utilised in experimental studies of stroke. In this regard the 
endothelin-1 model of transient focal ischaemia, extensively characterised in this thesis, 
compares favourably with the alternative rat models described in the literature, both in 
terms of variability in lesion size and the absence of mechanical damage to the endothelium 
that can occur following intra- or extra-vascular occlusion with filaments or clips.
One of the most important questions arising from my investigations concerns the nature of 
the biochemical mediators of reperfusion injury. As discussed in the Introduction to this 
thesis one of the most obvious candidates for this role are oxygen free radicals. A series of 
experiments has therefore been initiated to assess the contribution of free radicals to 
ischaemic-reperfusion injury in the endothelin-1 model by 1) measuring the levels of free 
radicals produced and 2) determining the neuroprotective efficacy of a free radical 
scavenger in this model. Future studies could also be directed towards further investigation 
of the reperfusion phase of the endothelin-1 model by measuring CBF at later time intervals 
than 2h  following endothelin-1 application to the MCA.
In conclusion the investigations reported in this thesis have established that topical 
application of endothelin-1 to the MCA is a viable model of transient focal cerebral 
ischaemia in the rat. This novel approach, in tandem with other experimental models, will 
hopefully allow the concept of reperfusion injury to be more fully investigated and 
understood in the near future.
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